



CURRICULUM VITAE

Luis E. Fayad M.D.

PRESENT TITLE AND AFFILIATION

Primary Appointment

Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

N/A

CITIZENSHIP

United States

Ecuador

HOME ADDRESS

3614 Bellefontaine
Houston, TX 77025

OFFICE ADDRESS

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd Unit 429
Unit Number: 429
Houston, TX 77030
Room Number: FC6.2018
Phone: 713-792-2860
Fax: 713-794-5656
Email: lefayad@mdanderson.org

EDUCATION

Degree-Granting Education

Catholic University of Guayaquil, Guayaquil, Ecuador, MD, 1985, Medicine

Postgraduate Training

Internal Medicine Program, Internal Medicine, University of Miami/Jackson Memorial Hospital, Miami, FL, 7/1990-6/1993

Hematology Fellowship, Hematology, University of Texas Health Science Center, Houston, TX, 7/1993-6/1994

Medical Oncology Fellowship, Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/1994-6/1997

CREDENTIALS

Board Certification

American Board of Internal Medicine, 1/1993-10/2022, Recertification Date: 10/2012

American Board of Internal Medicine Medical Oncol, 1/1997-10/2022, Recertification Date: 10/2012

American Board of Internal Medicine Hematology sub, 11/1998, Recertification Date: 12/2008

Licensures

Active

Texas, TX, J7482, 1/2005-11/2020

Controlled Substance Registration Certificate (DEA), TX, BF2955497, 8/2006-9/2021

Texas Controlled Substance Registration Certificate (DPS), TX, 50090808, 3/2008-11/2019

Inactive

Florida, FL, 0060679, 1/2006-1/2018

Arizona, AZ, 27581, 1/2006-12/2018

Nevada, NV, 08439, 1/2007-6/2009

EXPERIENCE/SERVICE

Academic Appointments

Hematology Oncologist, Nevada Cancer Center, Las Vegas, NV, 1/1997-1/2000

Assistant Professor, University of Nevada School of Medicine, Las Vegas, NV, 1/1998-1/2000

Assistant Professor, University of Texas M.D. Anderson Cancer Center, Houston, TX, 1/2000-9/2006

Staff Physician, Lyndon B. Johnson Hospital, Houston, TX, 1/2002-2009

Associate Professor, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, 9/2006-8/2019

Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2019-present

Administrative Appointments/Responsibilities

Clinical Medical Director, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2002-2015

Other Appointments/Responsibilities

Staff Physician, Lyndon B. Johnson Hospital, Houston, TX, 9/2002-2010

Endowed Positions

N/A

Consultantships

N/A

Military or Other Governmental Service

N/A

Institutional Committee Activities

Q & A of CCOP, Member, 1/1998-2004

CCOP, Member, 1/1998-2004

Institutional Review Board for Columbia Sunrise Hospital, Member, 1/1999-1/2000

IRB, Member, 1/1999-2011

Pharmacy and Therapeutics Committee, Member, 1/2001-2005

CCAG (Clinical Computing Advisory Group) Committee, Member, 1/2002-2007

CRC (Clinical Research Committee), Member, 9/2003-8/2006

Pharmacy Assistant Program, Medical Liaison, 2005-2011

Medical Records Committee, Alternative Member, 2005-2018

CME Advisory Committee, Member, 2008-8/2015

Lymphoma Planning Clinic, Director, 2010-9/2015

Provider Ambassador Network Focus Group, Member, 2010-2018

Conflict of Interest Committee, Member, 9/2016-present

HONORS AND AWARDS

Best Student Award, University of Arizona, 1993

Mentor Award 2005, M. D. Anderson Alumni and Faculty Association, 2005

Best Doctors of America, 2009-present

RESEARCH

Grants and Contracts

Funded

N/A

Pending

N/A

Other

N/A

Completed

Principal Investigator, Phase II Depsipeptide for Recurrent/refractory mantle cell lymphoma and DLBCL, n/a, 2006-2010, \$36,000

Principal Investigator, Principal Investigator, Translational Research Incentives (CTEP), approved to evaluate histone deacetylation in patients with DLBCL and MCL treated with HDAC inhibitor Depsipeptide, CTEP, 11/2006-10/2009, \$139,623

Not Funded

N/A

Protocols

Funded

Principal Investigator, Phase II study of liposomal tretinoin (ATRAGEN) acid for patients with relapsed or refractory indolent or aggressive B-cell or T-cell Non-Hodgkin's lymphoma or cutaneous T-cell lymphoma., DM98-008, PI - Luis Fayad, 1998-2005, \$500,000

Principal Investigator, A Phase I Trial of BBR 2778 in Combination with Cytarabine, Methylprednisolone and Cisplatin in the Treatment of Patients with Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma., DM01-398, 2001-2005, \$259,500

Principal Investigator, A Phase I Trial of BBR 2778 in Combination with Fludarabine, Dexamethasone and Rituximab in the Treatment of Patients with Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma., DM01-434, 2001-2007, \$299,010, Theradex

Principal Investigator, A Phase II, Open-Label, Randomized, Multicenter Trial to Evaluate the Preliminary Safety and Efficacy of HU1D10 in Patients with Relapsed or Refractory Grades I, II, or III B-Cell Non-Hodgkin's Lymphoma (including follicular, small Lymphocytic and marginal., DM01-397, 2002-2003, \$120,007

Principal Investigator, A Phase II Open Label, Randomized, Dose and Schedule Finding, Clinical Trial of Immunotherapy with AMG 412 in Subjects with Diffuse Large B-Cell Non-Hodgkin's Lymphoma., ID01-579, 2002-2004, \$100,735

Principal Investigator, Phase II study of vincristine sulfate liposomes injection (VSLI) in patients with relapsed or refractory Hodgkin's disease., ID01-597, 2002-2004, \$195,890

Principal Investigator, A Multi-center Phase II Study to Investigate the Safety and Activity of SDX-105 (Bendamustine) in Patients with Indolent Non-Hodgkins Lymphoma (NHL) who are Refractory to Rituximab, 2003-0904, 2004-2005, \$233,126, Salmedix, Inc.

Principal Investigator, A Phase I Study of CMC-544 Administered as a Single Agent in Subjects with Relapsed and Refractory B-cell Non-Hodgkins Lymphoma, 2004-0133, PI - Luis Fayad, 2004-2006, \$329,655, Wyeth-Ayerst Research Laboratories

Principal Investigator, A Phase I dose escalation safety/tolerance study of PPI-2458 in subjects with Non-Hodgkin's Lymphoma., 2004-0953, 2005-2008, \$211,640, Praecis Pharmaceuticals Inc.

Principal Investigator, Treatment with humanized anti-CD20 (HA20) for B-cell malignancies, 2005-0046, 2005-2008, \$226,771, Immunomedics

Principal Investigator, A Phase II multicenter trial of SAHA for large B-cell lymphoma, 2004-0828, 2005-2009, \$222,665

Principal Investigator, R-CHOP+Doxil, 2004-0305, 2005-2009

Principal Investigator, R-Chop+Zevalin, 2004-0683, 2005-2009

Principal Investigator, Zometa, 2005-0698, 2005-2009

Principal Investigator, A phase II randomized study of rituximab-HCVAD alternating with rituximab-methotrexate-cytarabine -vs- standard rituximab-CHOP every 21 days for patients with newly diagnosed high risk aggressive B-cell Non-Hodgkin's lymphoma in patients 60 years old or younger., 2005-0054, 2005-2010, \$210,000, Genentech, Inc.

Co-Principal Investigator, A Phase I study of a chimeric antibody against anti-interleukin-6 (CNTO 328) administered biweekly as an intravenous infusion in subjects with Non-Hodgkin's lymphomas, multiple myeloma, or Castleman's Disease, 2004-0492, PI - Razelle Kurzrock, MD, 2005-present, \$109,375

Principal Investigator, Double-blind, randomized, placebo-controlled trial of Favld-GM-CSF following R-CHOP as first-line therapy in high -intermediate and high-risk DLBCL., 2005-0908, 2005-present, \$834,325

Principal Investigator, Early Therapeutics Development with Phase II Emphasis(PP-9), 2003-0308, 2006-2008, \$20,840, National Cancer Institute-DHHS-NIH

Principal Investigator, Depsipeptide, a Histone Deacetylase Inhibitor, in Relapsed/Refractory MCL or DLNHL, 2005-0579, 2006-2010, \$35,559, SAIC-Frederick, Inc.

Principal Investigator, Phase I/II of CMC-544 administered with rituximab for patients with recurrent follicular or DLBCL., 2006-0415, 2006-2010, \$595,293, Wyeth-Ayerst Research Laboratories

Principal Investigator, PRELUDE: A Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin, 2006-0207, 2006-2011, \$154,910, Eli Lilly and Company

Principal Investigator, 2-Dose-Arm trial of Hu-Max-CD20, a fully human monoclonal anti-CD20 antibody in follicular lymphoma refractory to rituximab in combination chemotherapy., 2006-0645, 2007-2009, \$330,784, GenMab A/S

Principal Investigator, R-Chop+Enzastaurin, 2008-0125, 2008-2009, \$267,432

Principal Investigator, A single arm, safety and efficacy study of ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory aggressive lymphoma prior to autologous stem cell transplantation. Fully human monoclonal IgG1k-antibody., 2008-0841, 2008-2010, GlaxoSmithKline

Principal Investigator, Placebo-controlled Study of R-ICE Chemotherapy with and without SGN-40, 2007-0578, 2008-2010, \$562,230, PPD Development

Principal Investigator, Phase II study to investigate the safety and tolerability of RO5072759 versus rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin's lymphoma. Anti-CD20 antibody, 2009-0354, 2009-2010, \$323,724

Principal Investigator, A phase 2 study of inotuzumab ozogamicin (CMC-544) in subjects with indolent non-hodgkin's lymphoma (NHL). That is refractory to or has relapsed after rituximab and chemotherapy or radioimmunotherapy. Anti-CD22 immunotoxin antibody., 2009-0211, 2009-present, \$224,627, Wyeth-Ayerst Research Laboratories

Principal Investigator, An open-label, single-arm, phase 2 study of inotuzumab ozogamicin plus rituximab in subjects with relapsed/refractory CD22-positive diffuse large-b-cell lymphoma, eligible for autologous stem cell transplantation. Conjugate of a humanized IgG4 anti-CD22 antibody., 2009-0161, 2009-present, \$244,644

Principal Investigator, Randomized, double-blind, placebo-controlled, multicenter Phase III study of RAD001 vs matching placebo. HDAC inhibitor with mTor inhibitor, 2009-0793, 2009-present, \$355,873, Novartis

Co-Principal Investigator, A phase 2/3 multicenter, randomized open-label study to compare the efficacy and safety of lenalidomide (revlimid*) versus investigator's choice in patients with relapsed or refractory diffuse large-b cell lymphoma, 2010-0272, 2010-2011, Celgene

Principal Investigator, A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of CNTO 328 (Anti-IL-6 monoclonal antibody) plus best supportive care compared with subjects with multicentric castlemans disease. Anti-IL6 monoclonal antibody., 2009-0608, 2010-present, \$312,562

Principal Investigator, An open label multicenter study to evaluate the safety of long term treatment with siltuximab in subjects with multicentric castlemans disease, 2010-0907, 2011-2015

Principal Investigator, An open label randomized phase III study of inotuzumab ozogamicin administered in combination with rituximab compared to defined investigator's choice therapy in subjects with relapsed or refractory CD22-positive aggressive non-hodgkin lymphoma, 2010-0948, 2011-2015, Pfizer

Principal Investigator, A phase 2 randomized open label study for adults with relapsed or refractory DLBCL, 2012-0221, 2012-2016, Medimmune

Principal Investigator, A phase III open label multicenter randomized study of sequential zevalin (ibritumomab tiuxetan) versus observation in patients at least 60 years of age with newly diagnosed diffuse large b cell lymphoma in PET negative complete remission after R-Chop or R-Chop like therapy, 2012-0504, 2012-2016, Spectrum Pharmaceuticals

Principal Investigator, A randomized double blind phase II trial to evaluate the efficacy of two doses of fostamatinib in patients with relapsed or refractory diffuse large b cell lymphoma (DLBCL), 2012-0226, 2012-2016, AstraZeneca

Principal Investigator, FLT-PET/CT vs FDG-PET/CT for therapy monitoring of diffuse large b cell lymphoma, 2010-0822, 2012-2016, NCI

Principal Investigator, An open-label, Phase 1 study of R-CVP or R-GDP in combination with inotuzumab ozogamicin in subjects with CD22-positive non-hodgkin's lymphoma, 2010-0114, 2012-present, \$126,425, Wyeth Pharmaceuticals

Principal Investigator, A Phase 2 Study of Brentuximab vedotin in combination with standard of care treatment r-chop as front-line therapy in patients with DLBCL, 2013-0564, 2013-2016, Seattle Genetics

Principal Investigator, A phase 1b/2, Open-Label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination with Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects with Selected Advanced Solid Tumors or Aggressive B-Cell Lymphoma, 2014-0483, 2015-2016, Medimmune

Principal Investigator, A Multicenter Open-Label Phase 1b/2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, 2016-0800, PI - Luis Fayad, 2016-present

Principal Investigator, A Phase 1b study to evaluate the safety and efficacy of MEDI4736 as Monotherapy and in combination with tremelimumab or AZD9150 in subjects with relapsed or refractory diffuse large b cell lymphoma, 2015-1101, 2016-present, Medimmune

Principal Investigator, A randomized, open-label phase 2 study of denintuzumab mafodotin (SGN-CD19A) plus rituzimab, ifosfamide, carboplatin, and etoposide (19A+RICE), chemotherapy vs rice in the treatment of patients with relapsed or refractory diffuse large b cell lymphoma (DLBCL) who are candidates for autologous stem cell transplant, 2015-0993, 2016-present, Seattle Genetics

Unfunded

N/A

Patents and Technology Licenses

Patents

N/A

Technology Licenses

N/A

Grant Reviewer/Service on Study Sections

N/A

PUBLICATIONS

Peer-Reviewed Original Research Articles

1. Fayad L, Robertson LE, O'Brien S, Manning JT, Wright S, Hagemeister F, Cabanillas F, Keating MJ. Hodgkin's disease variant of Richter's syndrome: experience at a single institution. *Leuk Lymphoma* 23(3-4):333-7, 10/1996. PMID: 9031114.
2. Fayad L, Kantarjian H, O'Brien S, Seong D, Albitar M, Keating M, Talpaz M. Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases. *Leukemia* 11(5):767-71, 5/1997. PMID: 9180306.
3. DeLima M, Albitar M, O'Brien S, Pierce S, Kantarjian H, Andreeff M, Fayad L, Keating M, Estey E. Comparison of referring and tertiary cancer center physician's diagnoses in patients with leukemia. *Am J Med* 104(3):246-51, 3/1998. PMID: 9552087.
4. Cortes J, Fayad L, Kantarjian H, O'Brien S, Lee MS, Talpaz M. Association of HLA phenotype and response to interferon-alpha in patients with chronic myelogenous leukemia. *Leukemia* 12(4):455-62, 4/1998. PMID: 9557601.
5. Fayad L, Cabanillas F, Talpaz M, McLaughlin P, Kurzrock R. High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma. *Leuk Lymphoma* 30(5-6):563-71, 8/1998. PMID: 9711918.
6. Diamandidou E, Colome-Grimmer M, Fayad L, Duvic M, Kurzrock R. Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. *Blood* 92(4):1150-9, 8/1998. PMID: 9694702.
7. Rodriguez J, McLaughlin P, Hagemeister FB, Fayad L, Rodriguez MA, Santiago M, Hess M, Romaguera J, Cabanillas F. Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features. *Blood* 93(7):2202-7, 4/1999. PMID: 10090928.
8. Rodriguez J, Rodriguez MA, Fayad L, McLaughlin P, Swan F, Sarris A, Romaguera J, Andersson B, Cabanillas F, Hagemeister FB. ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease. *Blood* 93(11):3632-6, 6/1999. PMID: 10339468.
9. Diamandidou E, Colome M, Fayad L, Duvic M, Kurzrock R. Prognostic factor analysis in mycosis fungoides/Sezary syndrome. *J Am Acad Dermatol* 40(6 Pt 1):914-24, 6/1999. PMID: 10365922.
10. Cortes J, Fayad L, O'Brien S, Keating M, Kantarjian H. Persistence of peripheral blood and bone marrow blasts during remission induction in adult acute lymphoblastic leukemia confers a poor prognosis depending on treatment intensity. *Clin Cancer Res* 5(9):2491-7, 9/1999. PMID: 10499624.
11. Rodriguez J, McLaughlin P, Fayad L, Santiago M, Hess M, Rodriguez MA, Romaguera J, Hagemeister F, Kantarjian H, Cabanillas F. Follicular large cell lymphoma: long-term follow-

- up of 62 patients treated between 1973-1981. *Ann Oncol* 11(12):1551-6, 12/2000. PMID: 11205462.
12. Bibawi S, Abi-Said D, Fayad L, Anderlini P, Ueno NT, Mehra R, Khouri I, Giralt S, Gajewski J, Donato M, Claxton D, Braunschweig I, van Besien K, Andreeff M, Andersson BS, Estey EH, Champlin R, Przepiorka D. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. *Am J Hematol* 67(4):227-33, 8/2001. PMID: 11443634.
 13. Fayad L, Keating MJ, Reuben JM, O'Brien S, Lee BN, Lerner S, Kurzrock R. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. *Blood* 97(1):256-63, 2001. PMID: 11133769.
 14. Schlembach PJ, Wilder RB, Jones D, Ha CS, Fayad LE, Younes A, Hagemester F, Hess M, Cabanillas F, Cox JD. Radiotherapy alone for lymphocyte-predominant Hodgkin's disease. *Cancer J* 8(5):377-83, Sep-Oct, 9/2002. PMID: 12416895.
 15. Romaguera JE, Medeiros LJ, Hagemester FB, Fayad LE, Rodriguez MA, Pro B, Younes A, McLaughlin P, Goy A, Sarris AH, Dang NH, Samaniego F, Brown HM, Gagneja HK, Cabanillas F. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. *Cancer* 97(3):586-91, 2/2003. PMID: 12548600.
 16. Hosing C, Saliba RM, McLaughlin P, Andersson B, Rodriguez MA, Fayad L, Cabanillas F, Champlin RE, Khouri IF. Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma. *Ann Oncol* 14(5):737-44, 5/2003. PMID: 12702528.
 17. Goy A, Ramdas L, Remache YK, Gu J, Fayad L, Hayes KJ, Coombes KR, Barkoh BA, Katz R, Ford R, Cabanillas F, Gilles F. Establishment and characterization by gene expression profiling of a new diffuse large B-cell lymphoma cell line, EJ-1, carrying t(14;18) and t(8;14) translocations. *Lab Invest* 83(6):913-6, 6/2003. PMID: 12808126.
 18. Dang NH, Hagemester FB, Duvic M, Romaguera JE, Younes A, Jones D, Samuels B, Fayad LE, Pro B, Samaniego F, Sarris A, Goy A, McLaughlin P, Tong AT, Walker PL, Tiongson LP, Smith TL, Huh YO, Morimoto C, Rodriguez MA. Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes. *Oncol Rep* 10(5):1513-8, Sep-Oct, 9/2003. PMID: 12883733.
 19. Ha CS, Kong JS, McLaughlin P, Tucker SL, Fayad LE, Hess MA, Wilder RB, Cabanillas F, Cox JD. Stage III follicular lymphoma: long-term follow-up and patterns of failure. *Int J Radiat Oncol Biol Phys* 57(3):748-54, 11/2003. PMID: 14529780.
 20. Khouri IF, Lee MS, Saliba RM, Jun G, Fayad L, Younes A, Pro B, Acholonu S, McLaughlin P, Katz RL, Champlin RE. Non-ablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. *J Clin Oncol* 21(23):4407-12, 12/2003. PMID: 14645431.
 21. Chronowski GM, Wilder RB, Tucker SL, Ha CS, Younes A, Fayad L, Rodriguez MA, Hagemester FB, Barista I, Cabanillas F, Cox JD. Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy. *Int J Radiat Oncol Biol Phys* 55(1):36-43, 2003. PMID: 12504034.
 22. Fayad L. Durable Local responses with Subtherapeutic doses of concurrent Radiation and Gemcitabine in a patient with refractory Hodgkin's disease: Review of Halepota et al case. *Clin Adv in Hematol & Oncol.* 1(7):416, 2003.
 23. Fayad L, Pro B, Romaguera JE. Mantle cell lymphoma: A review. *Hematología, Citocinas, Y Terapia Celular* 2:100-112, 2003.
 24. Khouri IF, Lee MS, Saliba RM, Jun G, Fayad L, Younes A, Pro B, Acholonu S, McLaughlin P, Katz RL, Champlin RE. Non-ablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. *J Clin Oncol* 21(23):4407-12, 2003.
 25. Younes A, Fayad L, Pro B, McLaughlin P, Hagemester F, Mansfield P, Clayman G, Medeiros LJ, Manning J, Lewis J, Srivastava P. Safety and Efficacy of Heat Shock Protein-Peptide 96 Complex (HSPPC-96) Vaccine Therapy in Patients with Relapsed or Previously Untreated Low-Grade Non-Hodgkin Lymphoma. *Blood* 102(11):898a, 2003.
 26. Tsimberidou AM, Giles F, Duvic M, Fayad L, Kurzrock R. Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series. *Cancer* 100(2):342-9, 1/2004. PMID: 14716770.

27. Escalon MP, Champlin RE, Saliba RM, Acholonu SA, Hosing C, Fayad L, Giralt S, Ueno NT, Maadani F, Pro B, Donato M, McLaughlin P, Khouri IF. Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. *J Clin Oncol* 22(12):2419-23, 6/2004. PMID: 15197204.
28. Dang NH, Hagemeister FB, Pro B, McLaughlin P, Romaguera JE, Jones D, Samuels B, Samaniego F, Younes A, Wang M, Goy A, Rodriguez MA, Walker PL, Arredondo Y, Tong AT, Fayad L. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. *J Clin Oncol* 22(20):4095-102, 10/2004. e-Pub 9/2004. PMID: 15353540.
29. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. *J Clin Oncol* 23(4):667-75, 2/2005. e-Pub 12/2004. PMID: 15613697.
30. Khouri IF, Saliba RM, Hosing C, Okoroji GJ, Acholonu S, Anderlini P, Couriel D, De Lima M, Donato ML, Fayad L, Giralt S, Jones R, Korbling M, Maadani F, Manning JT, Pro B, Shpall E, Younes A, McLaughlin P, Champlin RE. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. *J Clin Oncol* 23(10):2240-7, 4/2005. PMID: 15800314.
31. Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Donato M, Giralt S, Andersson B, Ueno NT, Khouri I, De Lima M, Hosing C, Cohen A, Ippoliti C, Romaguera J, Rodriguez MA, Pro B, Fayad L, Goy A, Younes A, Champlin RE. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. *Bone Marrow Transplant* 35(10):943-51, 5/2005. PMID: 15806128.
32. Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang M, Beasley V, Medeiros LJ, Katz RL, Gagneja H, Samuels BI, Smith TL, Cabanillas FF. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. *J Clin Oncol* 23(28):7013-23, 10/2005. e-Pub 9/2005. PMID: 16145068.
33. Younes A, Pro B, Fayad L. Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma. *Blood* 107(4):1731-2, 2/2006. PMID: 16461762.
34. Zelenetz AD, Advani RH, Buadi F, Cabanillas F, Caligiuri MA, Czuczman MS, Damon LE, Fayad L, Flinn IW, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Kaminski MS, Lacasce AS, Nademanee A, Porcu P, Press O, Prosnitz L, Smith MR, Sotomayor EM, Vose JM, Yahalom J. Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology. *J Natl Compr Canc Netw* 4(3):258-310, 3/2006. PMID: 16507273.
35. Pro B, Fayad L, McLaughlin P, Romaguera J, Hagemeister FB, Rodriguez MA, Goy A, Loyer E, Younes A. Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma. *Leuk Lymphoma* 47(3):481-5, 3/2006. PMID: 16396772.
36. Liu Q, Fayad L, Cabanillas F, Hagemeister FB, Ayers GD, Hess M, Romaguera J, Rodriguez MA, Tsimberidou AM, Verstovsek S, Younes A, Pro B, Lee MS, Ayala A, McLaughlin P. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. *J Clin Oncol* 24(10):1582-9, 4/2006. PMID: 16575009.
37. Fayad L, Younes A. Novel treatment strategies for aggressive non-Hodgkin's lymphoma. *Expert Opin Pharmacother* 7(6):733-48, 4/2006. PMID: 16556089.
38. Tsimberidou AM, O'Brien S, Kantarjian HM, Koller C, Hagemeister FB, Fayad L, Lerner S, Bueso-Ramos CE, Keating MJ. Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience. *Cancer* 107(6):1294-302, 9/2006. PMID: 16902984.
39. Safdar A, Rodriguez MA, Fayad LE, Rodriguez GH, Pro B, Wang M, Romaguera JE, Goy AH, Hagemeister FB, McLaughlin P, Bodey GP, Kwak LW, Raad, II, Couch RB. Dose-

- related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma. *J Infect Dis* 194(10):1394-7, 11/2006. e-Pub 10/2006. PMID: 17054068.
40. Younes A, Fayad L, Romaguera J, Pro B, Goy A, Wang M. Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma. *Eur J Cancer* 42(17):2976-81, 11/2006. e-Pub 9/2006. PMID: 17008093.
 41. Oki Y, McLaughlin P, Fayad LE, Pro B, Mansfield PF, Clayman GL, Medeiros LJ, Kwak LW, Srivastaba PK, Younes A. Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. *Cancer* 109(1):77-83, 1/2007.
 42. Lim ST, Fayad L, Tulpule A, Modiano M, Cabanillas F, Laffranchi B, Allievi C, Bernareggi A, Levine AM. A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma. *Leuk Lymphoma* 48(2):374-80, 2/2007. PMID: 17325899.
 43. Dang NH, Pro B, Hagemester FB, Samaniego F, Jones D, Samuels BI, Rodriguez MA, Goy A, Romaguera JE, McLaughlin P, Tong AT, Turturro F, Walker PL, Fayad L. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. *Br J Haematol* 136(3):439-47, 2/2007. PMID: 17233846.
 44. Wang S, Wang S, Maeng H, Young DP, Prakash O, Fayad LE, Younes A, Samaniego F. K1 protein of human herpesvirus 8 suppresses lymphoma cell Fas-mediated apoptosis. *Blood* 109(5):2174-82, 3/2007. e-Pub 11/2006. PMID: PMC1801039.
 45. Fayad L, Hagemester F. Treatment of the patient with diffuse large B-cell lymphoma with medical co-morbidities: newer therapies needed. *Leuk Lymphoma* 48(4):657-8, 4/2007. PMID: 17454622.
 46. Iwuanyanwu E, Medeiros J, Romaguera JE, Fayad L. Mantle Cell Lymphoma with a Rare Involvement of the Testicle. *Leuk Lymphoma* 48(6)(6):1242-3, 6/2007. PMID: 17577795.
 47. Jabbour E, Hosing C, Ayers G, Nunez R, Anderlini P, Pro B, Khouri I, Younes A, Hagemester F, Kwak L, Fayad L. Pre-transplant positive PET/Gallium scans predict poor outcome in relapsed/refractory Hodgkin's lymphoma. *Cancer* 109(12):2481-9, 6/2007.
 48. Jabbour E, Hosing C, Ayers G, Nunez R, Anderlini P, Pro B, Khouri I, Younes A, Hagemester F, Kwak L, Fayad L. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. *Cancer* 109(12):2481-9, 6/2007. PMID: 17497648.
 49. Soriano AO, Thompson MA, Admirand JH, Fayad LE, Rodriguez AM, Romaguera JE, Hagemester FB, Pro B. Follicular dendritic cell sarcoma: A report of 14 cases and a review of the literature. *Am J Hematol* 82(8)(8):725-8, 8/2007. PMID: 17373675.
 50. Dang NH, Fayad L, McLaughlin P, Romaguera JE, Hagemester F, Goy A, Neelapu S, Samaniego F, Walker PL, Wang M, Rodriguez MA, Tong AT, Pro B. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma. *Br J Haematol* 138(4)(4):502-505, 8/2007. e-Pub 6/2007. PMID: 17608763.
 51. Fayad L, Thomas D, Romaguera J. Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas. *Clin Lymphoma Myeloma* 2:S57-62, 12/2007. PMID: 18284717.
 52. Hagemester FB, Fayad L. The FLIPI and the R-FLIPI: Are we finally ready to use them in Clinical Trials? *Am J Hem-Onc* 6(6):364-368, 2007.
 53. Provencio M, Fayad LE. [High-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma]. *Med Clin (Barc)* 130(2):60-5, 1/2008. PMID: 18221676.
 54. Friedberg JW, Williams ME, van der Jagt RH, Forero-Torres A, LaCasce AS, Fayad LE, Bessudo A, Camacho ES, Oliver JW, Chen L, Cohen P, Cheson BD, Robinson KS. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. *J Clin Oncol* 26(2):204-210, 1/2008. PMID: 18182663.
 55. Anderlini P; Saliba R; Acholonu S; Giralt SA; Andersson B; Veno NT; Hosing C; Khouri IF; Couril D; de Lima M; Qazilbash MH; Pro B; Romaguera J; Fayad L; Hagemester F; Younes A; Munsell MF; Champlin RE. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory

- Hodgkin's lymphoma: the updated MD Anderson Cancer Center experience. *Haematologica* 93(2):257-264, 2/2008. e-Pub 1/2008. PMID: 18223284.
56. Oki Y, Pro B, Fayad LE, Romaguera J, Samaniego F, Hagemeister F, Neelapu S, McLaughlin P, Goy A, Younes A. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. *Cancer* 112(4):831-836, 2/2008. PMID: 18085611.
 57. Overman MJ, Feng L, Pro B, McLaughlin P, Hess M, Samaniego F, Younes A, Romaguera JE, Hagemeister FB, Kwak L, Cabanillas F, Rodriguez MA, Fayad LE. The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma. *Ann Oncol* 112(4):553-559, 3/2008. e-Pub 12/2007. PMID: 18083690.
 58. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS, Medeiros LJ, Fayad L, Samaniego F, Alousi A, Anderlini P, Couriel D, de Lima M, Giralt S, Neelapu SS, Ueno NT, Samuels BI, Hagemeister F, Kwak LW, Champlin RE. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. *Blood* 111(12):5530-6. e-Pub 4/2008. PMID: 18411419.
 59. Zelenter AD, Advani RH, Byrd JC, Czuczman MS, Damon LE, Duvic M, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacase AS, Nademanee A, Olsen EA, Porcu P, Press O, Prosnitz L, Smith MR, Sotomayor EM, Vose JM, Yahalom J, Yunus F. Non-Hodgkin's lymphomas. *J Natl Compr Canc Netw* 6(4):356-421, 4/2008. PMID: 18433606.
 60. Shah JJ, Fayad L, Romaguera J. Mantle Cell International Prognostic Index (MIPI) not prognostic after R-hyper-CVAD. *Blood* 112(6):2583; author reply 2583-4, 9/2008. PMID: 18779406.
 61. Pro B, Leber B, Smith M, Fayad L, Romaguera J, Hagemeister F, Rodriguez A, McLaughlin P, Samaniego F, Zwiebel J, Lopez A, Kwak L, Younes A. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. *Br J Haematol* 143(3):355-60. e-Pub 9/2008. PMID: 18764869.
 62. Wang M, Fayad L, Cabanillas F, Hagemeister F, McLaughlin P, Rodriguez MA, Kwak LW, Zhou Y, Kantarjian H, Romaguera J. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma. *Cancer* 113(10):2734-41, 11/2008. PMID: 18973182.
 63. Esmaeli B, McLaughlin P, Pro B, Samaniego F, Gayed I, Hagemeister F, Romaguera J, Cabanillas F, Neelapu SS, Banay R, Fayad L, Wayne Saville M, Kwak LW. Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. *Ann Oncol* 20(4):709-14, 4/2009. e-Pub 1/2009. PMID: 19150940.
 64. Morschhauser F, Leonard JP, Fayad L, Coiffier B, Petillon MO, Coleman M, Schuster SJ, Dyer MJ, Horne H, Teoh N, Wegener WA, Goldenberg DM. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: Phase I/II results. *J Clin Oncol* 27(20):3346-53, 7/2009. e-Pub 5/2009. PMID: 19451441.
 65. Westin JR, Fayad LE. Beyond R-CHOP and the IPI in large-cell lymphoma: molecular markers as an opportunity for stratification. *Curr Hematol Malig Rep* 4(4):218-24, 10/2009. PMID: 20425411.
 66. Kim JE, Singh RR, Cho-Vega JH, Drakos E, Davuluri Y, Khokhar FA, Fayad L, Medeiros LJ, Vega F. Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-Cell lymphoma. *Mod Pathol* 22(10):1312-20, 10/2009. e-Pub 7/2009. PMID: 19593328.
 67. Ravandi F, Aribi A, O'Brien S, Faderl S, Jones D, Ferrajoli A, Huang X, York S, Pierce S, Wierda W, Kontoyiannis D, Verstovsek S, Pro B, Fayad L, Keating M, Kantarjian H. Phase II Study of Alemtuzumab in Combination With Pentostatin in Patients With T-Cell Neoplasms. *J Clin Oncol* 27(32):5425-30, 11/2009. e-Pub 10/2009. PMID: 19805674.
 68. Tomas JF, Dang J, Pro B, Rodriguez MA, McLaughlin P, Romaguera JE, Younes A, Hagemeister F, Cabanillas F, Podoloff D, Fayad LE. El tamizaje con galio despues del

- segundo y cuarto ciclos de quimioterapia es predictor de linfomas no Hodgkin. *Revista de Hematol* 11:5-14, 3/2010.
69. Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Byrd JC, Czuczman MS, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacasce AS, Mughal TI, Nademanee A, Porcu P, Press O, Prosnitz L, Reddy N, Smith MR, Sokol L, Swinnen L, Vose JM, Wierda WG, Yahalom J, Yunus F. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. *J Natl Compr Canc Netw* 8(3):288-334, 3/2010. PMID: 20202462.
 70. Advani A, Coiffier B, Czuczman MS, Dreyling M, Foran J, Gine E, Gisselbrecht C, Ketterer N, Nasta S, Rohatiner A, Schmidt-Wolf IG, Schuler M, Sierra J, Smith MR, Verhoef G, Winter JN, Boni J, Vandendries E, Shapiro M, Fayad L. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. *J Clin Oncol* 28(12):2085-93, 4/2010. e-Pub 3/2010. PMID: 20308665.
 71. Juweid ME, Thomas D, Menda Y, Tewson T, Graham MM, Herrmann K, Buck AK, Fayad L. PET/CT with 18F-FLT is unlikely to cause significant hepatorenal or hematologic toxicity. *J Nucl Med* 51(5):824-5, 5/2010. PMID: 20439512.
 72. Romaguera JE, Fayad LE, Feng L, Hartig K, Weaver P, Rodriguez MA, Hagemester FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak L, Wang M. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. *Br J Haematol* 150(2):200-8, 7/2010. e-Pub 5/2010. PMID: 20528872.
 73. van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, Sokol L, Crawford J, Cornfeld M, Qi M, Qin X, Herring J, Casper C, Kurzrock R. Siltuximab, a Novel Anti-Interleukin-6 Monoclonal Antibody, for Castleman's Disease. *J Clin Oncol* 28(23):3701-8, 8/2010. e-Pub 7/2010. PMID: 20625121.
 74. Phan J, Mazloom A, Medeiros LJ, Zreik TG, Wogan C, Shihadeh F, Rodriguez MA, Fayad L, Fowler N, Reed V, Horace P, Dabaja BS. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. *J Clin Oncol* 28(27):4170-6, 9/2010. e-Pub 8/2010. PMID: 20713859.
 75. Jones JA, Fayad LE, Elting LS, Rodriguez MA. Body mass index and outcomes in patients receiving chemotherapy for intermediate-grade B-cell non-Hodgkin lymphoma. *Leuk Lymphoma* 51(9):1649-57, 9/2010. PMID: 20807093.
 76. Mazloom A, Medeiros LJ, McLaughlin PW, Reed V, Cabanillas FF, Fayad LE, Pro B, Gonzalez G, Iyengar P, Urbauer DL, Dabaja BS. Marginal zone lymphomas: factors that affect the final outcome. *Cancer* 116(18):4291-8, 9/2010. e-Pub 6/2010. PMID: 20549822.
 77. Zhou X, Teegala S, Huen A, Ji Y, Fayad L, Hagemester FB, Gladish G, Vadhan-Raj S. Incidence and risk factors of venous thromboembolic events in lymphoma. *Am J Med* 123(10):935-41, 10/2010. PMID: 20920696.
 78. Romaguera JE, Fayad LE, McLaughlin P, Pro B, Rodriguez A, Wang M, Weaver P, Hartig K, Kwak LW, Feldman T, Smith J, Ford P, Goldberg S, Pecora A, Goy A. Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma. *Br J Haematol* 151(1):47-53, 10/2010. e-Pub 8/2010. PMID: 20735402.
 79. Chen Z, Ayala P, Wang M, Fayad L, Katz RL, Romaguera J, Caraway N, Neelapu SS, Kwak LW, Simmons PJ, McCarty N. Prospective isolation of clonogenic mantle cell lymphoma-initiating cells. *Stem Cell Res* 5(3):212-25, 11/2010. e-Pub 8/2010. PMID: PMC2952723.
 80. Greaves WO, Bueso-Ramos C, Fayad L. Classical Hodgkin's Lymphoma Associated With Langerhans Cell Histiocytosis: Multiagent Chemotherapy Resulted in Histologic Resolution of Both the Classical Hodgkin's Lymphoma and Langerhans Cell Proliferation Components. *J Clin Oncol* 29(4):e76-8, 2/2011. e-Pub 11/2010. PMID: 21041711.
 81. Thomas DA, O'Brien S, Faderl S, Manning JT, Romaguera J, Fayad L, Hagemester F, Medeiros J, Cortes J, Kantarjian H. Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases? *Curr Hematol Malig Rep* 6(1):58-66, 3/2011. PMID: 21191675.

82. Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen LJ, Tsien C, Vose JM, Wierda WG, Yahalom J, Zafar N. Non-Hodgkin's Lymphomas. *J Natl Compr Canc Netw* 9(5):484-560, 5/2011. PMID: 21550968.
83. Fanale M, Fayad L, Pro B, Samaniego F, Liboon MJ, Nunez C, Horowitz S, Anderlini P, Popat U, Ji Y, Kwak LW, Younes A. Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma. *Br J Haematol* 154(2):284-6, 7/2011. e-Pub 4/2011. PMID: 21517809.
84. Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez MA, Hagemeister FB, Buesco-Ramos CE, Zhou X, McLaughlin PW, Fowler N, Shah JJ, Orlowski RZ, Samaniego F, Wang M, Cortes JE, Younes A, Kwak LW, Sarlis NJ, Romaguera JE. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. *Ann of Oncol* 10:1093, 10/2011.
85. Jones RJ, Baladandayuthapani V, Neelapu S, Fayad LE, Romaguera JE, Wang M, Sharma R, Yang D, Orlowski RZ. HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma. *Blood* 118(15):4140-9, 10/2011. e-Pub 8/2011. PMID: 21844567.
86. Srokowski TP, Liebmann JE, Modiano MR, Cohen GI, Pro B, Romaguera JE, Kuepfer C, Singer JW, Fayad LE. Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: Phase 1 Study With a Dose-Expansion Cohort. *Cancer* 117(22):5067-73, 11/2011. e-Pub 6/2011. PMID: 21681734.
87. Li S, Lin P, Fayad LE, Lennon PA, Miranda RN, Yin CC, Lin E, Medeiros LJ. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. *Mod Pathol* 25(1):145-56, 1/2012. e-Pub 10/2011. PMID: 22002575.
88. Shah N, Cabanillas F, McIntyre B, Feng L, McLaughlin P, Rodriguez MA, Romaguera J, Younes A, Hagemeister FB, Kwak L, Fayad L. Prognostic value of serum CD44, ICAM-1 and VCAM-1 levels in patients with indolent non-Hodgkin's lymphomas. *Leuk Lymphoma* 53(1):50-6, 1/2012. e-Pub 10/2011. PMID: 21895545.
89. Jung HJ, Chen Z, Fayad L, Wang M, Romaguera J, Kwak LW, McCarty N. Bortezomib-resistant nuclear factor κB expression in stem-like cells in mantle cell lymphoma. *Exp Hematol* 40(2):107-18.e2, 2/2012. e-Pub 10/2011. PMID: 22024108.
90. Jung HJ, Chen Z, Wang M, Fayad L, Romaguera J, Kwak LW, McCarty N. Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma (MCL) via manipulation of tissue transglutaminase activities. *Blood* 119(11):2568-78, 3/2012. e-Pub 1/2012. PMID: 22294726.
91. Oki Y, Copeland A, Hagemeister F, Fayad LE, Fanale M, Romaguera J, Younes A. Experience with obatoclox mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma. *Blood* 119(9):2171-2, 3/2012. PMID: 22383790.
92. Lin P, Dickason TJ, Fayad LE, Lennon PA, Hu P, Garcia M, Routbort MJ, Miranda R, Wang X, Qiao W, Medeiros LJ. Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. *Cancer* 118(6):1566-73, 3/2012. e-Pub 8/2011. PMID: 21882178.
93. Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebriaei P, Rytting M, York S, Ravandi F, Kwari M, Faderl S, Rios MB, Cortes J, Fayad L, Tarnai R, Wang SA, Champlin R, Advani A, O'Brien S. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. *Lancet Oncol* 13(4):403-11, 4/2012. e-Pub 2/2012. PMID: 22357140.
94. Czuczman MS, Fayad L, Delwail V, Cartron G, Jacobsen E, Kuliczowski K, Link BK, Pinter-Brown L, Radford J, Hellmann A, Gallop-Evans E, Dirienzo CG, Goldstein N, Gupta I, Jewell RC, Lin TS, Lisby S, Schultz M, Russell CA, Hagenbeek A, on behalf of the 405 Study Investigators. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. *Blood* 119(16):3698-3704, 4/2012. e-Pub 3/2012. PMID: 22389254.

95. Oki Y, Copeland A, Romaguera J, Fayad L, Fanale M, Faria Sde C, Medeiros LJ, Ivy P, Younes A. Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphoma. *Leuk Lymphoma* 53(5):990-2, 5/2012. e-Pub 3/2012. PMID: 21988665.
96. Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Dabaja BS, Rodriguez MA, Dang N, Kwak LW, Neelapu SS, Fayad LE. Phase II study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. *Blood* 119(18):4123-8, 5/2012. e-Pub 2/2012. PMCID: PMC3359733.
97. Weng J, Rawal S, Park HJ, Sharma R, Fayad LE, Fanale M, Romaguera JE, Luong A, Kwak LW, Neelapu SS. TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas. *Blood*, 5/2012.
98. Wang M, Fayad LE, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, Samaniego F, McLaughlin P, Fanale M, Younes A, Cabanillas F, Fowler N, Newberry KJ, Sun L, Young KH, Champlin R, Kwak LW, Feng L, Badillo M, Bejarano M, Hartig K, Chen W, Chen Y, Byrne C, Bell N, Zeldis J, Romaguera JE. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. *Lancet Oncology* 13(7):716-723, 6/2012.
99. Aladily TN, Medeiros LJ, Amin MB, Haideri N, Ye D, Azevedo SJ, Jorgensen JL, de Peralta-Venturina M, Mustafa EB, Young KH, You MJ, Fayad LE, Blenc AM, Miranda RN. Anaplastic Large Cell Lymphoma Associated With Breast Implants: A Report of 13 Cases. *Am J Surg Pathol* 36(7):1000-1008, 7/2012. PMID: 22613996.
100. Chen Z, Romaguera J, Wang M, Fayad L, Kwak LW, McCarty N. Verapamil synergistically enhances cytotoxicity of bortezomib in mantle cell lymphoma via induction of reactive oxygen species production. *Br J Haematol* 159(2):243-6, 10/2012. e-Pub 8/2012. PMCID: PMC3460105.
101. Batty N, Ghonimi E, Feng L, Fayad L, Younes A, Rodriguez MA, Romaguera JE, McLaughlin P, Samaniego F, Kwak LW, Hagemeister FB. The Absolute Monocyte and Lymphocyte Prognostic Index for Patients With Diffuse Large B-Cell Lymphoma Who Receive R-CHOP. *Clin Lymphoma Myeloma Leuk*. e-Pub 11/2012. PMID: 23137719.
102. Fayad LE, Offner F, Smith MR, Verhoef G, Johnson P, Kaufman JL, Rohatiner A, Advani A, Foran J, Hess G, Coiffier B, Czuczman M, Giné E, Durrant S, Kneissl M, Luu KT, Hua SY, Boni J, Vandendries E, Dang NH. Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab. *J Clin Oncol*. e-Pub 1/2013. PMID: 23295790.
103. Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen L, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer MA, Naganuma M. Non-Hodgkin's Lymphomas, Version 1.2013. *J Natl Compr Canc Netw* 11(3):257-273, 3/2013. PMID: 23486452.
104. Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera JE, Neelapu SS, Hagemeister F, Fanale M, McLaughlin P, Oki Y, Pro B, Rodriguez MA, Shah J, Thomas S, Younes A, Hosing C, Zhang L, Newberry K, Desai M, Badillo M, Bejarano M, Sun L, Young KH, Samuel C, Hartig K, Chen W, Byrne C, Bell N, Takashida K, Champlin R, Kwak L, Fayad L. Lenalidomide in combination with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma, follicular grade 3 lymphoma, and transformed B cell lymphoma: a phase 2 clinical trial. *Leukemia*, 4/2013. e-Pub 4/2013. PMID: 23545991.
105. Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera JE, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B, Shah J, Thomas S, Younes A, Hosing C, Zhang L, Newberry KJ, Desai M, Cheng N, Badillo M, Bejarano M, Chen Y, Young KH, Champlin R, Kwak L, Fayad LE. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular, and transformed lymphoma: a phase II clinical trial. *Leukemia*, 4/2013. e-Pub 4/2013. PMID: 23545991.

106. Westin JR, Thompson MA, Cataldo VD, Fayad LE, Fowler N, Fanale MA, Neelapu S, Samaniego F, Romaguera J, Shah J, McLaughlin P, Pro B, Kwak LW, Sanjorjo P, Murphy WA, Jimenez C, Toth B, Dong W, Hagemester FB. Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial. *Clin Lymphoma Myeloma Leuk* 13(2):99-105, 4/2013. e-Pub 12/2012. PMID: 23276888.
107. Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani S, van de Velde H, Qin X, Puchalski TA, Hall B, Reddy M, Qi M, Van Rhee F. A Phase I, Open-Label Study of Siltuximab, an Anti-IL-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease. *Clin Cancer Res*. e-Pub 5/2013. PMID: 23659971.
108. Matasar MJ, Czuczman MS, Rodriguez MA, Fennessy M, Shea TC, Spitzer G, Lossos IS, Kharfan-Dabaja MA, Joyce R, Fayad L, Henkel K, Liao Q, Edvardsen K, Jewell RC, Fecteau D, Singh RP, Lisby S, Moskowitz CH. Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. *Blood*. e-Pub 5/2013. PMID: 23692856.
109. Hagemester F, Rodriguez MA, Deitcher SR, Younes A, Fayad LE, Goy A, Dang NH, Forman A, McLaughlin P, Medeiros LJ, Pro B, Romaguera JE, Samaniego F, Silverman JA, Sarris A, Cabanillas F. Long term results of a phase 2 study of vincristine sulfate liposome injection (marqibo) substituted for non-liposomal vincristine in CHOP with or without rituximab for patients with untreated aggressive non-hodgkin's lymphomas. *Br J Haematol*, 6/2013. e-Pub 6/2013. PMID: 238027358.
110. Oki Y, Younes A, Copeland A, Hagemester F, Fayad LE, McLaughlin P, Shah J, Fowler N, Romaguera J, Kwak LW, Pro B. Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma. *Br J Haematol* 162(1):138-41, 7/2013. e-Pub 4/2013. PMID: 23590726.
111. Loo EY, Medeiros LJ, Aladily TN, Hoehn D, Kanagal-Shamanna R, Young KH, Lin P, Bueso-Ramos CE, Manning JT, Patel K, Thomazy V, Brynes RK, Goswami M, Fayad LE, Miranda RN. Classical hodgkin lymphoma arising in the setting of iatrogenic immunodeficiency: a clinicopathologic study of 10 cases. *Am J Surg Pathol* 37(8):1290-7, 8/2013. e-Pub 6/2013. PMID: 23774171.
112. Romaguera JE, Fayad LE, Wang M, McLaughlin PW, Neelapu S. Nuclear Translocation of B-cell specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma. *PLOS one*, 9/2013. PMID: 23936317.
113. Jain P, Fayad LE, Rosenwald A, Young KH, O'Brien S. Recent advances in de novo CD5(+) Diffuse Large B cell Lymphoma (DLBCL). *Am J Hematol* 88(9):798-802, 9/2013. e-Pub 6/2013. PMID: 23695956.
114. Dabaja BS, Phan J, Mawlawi O, Medeiros LJ, Etzel C, Liang FW, Podoloff D, Oki Y, Hagemester FB, Chuang H, Fayad LE, Westin JR, Shihadeh F, Allen PK, Wogan CF, Rodriguez MA. Clinical Implications of PET-Negative Residual CT Masses after Chemotherapy for Diffuse Large B-Cell Lymphoma. *Leuk Lymphoma* 54(12):2631-8, 12/2013. e-Pub 5/2013. PMID: PMC3827734.
115. Oki Y, Buglio D, Fanale M, Fayad L, Copeland A, Romaguera J, Kwak LW, Pro B, de Castro Faria S, Neelapu S, Fowler N, Hagemester F, Zhang J, Zhou S, Feng L, Younes A. Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma. *Clin Cancer Res* 19(24):6882-90, 12/2013. e-Pub 10/2013. PMID: 24097867.
116. Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S, Hagemester FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. *Br J Haematol* 163(5):611-20, 12/2013. e-Pub 10/2013. PMID: 24117234.
117. Miranda RN, Aladily TN, Prince HM, Kanagal-Shamanna R, de Jong D, Fayad LE, Amin MB, Haideri N, Bhagat G, Brooks GS, Shifrin DA, O'Malley DP, Cheah CY, Bacchi CE, Gualco G, Li S, Keech JA, Hochberg EP, Carty MJ, Hanson SE, Mustafa E, Sanchez S, Manning JT, Xu-Monette ZY, Miranda AR, Fox P, Bassett RL, Castillo JJ, Beltran BE, de Boer JP,

- Chakhachiro Z, Ye D, Clark D, Young KH, Medeiros LJ. Breast Implant-Associated Anaplastic Large-Cell Lymphoma: Long-Term Follow-Up of 60 Patients. *J Clin Oncol* 32(2):114-20, 1/2014. e-Pub 12/2013. PMID: 24323027.
118. Bollard CM, Gottschalk S, Torrano V, Diouf O, Ku S, Hazrat Y, Carrum G, Ramos C, Fayad L, Shpall EJ, Pro B, Liu H, Wu MF, Lee D, Sheehan AM, Zu Y, Gee AP, Brenner MK, Heslop HE, Rooney CM. Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins. *J Clin Oncol* 32(8):798-808, 3/2014. e-Pub 12/2013. PMID: PMC3940538.
 119. Westin J, Oki Y, Fayad L. Could treatment with R-HCVAD/R-MA as compared to R-CHOP truly result in improved outcomes for patients with high-risk diffuse large B cell lymphoma? - Response to Landsburg et al. *Br J Haematol* 165(1):146-7, 4/2014. e-Pub 12/2013. PMID: 24329994.
 120. Oki Y, Chuang H, Chasen B, Jessop A, Pan T, Fanale M, Dabaja B, Fowler N, Romaguera J, Fayad L, Hagemester F, Rodriguez MA, Neelapu S, Samaniego F, Kwak L, Younes A. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. *Br J Haematol* 165(1):112-6, 4/2014. e-Pub 1/2014. PMID: 24386943.
 121. Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Sokol L, Swinnen LJ, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H. Non-Hodgkin's Lymphomas, Version 2.2014. *J Natl Compr Canc Netw* 12(6):916-46, 6/2014. PMID: 24925202.
 122. Dabaja BS, Hess K, Shihadeh F, Podoloff DA, Medeiros LJ, Mawlawi O, Arzu I, Oki Y, Hagemester FB, Fayad LE, Reed VK, Kadir A, Wogan CF, Rodriguez A. Positron Emission Tomography/Computed Tomography Findings During Therapy Predict Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemotherapy Alone but Not in Those Who Receive Consolidation Radiation. *Int J Radiat Oncol Biol Phys* 89(2):384-91, 6/2014. e-Pub 4/2014. PMID: 24721592.
 123. Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemester FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JR. Double Hit Lymphoma: the MD Anderson Cancer Center clinical experience. *Br J Haematol* 166(6):891-901, 9/2014. e-Pub 6/2014. PMID: 24943107.
 124. Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Saad AA, Sokol L, Swinnen LJ, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H. Non-Hodgkin's Lymphomas, Version 4.2014. *J Natl Compr Canc Netw* 12(9):1282-303, 9/2014. PMID: 25190696.
 125. Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemester FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlovski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. *Lancet Oncol* 15(12):1311-8, 11/2014. e-Pub 10/2014. PMID: 25439689.
 126. Fayad L, Ansell SM, Advani R, Coiffier B, Stuart R, Bartlett NL, Forero-Torres A, Kuliczowski K, Belada D, Ng E, Drachman JG. Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. *Leuk Lymphoma*:1-10. e-Pub 2/2015. PMID: 25651427.
 127. Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Saad AA, Sokol L, Swinnen LJ, Tsien C, Vose JM, Wilson L, Yahalom J, Zafar N, Dwyer M, Sundar H. Chronic lymphocytic leukemia/small

- lymphocytic lymphoma, version 1.2015. *J Natl Compr Canc Netw* 13(3):326-62, 3/2015. PMID: 25736010.
128. Oki Y, Ewer MS, Lenihan DJ, Fisch MJ, Hagemeister FB, Fanale M, Romaguera J, Pro B, Fowler N, Younes A, Astrow AB, Huang X, Kwak LW, Samaniego F, McLaughlin P, Neelapu SS, Wang M, Fayad LE, Durand JB, Rodriguez MA. Pegylated Liposomal Doxorubicin Replacing Conventional Doxorubicin in Standard R-CHOP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma: An Open Label, Single Arm, Phase II Trial. *Clin Lymphoma Myeloma Leuk* 15(3):152-8, 3/2015. e-Pub 9/2014. PMID: PMC4344896.
 129. Tao R, Allen PK, Rodriguez A, Shihadeh F, Pinnix CC, Arzu I, Reed VK, Oki Y, Westin JR, Fayad LE, Medeiros LJ, Dabaja B. Benefit of Consolidative Radiation Therapy for Primary Bone Diffuse Large B-Cell Lymphoma. *Int J Radiat Oncol Biol Phys* 92(1):122-9, 5/2015. e-Pub 3/2015. PMID: 25754633.
 130. Beitinjaneh A, Saliba RM, Medeiros LJ, Turturro F, Rondon G, Korbling M, Fayad L, Fanale MA, Alousi AM, Anderlini P, Betul O, Popat UR, Pro B, Khouri IF. Comparison of Survival in Patients with T Cell Lymphoma after Autologous and Allogeneic Stem Cell Transplantation as a Frontline Strategy or in Relapsed Disease. *Biol Blood Marrow Transplant* 21(5):855-9, 5/2015. e-Pub 1/2015. PMID: PMC4408269.
 131. Pinnix CC, Smith GL, Milgrom S, Osborne EM, Reddy JP, Akhtari M, Reed V, Arzu I, Allen PK, Wogan CF, Fanale MA, Oki Y, Turturro F, Romaguera J, Fayad L, Fowler N, Westin J, Nastoupil L, Hagemeister FB, Rodriguez MA, Ahmed S, Nieto Y, Dabaja B. Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma. *Int J Radiat Oncol Biol Phys* 92(1):175-82, 5/2015. PMID: PMC4418193.
 132. Pinnix CC, Dabaja B, Ahmed MA, Chuang HH, Costelloe C, Wogan CF, Reed V, Romaguera JE, Neelapu S, Oki Y, Rodriguez MA, Fayad L, Hagemeister FB, Nastoupil L, Turturro F, Fowler N, Fanale MA, Nieto Y, Khouri IF, Ahmed S, Medeiros LJ, Davis RE, Westin J. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography. *Int J Radiat Oncol Biol Phys* 92(1):113-21, 5/2015. PMID: PMC4418191.
 133. Oki Y, Neelapu SS, Fanale M, Kwak LW, Fayad L, Rodriguez MA, Wallace M, Klinger M, Carlton V, Kong K, Faham M, Younes A. Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach. *Br J Haematol* 169(5):689-93, 6/2015. e-Pub 3/2015. PMID: 25818067.
 134. Samaniego F, Hagemeister F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad L, Younes A, Feng L, Berkova Z, Khashab T, Sehgal L, Vega-Vasquez F, Kwak LW. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas. *Br J Haematol* 169(6):814-23, 6/2015. e-Pub 3/2015. PMID: 25828695.
 135. van Rhee F, Casper C, Voorhees PM, Fayad LE, van de Velde H, Vermeulen J, Qin X, Qi M, Tromp B, Kurzrock R. A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease. *Oncotarget* 6(30):30408-19, 10/2015. e-Pub 8/2015. PMID: 26327301.
 136. Karuturi M, Younes A, Fayad L, Kwak L, Pro B, Shah J, Oki Y, Simien R, Liboon MJ, Hutto T, Feng L, Horowitz S, Nieto Y, Anderlini P, Alousi A, Popat U, Medeiros LJ, Miranda R, Fanale M. ICE (Ifosfamide, Carboplatin, Etoposide) with or without Bortezomib in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of a Randomized Phase II Trial. *Leuk Lymphoma*:1-8. e-Pub 10/2015. PMID: 25804933.
 137. Sehn LH, Goy A, Offner FC, Martinelli G, Caballero MD, Gadeberg O, Baetz T, Zelenetz AD, Gaidano G, Fayad LE, Buckstein R, Friedberg JW, Crump M, Jaksic B, Zinzani PL, Padmanabhan Iyer S, Sahin D, Chai A, Fingerle-Rowson G, Press OW. Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study. *J Clin Oncol* 33(30):3467-74, 10/2015. e-Pub 8/2015. PMID: 26282650.
 138. Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MV,

- Mohseni M, Lawson D, Reimer C, Blakey DC, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. *Sci Transl Med* 7(314):314ra185, 11/2015. PMID: 26582900.
139. Fowler NH, Nastoupil LJ, Hagemester FB, Neelapu SS, Fayad LE, LeBlanc D, Samaniego F, Cheah CY. Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma. *Haematologica* 100(11):e454-7, 11/2015. e-Pub 8/2015. PMID: 26250576.
 140. Jain P, Verstovsek S, Loghavi S, Jorgensen JL, Patel KP, Estrov Z, Fayad L, Pemmaraju N. Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis -TAFRO syndrome. *Am J Hematol* 90(11):1091-2, 11/2015. e-Pub 4/2015. PMID: PMC4580493.
 141. Wang ML, Lee H, Chuang H, Wagner-Bartak N, Hagemester F, Westin J, Fayad L, Samaniego F, Turturro F, Oki Y, Chen W, Badillo M, Nomie K, Rosa MD, Zhao D, Lam L, Addison A, Zhang H, Young KH, Li S, Santos D, Medeiros LJ, Champlin R, Romaguera J, Zhang L. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. *Lancet Oncol*. e-Pub 11/2015. PMID: 26640039.
 142. Oki Y, Fanale M, Romaguera J, Fayad L, Fowler N, Copeland A, Samaniego F, Kwak LW, Neelapu S, Wang M, Feng L, Younes A. Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. *Br J Haematol* 171(4):463-70, 11/2015. e-Pub 7/2015. PMID: 26213141.
 143. Chihara D, Pro B, Loghavi S, Miranda RN, Medeiros LJ, Fanale MA, Hagemester FB, Fayad LE, Romaguera JE, Samaniego F, Neelapu SS, Younes A, Fowler NH, Rodriguez MA, Wang M, Kwak LW, McLaughlin P, Dang NH, Oki Y. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. *Br J Haematol* 171(4):509-16, 11/2015. e-Pub 8/2015. PMID: 26260306.
 144. Mathur R, Sehgal L, Braun FK, Berkova Z, Romaguerra J, Wang M, Rodriguez MA, Fayad L, Neelapu SS, Samaniego F. Targeting Wnt pathway in mantle cell lymphoma-initiating cells. *J Hematol Oncol* 8:63, 2015. e-Pub 6/2015. PMID: PMC4460883.
 145. Hainsworth JD, Arrowsmith ER, McCleod M, Hsi ED, Hamid O, Shi P, Lin BK, Fayad LE. An open-label, randomized, phase 2 Study of R-CHOP plus enzastaurin versus R-CHOP in the first-line treatment of patients with intermediate- or high-risk diffuse large B-cell lymphoma. *Leuk Lymphoma* 57(1):1-11, 1/2016. e-Pub 10/2015. PMID: 25956042.
 146. Cheah CY, Chihara D, Ahmed M, Davis RE, Nastoupil LJ, Phansalkar K, Hagemester FB, Fayad LE, Westin JR, Oki Y, Fanale MA, Romaguera JE, Wang ML, Lee H, Turturro F, Samaniego F, Rodriguez MA, Neelapu SS, Fowler NH. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. *Ann Oncol*. e-Pub 1/2016. PMID: 26802151.
 147. Chihara D, Cheah CY, Westin JR, Fayad LE, Rodriguez MA, Hagemester FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak LW, Wang ML, Romaguera JE. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. *Br J Haematol* 172(1):80-8, 1/2016. e-Pub 12/2015. PMID: 26648336.
 148. Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Lunning M, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H. Diffuse Large B-Cell Lymphoma Version 1.2016. *J Natl Compr Canc Netw* 14(2):196-231, 2/2016. PMID: 26850490.
 149. Minamimoto R, Fayad L, Advani R, Vose J, Macapinlac H, Meza J, Hankins J, Mottaghy F, Juweid M, Quon A. Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring. *Radiology*:150689. e-Pub 2/2016. PMID: 26854705.

150. Pinnix CC, Shah JJ, Chuang H, Costelloe CM, Medeiros LJ, Wogan CF, Reed V, Smith GL, Milgrom S, Patel K, Huo J, Turturro F, Romaguera J, Fayad L, Oki Y, Fanale MA, Westin J, Nastoupil L, Hagemeister FB, Rodriguez A, Qazilbash M, Shah N, Bashir Q, Ahmed S, Nieto Y, Hosing C, Rohren E, Dabaja B. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. *Clin Lymphoma Myeloma Leuk* 16(3):122-8, 3/2016. e-Pub 12/2015. PMID: 26795083.
151. Cheah CY, Chihara D, Horowitz S, Sevin A, Oki Y, Zhou S, Fowler NH, Romaguera JE, Turturro F, Hagemeister FB, Fayad LE, Wang M, Neelapu SS, Nastoupil LJ, Westin JR, Rodriguez MA, Samaniego F, Anderlini P, Nieto Y, Fanale MA. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. *Ann Oncol*. e-Pub 4/2016. PMID: 27091808.
152. Lenihan DJ, Stevens PL, Massey M, Plana JC, Araujo DM, Fanale MA, Fayad LE, Fisch MJ, Yeh ET. The Utility of Point of Care Biomarkers to Detect Cardiotoxicity during Anthracycline Chemotherapy: A Feasibility Study. *J Card Fail* 22(6):433-8, 6/2016. e-Pub 4/2016. PMID: 27079675.
153. Pinnix CC, Osborne EM, Chihara D, Lai P, Zhou S, Ramirez MM, Oki Y, Hagemeister FB, Rodriguez AM, Samaniego F, Fowler N, Romaguera JE, Turturro F, Fayad L, Westin JR, Nastoupil L, Neelapu SS, Cheah CY, Dabaja BS, Milgrom SA, Smith GL, Horace P, Milbourne A, Wogan CF, Ballas L, Fanale MA. Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy. *JAMA Oncol* 2(8):1065-9, 8/2016. PMID: 27227654.
154. Horwitz SM, Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Hoppe RT, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Lunning M, Nademanee A, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H, Porcu P. NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. *J Natl Compr Canc Netw* 14(9):1067-79, 9/2016. PMID: 27587620.
155. Thuro BA, Ning J, Peng SA, Pace ST, Dudeja G, Ozgur O, Turturro F, Samaniego F, Hagemeister FB, Fayad LE, Fowler NH, Pinnix CC, Debnam JM, Esmaeli B. Rates of Positive Findings on Positron Emission Tomography and Bone Marrow Biopsy in Patients With Ocular Adnexal Lymphoma. *Ophthal Plast Reconstr Surg*. e-Pub 9/2016. PMID: 27636243.
156. Chihara D, Westin JR, Oki Y, Ahmed MA, Do B, Fayad LE, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu SS, Rodriguez MA, Fowler NH, Wang M, Davis RE, Nastoupil LJ. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. *Cancer* 122(20):3145-3151, 10/2016. e-Pub 6/2016. PMID: 27351173.
157. Chen Y, Neelapu S, Feng L, Bi W, Yang TH, Wang M, Fanale MA, Westin JR, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Fowler NH, McLaughlin P, Cabanillas F, Oki Y, Nastoupil LJ, Rodriguez A. Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β 2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model. *Br J Haematol* 175(2):290-299, 10/2016. e-Pub 7/2016. PMID: 27448187.
158. Cheah CY, Nastoupil LJ, McLaughlin P, Fanale MA, Neelapu SS, Fayad LE, Hagemeister FB, Fowler NH. Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity. *Br J Haematol* 175(3):531-533, 11/2016. e-Pub 12/2015. PMID: 26683805.
159. Wierda WG, Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Caimi P, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Martin MG, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Snyder ED, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Dwyer MA, Sundar H.

- NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017. *J Natl Compr Canc Netw* 15(3):293-311, 3/2017. PMID: 28275031.
160. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Hosing C, Nieto YL, Oki Y. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. *Br J Haematol* 176(5):750-758, 3/2017. e-Pub 12/2016. PMID: 27983760.
 161. Lee HJ, Romaguera JE, Feng L, Desai AP, Zhang L, Fanale M, Samaniego F, Hagemeister FB, Fayad LE, Rodriguez MA, Medeiros JL, Hartig K, Nomie K, Ahmed M, Badillo M, Ye H, Oki Y, Lin P, Nastoupil L, Westin J, Wang M. Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma. *Oncologist* 22(5):549-553, 5/2017. e-Pub 4/2017. PMID: PMC5423503.
 162. Fanale MA, Cheah CY, Rich A, Medeiros LJ, Lai CM, Oki Y, Romaguera JE, Fayad LE, Hagemeister FB, Samaniego F, Rodriguez MA, Neelapu SS, Lee HJ, Nastoupil L, Fowler NH, Turturro F, Westin JR, Wang ML, McLaughlin P, Pinnix CC, Milgrom SA, Dabaja B, Horowitz SB, Younes A. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma. *Blood* 130(4):472-477, 7/2017. e-Pub 5/2017. PMID: PMC5578726.
 163. Chihara D, Westin JR, Miranda RN, Cheah CY, Oki Y, Turturro F, Romaguera JE, Neelapu SS, Nastoupil LJ, Fayad LE, Rodriguez MA, Fowler NH, Orlowski RZ, Wang M, Hagemeister FB, Medeiros LJ, Fanale MA. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma. *Br J Haematol* 179(3):503-506, 11/2017. e-Pub 7/2016. PMID: 27378601.
 164. Milgrom SA, Pinnix CC, Chuang H, Oki Y, Akhtari M, Mawlawi O, Garg N, Gunther JR, Reddy JP, Smith GL, Rohren E, Hagemeister FB, Lee HJ, Fayad LE, Dong W, Osborne EM, Abou Yehia Z, Fanale M, Dabaja BS. Early-stage Hodgkin lymphoma outcomes after combined modality therapy according to the post-chemotherapy 5-point score: can residual pet-positive disease be cured with radiotherapy alone? *Br J Haematol* 179(3):488-496, 11/2017. e-Pub 8/2017. PMID: 28832956.
 165. Chihara D, Fowler NH, Oki Y, Fanale MA, Fayad LE, Westin JR, Hagemeister FB. Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement. *Br J Haematol* 179(5):851-854, 12/2017. e-Pub 8/2016. PMID: 27502933.
 166. Ho JC, Dabaja BS, Milgrom SA, Smith GL, Reddy JP, Mazloom A, Young KH, Deng L, Medeiros LJ, Dong W, Allen PK, Andraos TY, Fowler NH, Nastoupil LJ, Oki Y, Fayad LE, Turturro F, Neelapu SS, Westin J, Hagemeister FB, Rodriguez MA, Pinnix CC. Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma(). *Leuk Lymphoma* 58(12):1-12, 12/2017. e-Pub 5/2017. PMID: 28482717.
 167. Strati P, Fowler N, Pina-Oviedo S, Medeiros LJ, Overman MJ, Romaguera JE, Nastoupil L, Wang M, Hagemeister FB, Rodriguez A, Oki Y, Westin J, Turturro F, Neelapu SS, Fayad L. Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP. *Clin Lymphoma Myeloma Leuk* 18(1):e103-e108, 1/2018. e-Pub 11/2017. PMID: 29196178.
 168. Hu B, Younes A, Westin JR, Turturro F, Claret L, Feng L, Fowler N, Neelapu S, Romaguera J, Hagemeister FB, Rodriguez MA, Samaniego F, Fayad LE, Copeland AR, Nastoupil LJ, Nieto Y, Fanale MA, Oki Y. Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma. *Leuk Lymphoma* 59(4):863-870, 4/2018. e-Pub 8/2017. PMID: 28792260.
 169. Milgrom SA, Pinnix CC, Chi TL, Vu TH, Gunther JR, Sheu T, Fowler N, Westin JR, Nastoupil LJ, Oki Y, Fayad LE, Neelapu S, Rodriguez MA, Hagemeister FB, Fanale MA, Lee HJ, Hosing C, Ahmed S, Nieto Y, Shpall EJ, Dabaja BS. Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma. *Int J Radiat Oncol Biol Phys* 100(5):1146-1154, 4/2018. e-Pub 1/2018. PMID: 29452771.

170. Jain P, Romaguera J, Srour SA, Lee HJ, Hagemeister F, Westin J, Fayad L, Samaniego F, Badillo M, Zhang L, Nastoupil L, Kanagal-Shamanna R, Fowler N, Wang ML. Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). *Br J Haematol*. e-Pub 5/2018. PMID: 29785709.
171. Chahoud J, Sui D, Erwin WD, Gulbis AM, Korbling M, Zhang M, Ahmed S, Alatrash G, Anderlini P, Ciurea SO, Oran B, Fayad LE, Bassett RL, Jabbour EJ, Medeiros LJ, Macapinlac HA, Young KH, Khouri IF. Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma. *Clin Cancer Res* 24(10):2304-2311, 5/2018. e-Pub 2/2018. PMCID: PMC5955837.
172. Chihara D, Fowler NH, Oki Y, Fanale MA, Nastoupil LJ, Westin JR, Fayad LE, Neelapu SS, Cheah CY. Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis. *Oncotarget* 9(48):28897-28902, 6/2018. e-Pub 6/2018. PMCID: PMC6034756.
173. Romaguera JE, Wang M, Feng L, Fayad LE, Hagemeister F, McLaughlin P, Rodriguez MA, Fanale M, Orlowski R, Kwak LW, Neelapu S, Oki Y, Pro B, Younes A, Samaniego F, Fowler N, Hartig K, Valentinetti M, Smith J, Ford P, Naig A, Medeiros LJ, Kantarjian HM, Goy A. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. *Cancer* 124(12):2561-2569, 6/2018. e-Pub 5/2018. PMID: 29723393.
174. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Ju Lee H, Oki Y, Wang M, Samaniego F, Chi L, Esmali B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. *Head Neck* 40(6):1335, 6/2018. e-Pub 2/2018. PMID: 29851218.
175. Pinnix CC, Cella L, Andraos TY, Ayoub Z, Milgrom SA, Gunther J, Thosani S, Wogan C, Conson M, D'Avino V, Oki Y, Fanale M, Lee HJ, Neelapu S, Fayad L, Hagemeister F, Rodriguez MA, Nastoupil LJ, Nieto Y, Qiao W, Pacelli R, Dabaja B. Predictors of Hypothyroidism in Hodgkin Lymphoma Survivors After Intensity Modulated Versus 3-Dimensional Radiation Therapy. *Int J Radiat Oncol Biol Phys* 101(3):530-540, 7/2018. e-Pub 3/2018. PMID: 29681481.
176. Sagiv O, Thakar SD, Manning JT, Kandl TJ, Fayad LE, Fowler N, Hagemeister FB, Fanale MA, Pinnix CC, Samaniego F, Esmali B. Prevalence of a Histologic Change of Ocular Adnexal Lymphoma in Patients With a History of Lymphoma. *Ophthalmic Plast Reconstr Surg*. e-Pub 8/2018. PMID: 30124609.
177. Dang NH, Ogura M, Castaigne S, Fayad LE, Jerkeman M, Radford J, Pezzutto A, Bondarenko I, Stewart DA, Shnaidman M, Sullivan S, Vandendries E, Tobinai K, Ramchandren R, Hamlin PA, Giné E, Ando K. Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. *Br J Haematol* 182(4):583-586, 8/2018. e-Pub 7/2017. PMCID: PMC6200343.
178. Strati P, Chihara D, Oki Y, Fayad LE, Fowler N, Nastoupil L, Romaguera JE, Samaniego F, Garg N, Feng L, Wesson ET, Ruben CE, Stafford MD, Nieto Y, Khouri IF, Hosing C, Horowitz SB, Kamble RT, Fanale MA. A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. *Haematologica* 103(9):e416-e418, 9/2018. e-Pub 4/2018. PMCID: PMC6119133.
179. Jain P, Kanagal-Shamanna R, San Lucas FA, Nastoupil L, Romaguera J, Fayad L, Oki Y, Westin JR, Medeiros LJ, Wang M, Fowler N. Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors. *Br J Haematol* 182(5):718-723, 9/2018. e-Pub 8/2017. PMCID: PMC5904008.
180. Sheu T, Milgrom SA, Andraos TY, Gunther JR, Chi L, Nastoupil L, Fowler N, Oki Y, Fanale MA, Fayad LE, Hagemeister F, Neelapu SS, Medeiros LJ, Hosing C, Nieto Y, Ahmed S, Alousi AM, Dabaja B, Pinnix CC. Response-adapted radiation therapy for newly diagnosed

- primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy. *Adv Radiat Oncol* 3(4):639-646, Oct-Dec, 10/2018. e-Pub 7/2018. PMCID: PMC6200878.
181. Jain P, Kanagal-Shamanna R, Zhang S, Ahmed M, Ghorab A, Zhang L, Ok CY, Li S, Hagemeister F, Zeng D, Gong T, Chen W, Badillo M, Nomie K, Fayad L, Medeiros LJ, Neelapu S, Fowler N, Romaguera J, Champlin R, Wang L, Wang ML. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. *Br J Haematol* 183(4):578-587, 11/2018. e-Pub 9/2018. PMID: 30175400.
 182. Reilley MJ, McCoon P, Cook C, Lyne P, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Curran M, Liu Q, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MVP, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR, Hong DS. STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial. *J Immunother Cancer* 6(1):119, 11/2018. e-Pub 11/2018. PMCID: PMC6240242.
 183. Ludmir EB, Milgrom SA, Pinnix CC, Gunther JR, Westin J, Oki Y, Fayad LE, Medeiros LJ, Dabaja BS, Nastoupil LJ. Primary breast diffuse large B-cell lymphoma: treatment strategies and patterns of failure. *Leuk Lymphoma* 59(12):1-8, 12/2018. e-Pub 4/2018. PMID: 29697005.
 184. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Oki Y. The risk of central nervous system relapses in patients with peripheral T-cell lymphoma. *PLoS One* 13(3):e0191461, 2018. e-Pub 3/2018. PMCID: PMC5851529.
 185. Yoder AK, Gunther JR, Milgrom SA, Mirkovic D, Nastoupil L, Neelapu S, Fanale M, Fowler N, Westin J, Lee HJ, Rodriguez MA, Iyer SP, Fayad L, Nieto YL, Hosing C, Ahmed S, Medeiros LJ, Khoury JD, Garg N, Amini B, Dabaja BS, Pinnix CC. Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy. *Clin Lymphoma Myeloma Leuk* 19(1):e51-e61, 1/2019. e-Pub 9/2018. PMID: 30360985.
 186. Strati P, Fanale MA, Oki Y, Turturro F, Fayad LE, Bartlett NL, Gladstone DE, Kasamon YL, Portlock CS, Wilson WH, Goy A, Younes A, Lee HJ. Rituximab with ABVD vs ABVD for advanced stage high-risk classical Hodgkin lymphoma: a randomized phase II study. *Haematologica* 104(2):e65-e67, 2/2019. e-Pub 9/2018. PMCID: PMC6355491.
 187. Ludmir EB, Milgrom SA, Pinnix CC, Gunther JR, Westin J, Fayad LE, Khoury JD, Medeiros LJ, Dabaja BS, Nastoupil LJ. Emerging Treatment Strategies for Primary Breast Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue. *Clin Lymphoma Myeloma Leuk* 19(4):244-250, 4/2019. e-Pub 1/2019. PMID: 30686775.
 188. Sharman JP, Forero-Torres A, Costa LJ, Flinn IW, Inhorn L, Kelly K, Bessudo A, Fayad LE, Kaminski MS, Evens AM, Flowers CR, Sahin D, Mundt KE, Sandmann T, Fingerle-Rowson G, Vignal C, Mobasher M, Zelenetz AD. Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study. *Leuk Lymphoma* 60(4):1-10, 4/2019. e-Pub 10/2018. PMCID: PMC6445782.
 189. Chihara D, Oki Y, Fanale MA, Westin JR, Nastoupil LJ, Neelapu S, Fayad L, Fowler NH, Cheah CY. Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement. *Br J Haematol* 185(2):334-338, 4/2019. e-Pub 7/2018. PMID: 29978452.
 190. Pinnix CC, Milgrom SA, Cheah CY, Gunther JR, Ludmir EB, Wogan CF, Nastoupil LJ, Neelapu SS, Westin J, Lee HJ, Iyer SP, Steiner RE, Fayad LE, Fowler NH, Wang ML, Samaniego F, Rodriguez MA, Rich AE, Medeiros LJ, Dabaja BS. Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma. *Blood Adv* 3(9):1356-1367, 5/2019. PMCID: PMC6517662.
 191. Khashab T, Hagemeister F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad L, Younes A, Feng L, Vega F, Kwak LW, Samaniego F. Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab

- therapy for indolent non-Hodgkin lymphoma. *Br J Haematol* 185(4):670-678, 5/2019. e-Pub 2/2019. PMID: 30820940.
192. Chihara D, Oki Y, Fanale MA, Westin JR, Nastoupil LJ, Neelapu S, Fayad L, Fowler NH, Cheah CY. Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ? *Ann Hematol* 98(5):1169-1176, 5/2019. e-Pub 1/2019. PMID: 30617643.
 193. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Yehia Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemester F, Lee HJ, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. *Head Neck* 41(5):1546, 5/2019. e-Pub 3/2019. PMID: 30990235.
 194. Strati P, Lee ST, Teegavarupu P, Karri A, Anireddy S, Hagemester FB, Romaguera J, Fayad LE, Rodriguez MA, Samaniego F, Fowler N, Westin J, Wang M, Lee HJ, Pinnix C, Gunther JR, Dabaja B, Feng L, Davis RE, Neelapu SS. Frontline antibiotic therapy for early-stage *Helicobacter pylori*-negative gastric MALT lymphoma. *Am J Hematol* 94(6):E150-E153, 6/2019. e-Pub 3/2019. PMID: 30785215.
 195. Becnel MR, Nastoupil LJ, Samaniego F, Davis RE, You MJ, Green M, Hagemester FB, Fanale MA, Fayad LE, Westin JR, Wang M, Oki Y, Forbes SG, Feng L, Neelapu SS, Fowler NH. Lenalidomide plus rituximab (R2) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial. *Br J Haematol* 185(5):874-882, 6/2019. e-Pub 3/2019. PMID: PMC6619290.
 196. Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Bartlett NL, Caimi PF, Chang JE, Chavez JC, Christian B, Fayad LE, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Mehta A, Nademanee A, Rabinovitch R, Reddy N, Reid E, Roberts KB, Smith SD, Snyder ED, Swinnen LJ, Vose JM, Dwyer MA, Sundar H. NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019. *J Natl Compr Canc Netw* 17(6):650-661, 6/2019. PMID: 31200358.
 197. Strati P, Nastoupil LJ, Fayad LE, Samaniego F, Adkins S, Neelapu SS. Safety of CAR T-Cell Therapy in Patients with B-Cell Lymphoma and Chronic Hepatitis B or C Virus Infection. *Blood* 133(26):2800-2802, 6/2019. e-Pub 5/2019. PMID: 31101626.
 198. Saini NY, Saliba RM, Rondon G, Maadani F, Papat U, Hosing CM, Oran B, Bashir Q, Olson A, Nieto Y, Alousi A, Kebriaei P, Srour S, Mehta R, Anderlini P, Shpall EJ, Qazilbash MH, Khouri IF, Fayad L, Lee H, Fowler N, Parmar S, Westin J, Hagemester F, Champlin RE, Ciurea SO. Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. *Biol Blood Marrow Transplant* 25(7):1340-1346, 7/2019. e-Pub 2/2019. PMID: 30763728.
 199. Ayoub Z, Andraos T, Milgrom SA, Pinnix CC, Dabaja BS, Ng SP, Gunther JR, Khoury JD, Fowler NH, Neelapu SS, Samaniego F, Fayad LE, Nastoupil LJ. Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy. *Leuk Lymphoma* 60(10):1-9, 10/2019. e-Pub 4/2019. PMID: 30942648.
 200. Sathyanarayanan V, Issa A, Pinto R, Fayad LE, Loghavi S, Hagemester F, Westin JR. Rosai-Dorfman Disease: The MD Anderson Cancer Center Experience. *Clin Lymphoma Myeloma Leuk* 19(11):709-714, 11/2019. e-Pub 7/2019. PMID: 31446000.
 201. Andraos TY, Ayoub Z, Nastoupil LJ, Milgrom SA, Pinnix CC, Ng SP, Gunther JR, Fowler NH, Neelapu SS, Samaniego F, Fayad LE, Dabaja BS. Additional therapy improves outcomes in completely resected, limited-stage follicular lymphoma. *Leuk Lymphoma* 60(13):1-8, 12/2019. e-Pub 6/2019. PMID: 31234671.
 202. Strati P, Nastoupil LJ, Davis RE, Fayad LE, Fowler N, Hagemester FB, Kwak L, Oki Y, Wang M, Westin J, Ruben CE, Wesson ET, Piekarz R, Fanale MA, Lee HJ. A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas. *Haematologica* 105(1):e26-e28, 1/2020. e-Pub 5/2019. PMID: PMC6939506.
 203. Hu B, Nastoupil LJ, Loghavi S, Westin JR, Thakral B, Fayad LE, Hagemester F, Neelapu S, Samaniego F, Lee HJ, Wang ML, Fanale M, Fowler N, Oki Y. De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era. *Leuk Lymphoma* 61(2):1-9, 2/2020. e-Pub 9/2019. PMID: 31533521.
 204. Jain P, Zhang S, Kanagal-Shamanna R, Ok CY, Nomie K, Gonzalez GN, Gonzalez-Pagan O, Hill HA, Lee HJ, Fayad L, Westin J, Nastoupil L, Hagemester F, Chen W, Oriabure O, Badillo

- M, Jiang C, Yixin Y, Li S, Tang G, Yin CC, Patel KP, Medeiros LJ, Nair R, Ahmed S, Iyer SP, Thirumurthi S, Champlin R, Xu G, Tinsu P, Santos D, Wang R, Han G, Zhang J, Song X, Neelapu S, Romaguera J, Futreal A, Flowers C, Fowler N, Wang L, Wang ML. Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. *Blood Adv* 4(6):1038-1050, 3/2020. PMID: PMC7094021.
205. van Rhee F, Casper C, Voorhees PM, Fayad LE, Gibson D, Kanhai K, Kurzrock R. Long-term safety of siltuximab in patients with idiopathic multicentric Castlemann disease: a prespecified, open-label, extension analysis of two trials. *Lancet Haematol* 7(3):e209-e217, 3/2020. e-Pub 2/2020. PMID: 32027862.
 206. Zhao S, Kanagal-Shamanna R, Navsaria L, Ok CY, Zhang S, Nomie K, Han G, Hao D, Hill HA, Jiang C, Yao Y, Nastoupil L, Westin J, Fayad L, Nair R, Steiner R, Ahmed S, Samaniego F, Iyer SP, Oriabure O, Chen W, Song X, Zhang J, Badillo M, Moghrabi O, Aranda J, Tang G, Yin CC, Patel K, Medeiros LJ, Li S, Vega F, Thirumurthi S, Xu G, Neelapu S, Flowers CR, Romaguera J, Fowler N, Wang L, Wang ML, Jain P. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. *Am J Hematol* 95(6):623-629, 6/2020. e-Pub 4/2020. PMID: 32239765.
 207. Strati P, Ahmed MA, Nastoupil LJ, Feng L, Hagemeister FB, Fayad LE, Rodriguez MA, Samaniego F, Wang M, Westin JR, Lee HJ, Iyer SP, Parmar S, Ahmed S, Nair R, Steiner RE, Noorani M, Flowers CR, Davis RE, Fowler NH, Neelapu SS. Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL. *Leuk Lymphoma* 61(6):1-8, 6/2020. e-Pub 1/2020. PMID: 31971032.
 208. Pinnix CC, Gunther JR, Dabaja BS, Strati P, Fang P, Hawkins MC, Adkins S, Westin J, Ahmed S, Fayad L, Lee HJ, Nair R, Steiner RE, Iyer SP, Rodriguez MA, Wang M, Flowers C, Neelapu SS, Nastoupil LJ. Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. *Blood Adv* 4(13):2871-2883, 7/2020. PMID: PMC7362355.
 209. Strati P, Varma A, Adkins S, Nastoupil LJ, Westin J, Hagemeister FB, Fowler NH, Lee HJ, Fayad LE, Samaniego F, Ahmed S, Chen Y, Horowitz S, Arafat S, Johncy S, Kebriaei P, Mulanovich VE, Ariza Heredia E, Neelapu SS. Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. *Haematologica*. e-Pub 7/2020. PMID: 32732355.
 210. Strati P, Ahmed MA, Fowler NH, Nastoupil LJ, Samaniego F, Fayad LE, Hagemeister FB, Romaguera JE, Rodriguez A, Wang M, Westin JR, Cheah C, Noorani M, Feng L, Davis RE, Neelapu SS. Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma. *Haematologica* 105(7):1907-1913, 7/2020. e-Pub 10/2019. PMID: PMC7327641.
 211. Strati P, Nastoupil LJ, Westin J, Fayad LE, Ahmed S, Fowler NH, Hagemeister FB, Lee HJ, Iyer SP, Nair R, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Adkins S, Claussen CM, Martinez CS, Hawkins MC, Johnson NA, Singh P, Mistry HE, Horowitz S, George S, Feng L, Kebriaei P, Shpall EJ, Neelapu SS, Tummala S, Chi TL. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. *Blood Adv* 4(16):3943-3951, 8/2020. PMID: PMC7448589.
 212. Guber G, Gunther J, Fang P, Milgrom S, Korivi BR, Jensen CT, Wagner-Bartak NA, Ahmed S, Lee HJ, Nair R, Steiner R, Parmar S, Iyer S, Westin J, Fayad L, Rodriguez MA, Neelapu S, Nastoupil L, Flowers CR, Dabaja BS, Pinnix CC. Imaging Surveillance of Limited-stage Classic Hodgkin Lymphoma Patients After PET-CT-documented First Remission. *Clin Lymphoma Myeloma Leuk* 20(8):533-541, 8/2020. e-Pub 2/2020. PMID: 32291233.
 213. Strati P, Jain P, Johnson RJ, Forbes SG, Feng L, Samaniego F, Rodriguez MA, Fayad LE, Hagemeister F, Westin J, Wang ML, Neelapu SS, Nastoupil L, Fowler N. Long Term Follow-Up of Lenalidomide and Rituximab as Initial Treatment of Follicular Lymphoma. *Blood*. e-Pub 9/2020. PMID: 32932518.
 214. Chin CK, Lim KJ, Lewis K, Jain P, Qing Y, Feng L, Cheah CY, Seymour JF, Ritchie D, Burbury K, Tam CS, Fowler NH, Fayad LE, Westin JR, Neelapu SS, Hagemeister FB, Samaniego F, Flowers CR, Nastoupil LJ, Dickinson MJ. Autologous stem cell transplantation

- for untreated transformed indolent B-cell lymphoma in first remission: an international, multi-centre propensity-score-matched study. *Br J Haematol.* e-Pub 10/2020. PMID: 33065767.
215. Deng Q, Han G, Puebla-Osorio N, Ma MCJ, Strati P, Chasen B, Dai E, Dang M, Jain N, Yang H, Wang Y, Zhang S, Wang R, Chen R, Showell J, Ghosh S, Patchva S, Zhang Q, Sun R, Hagemeister F, Fayad L, Samaniego F, Lee HC, Nastoupil LJ, Fowler N, Eric Davis R, Westin J, Neelapu SS, Wang L, Green MR. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. *Nat Med.* e-Pub 10/2020. PMID: 33020644.
 216. Janku F, Park H, Call SG, Madwani K, Oki Y, Subbiah V, Hong DS, Naing A, Velez-Bravo VM, Barnes TG, Hagemeister FB, Falchook GS, Karp DD, Wheler JJ, Piha-Paul SA, Garrido-Laguna I, Shpall EJ, Fayad LE, Neelapu SS, Meric-Bernstam F, Kurzrock R, Fanale MA. Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. *Clin Cancer Res* 26(21):5579-5587, 11/2020. e-Pub 10/2020. PMID: 33055173.
 217. Furqan F, Watson G, Samaniego F, Fayad LE, Rashmi Kanagal-Shamanna , Morrison MW, Thompson PA, Steiner RE, Chi L, Dabaja B, Pinnix CC, Neelapu SS, Nastoupil LJ, Strati P. Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement. *Leuk Lymphoma* 61(12):1-5, 12/2020. e-Pub 7/2020. PMCID: PMC7683361.
 218. Chin CK, Rodriguez MA, Qing Y, Feng L, Samaniego F, Jain P, Noorani M, Fowler NH, Fayad LE, Westin JR, Neelapu SS, Hagemeister FB, Flowers CR, Nastoupil LJ. Impact of maintenance rituximab in patients with de novo transformed indolent B cell lymphoma. *Leuk Lymphoma* 61(12):1-5, 12/2020. e-Pub 7/2020. PMID: 32628087.
 219. Ciurea SO, Kongtim P, Srour S, Saini N, Im J, Ramdial J, Khouri I, Anderlini P, Popat U, Hosing C, Champlin RE, Lee HJ, Fayad LE, Hagemeister FB, Bica AM, Lipan L, Craciun O, Jercan CG, Tanase A, Colita A. Can we cure refractory Hodgkin's lymphoma with transplantation? *Bone Marrow Transplant* 56(1):278-281, 1/2021. e-Pub 7/2020. PMID: 32636464.
 220. Augustyn A, Medeiros LJ, Ludmir EB, Gunther J, Fang P, Li S, Ok CY, Bankston ME, Verma V, Pasalic D, Ahmed S, Nastoupil LJ, Westin JR, Strati P, Neelapu SS, Nair R, Steiner RE, Iyer SP, Rodriguez A, Fayad LE, Flowers CR, Dabaja BS, Pinnix CC. The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. *Leuk Lymphoma*:1-12. e-Pub 1/2021. PMID: 33480830.
 221. Wilson NR, Fang H, Loghavi S, Wang W, Tang G, Haltom RO, Rausch CR, McClain KL, Rao KV, Popat UR, Fayad LE, Champa N, Calvo KR, Allen CE, Kadia TM, Pemmaraju N. Treating Rosai-Dorfman disease and RAS-associated autoimmune leucoproliferative disorder with malignant transformation. *Br J Haematol* 192(3):667-671, 2/2021. e-Pub 11/2020. PMID: 33238033.
 222. Witzig TE, Tobinai K, Rigacci L, Ikeda T, Vanazzi A, Hino M, Shi Y, Mayer J, Costa LJ, Bermudez Silva CD, Zhu J, Belada D, Bouabdallah K, Kattan JG, Kuruvilla J, Kim WS, Larouche JF, Ogura M, Oczan M, Fayad LE, Wu C, Fan J, Louveau AL, Voi M, Cavalli F. Adjuvant everolimus in high-risk diffuse large B-cell lymphoma. Submitted.
 223. Milgrom SA, Pinnix CC, Akhtari M, Oki Y, Smith GL, Reddy JP, Gunther JR, Mawlawi O, Garg N, Rohren E, Chuang H, Hagemeister FB, Lee HJ, Fayad LE, Dong W, Osborne EM, Yehia A, Fanale M, Dabaja BS. Early-Stage Hodgkin Lymphoma Outcomes After Combined Modality Therapy According to the Deauville 5-Point Score. *Annals of Oncol.* Submitted.
 224. Batty N, Ghonimi E, Feng L, Fayad LE, Younes A, Rodriguez MA, Romaguera JE, McLaughlin P, Samaniego F, Kwak LW, Hagemeister FB. Economics Impact on Use of Blood Transfusions and Erythropoietin-Stimulating Agents in Patients with Diffuse Large B-Cell Lymphoma. *Cancer.* Submitted.
 225. Samaniego F, Hagemeister F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad LE, Younes A, Feng L, Berkova Z, Khashab T, Sehgal L, Vega-Vasquez F, Kwak LW. Pentostatin, Cyclophosphamide, and Rituximab (PCR) for Previously Untreated Advanced Stage, Low-grade B-cell Lymphomas. Submitted.

226. Fanale MA, Cheah C, Rich A, Medeiros LJ, Lai CM, Oki Y, Romaguera JE, Fayad LE, Hagemester F, Samaniego F, Rodriguez MA, Neelapu S, Lee HJ, Nastoupil L, Fowler N, Turturro F, Westin J, Wang M, McLaughlin P, Pinnix C, Milgrom S, Dabaja B, Horowitz S, Younes A. Potential Improvement of Clinical Outcomes for Advanced Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma Patients Treated With R-CHOP. Submitted.
227. Dabaja B, Milgrom S, Smith G, Romaguera JE, Turturro F, Fowler N, Fayad LE, Nastoupil L, Westin J, Neelapu S, Rodriguez MA, Fanale M, Hagemester FB, Lee HJ, Oki Y, Wang B, Samaniego F, Chi L. Ultra- Low- Dose Radiation Therapy for Definitive Management of Ocular Adnexal B- Cell Lymphoma. Head & Neck. Submitted.

Invited Articles

N/A

Editorials

1. Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemester F, Fanale M, Samaniego F, Feng L, Baladandayuthapani V, Wang Z, Ma W, Gao Y, Wallace M, Vence LM, Radvanyi L, Muzzafar T, Rotem-Yehudar R, Davis RE, Neelapu SS. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. *Lancet Oncol* 15(1):69-77, 1/2014. e-Pub 12/2013. PMID: 24332512.

Other Articles

1. Provencio M; Fayad LE. High-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma. *Medicina clinica* 130(2):60-65, 1/2008.

Abstracts

1. Rodriguez J, Rodriguez MA, Fayad L, Hagemester F, McLaughlin P, Swan F, Sarris A, Romaguera J, Andersson B, Cabanillas F. ASAP is an effective salvage regimen in patients with refractory or recurrent Hodgkin's disease. . *Blood* 90(Suppl 1):1518, 1997.
2. Rodriguez J, Fayad L, Santiago M, Hess M, Rodriguez MA, Romaguera J, Hagemester F, Cabanillas F, McLaughlin P. Follicular Large Cell lymphoma (FLCL) long-term results at M.D. Anderson Cancer Center. . *Blood* 90(Suppl 1):839, 1997.
3. Fayad L, Podoloff D, Rodriguez J, Hagemester F, Younes A, Sarris A, Rodriguez MA, Romaguera J, McLaughlin P, Cabanillas F. Gallium (67Ga) scan results after second course of chemotherapy correlates with clinical outcome in aggressive poor prognosis non-Hodgkin's lymphoma (APPNHL) treated with alternating tripple therapy regimen (ATT). . *Blood* 90(Suppl 1):836, 1997.
4. Fayad L, Cabanillas F, Talpaz M, McLaughlin P, Kurzrock R. High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphomas. . *Blood* 90(Suppl 1):3891, 1997.
5. Diamandidou E, Colome M, Fayad L, Duvic M, Kurzrock R. Prognostic factors analysis in Mycosis Fungoides/Sezary syndrome. *Blood* 90(Suppl 1):3887, 1997.
6. Fayad L, Przepiorka D, Folloder J, Khouri I, Anderlini P, Körbling M, Champlin R, Lichtiger B. The risk of engraftment-related hemolysis is not greater after ABO-mismatched allogeneic blood stem cell rather than marrow transplantation. . *Blood* 90(Suppl 1):169, 1997.
7. Fayad L, Kurzrock R, Keating M, O'Brien S, Kantarjian H, Andreeff M, Pierce S, Talpaz M, Freireich E, Estey E. Treatment of hairy cell leukemia (HCL) with 2CdA: Long term follow-up at M.D Anderson Cancer Center. . *Blood* 90(Suppl 1):2363, 1997.
8. Fayad L, Rodriguez MA, Rodriguez J, Hagemester F, Younes A, Sarris A, Romaguera J, McLaughlin P, Cabanillas F. Gallium (67 Ga) scan result after second or more cycles of chemotherapy correlates with clinical outcome in aggressive good prognosis NHL (AGPNHL) treated with CHOP containing regimen. *Proceedings of the ASCO* 18:24a (#54), 1999.
9. Fayad L, Kurzrock R, Keating MJ, O'Brien S, Talpaz M. High serum Interleukin-6 (sIL-6) and serum interleukin-10 (sIL-10) correlates with poor survival in chronic lymphocytic leukemia (CLL) patients (PTS). . *Proceedings of ASCO* 18:24a (#86), 1999.
10. Emmanuelidis CTouroutoglou N, Diamandidis D, Fayad L, Wolf C, Territo M. unrelated allogeneic non-myeloablativebone marrow transplant is feasible and effective. *Proceedings ASH, Blood* 96(Supplement):360b (#5311), 2000.

11. Dang NH, Hagemeister FB, Duvic M, Romaguera JE, Younes A, Rodriguez MA, Sarris AH, Jones D, East K, Gomez R, Fayad LE, Pro B, McLaughlin P, Samaniego F, Goy A, Cabanillas F. Phase II study of Pentostatin for relapsed T cell lymphomas: Efficacy and effect on CD26+ T cells. *Blood* 98(11):Part I of II (#548), 11/2001.
12. Fayad L, Romaguera J, Pro B, Younes A, Dang N, Samaniego F, Garcia P, Sarris A, Rodriguez MA, Hagemeister F, McLaughlin P, Goy A, Cabanillas F, P Rodriguez. Primary Mediastinal Large B-Cell lymphoma (PMLBL): Poor prognosis in patients with extranodal sites. *Blood* 98(11):Part I of II (#1419), 11/2001.
13. Fayad L, Estey E, Thomas D, O'Brien S, Keating M, Koller C, Pierce S, Talpaz S, Boyer K, Freireich E, Kantarjian H, Kurzrock R. Treatment of Hairy Cell Leukemia with Cladribine (2CDA): Long-term follow-up at M.D. Anderson Cancer Center. *Blood* 98(11) (#2659), 11/2001.
14. Giles F, Belanger R, Toor A, McLaughlin P, Fayad L, Beran M, Albitar M, Vose J. A phase I/II multi-center study of Troxatyl[®] in patients with refractory chronic lymphocytic leukemia (CLL), lymphoma or multiple myeloma. . *Blood* 98:4902, 2001.
15. Khouri I F, Saliba RM, Acholonu S, Andersson B, Bibawi S, de Lima M, Fayad L, Giralt S, Fayad L, Hagemeister FB, Hosing C, Korbling M, Rodriguez MA, Romaguera J, Cabanillas F, Champlin RE. Allogeneic Transplantation for Poor Risk Mantle Cell Lymphoma (MCL): Chemosensitivity Predicts Superior Outcome. . *Blood* 98:1745, 2001.
16. Younes A, McLaughlin P, Hagemeister FB, Pro B, Samaniego F, Romaguera JE, Dang NH, Fayad L, Goy A, Rodriguez MA, Cabanillas F. High Response Rate and Complete Remission Rate Achieved by Adding Rituximab to Taxol Plus Topotecan (TTR) with G-CSF Support for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Lymphoma. . *Blood* 98:1456, 2001.
17. Khouri I F, Saliba RM, Giralt S, Okoroji GJ, Younes A, Fayad L, Korbling M, Rodriguez MA, Couriel D, Bibawi S, Hosing C, McMannis J, Cabanillas F, Champlin RE. Long Term Remission and Low Mortality Achieved with Cisplatin, Fludarabine, Cytarabine Nonablative Preparative Regimen and Allogeneic Stem Transplantation (AST) for Histologically Aggressive Non-Hodgkins Lymphoma (NHL). . *Blood* 98:795, 2001.
18. Romaguera J, Cabanillas F, Dang NH, Goy A, Hagemeister HB, Fayad L, McLaughlin P, Pro B, Rodriguez MA, Samaniego F, Sarris AH, Younes A, Medeiros J. Mantle Cell Lymphoma (MCL) – High Rates of Complete Remission (CR) and Prolonged Failure-Free Survival (FFS) with Rituxan-HyperCVAD (R-HCVAD) without Stem Cell Transplant (SCT). . *Blood* 98:3030, 2001.
19. Rodriguez MA, Dang NH, East K, Fayad L, Goy A, Hagemeister FB, McLaughlin P, Pro B, Romaguera J, Samaniego F, Sarris A, Younes A, Cabanillas F. Melatonin Did Not Prevent CHOP-Induced Myelosuppression in Patients with Aggressive Lymphoma: Results of a Randomized Study. . *Blood* 98:4718, 2001.
20. Touroutoglou N, Wierman A, Diamandidis D, Fayad L, Gollard R, Boedeker H, Nagy MN, Klimek S, Giron S. Neutrexin (TMTX), 5-Fluorouracil (5FU) and Leucovorin (LCV), (NFL) in previously untreated patients with metastatic Colorectal Cancer (CRC). . *Proceedings of the American Society of Clinical Oncology* 20(Part II of II) (#2175), 2001.
21. Khouri I F, Saliba RM, Lee M-S, Giralt S, Younes A, Couriel D, Fayad L, De Lima M, Hagemeister FB, Hosing C, McLaughlin P, Ueno N, Rodriguez MA, Korbling M, Gajewsky J, Cabanillas F, Champlin RE. Nonablative Allogeneic Stem Cell Transplantation (AST) for Non-Hodgkin's Lymphoma (NHL): Improved Outcome with Low Incidence of Acute GVHD and Treatment Related Mortality. *Blood* 98:1746, 2001.
22. Sarris AH, Visco C, Medeiros LJ, Mesina OM, Rassidakis G, Rodriguez MA, McLaughlin P, Goy A, Hagemeister FB, Romaguera JE, Samaniego F, Dang NH, Pro B, Fayad L, Chul H, Wilder R, Cox J, Cabanillas F. Non-Hodgkin's Lymphoma Involving the Testis: Results of Treatment with CHOP, Intrathecal Methotrexate and Scrotal Radiotherapy. . *Blood* 87:1457, 2001.
23. McLaughlin P, Rodriguez MA, Reuben J, East K, Grimm E, Hagemeister FB, Fayad L, Sarris A. Rituximab in Combination with GM-CSF (Leukine) for Patients with Recurrent Indolent Lymphoma. . *Blood* 98:2536, 2001.

24. Thomas DA, O'Brien S, Cortes J, Faderl S, Fayad L, Carcia-Manero G, Wierda W, Verstovsek S, Kornblau S, Pierce S, Kantarjian H, Keating M. Treatment of splenic lymphoma with Villous lymphocytes (SLVL) and Marginal cell Lymphomas (MZL) with single agent Rituximab. *Blood* 98:563, 2001.
25. Rodriguez MA, Sarris A, East K, Dang N, Fayad LE, Goy A, Hagemeister F, McLaughlin P, Pro B, Romaguera JE, Samaniego F, Younes A, Cabanillas F. A Phase II study of Liposomal Vincristine in CHOP with Rituximab for Patients with Untreated Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL): A Safe and Effective Combination. . *Blood* 100:338, 2002.
26. Younes A, McLaughlin P, Pro B, Hagemeister F, Fayad LE, Romaguera JE. Activity of Oxaliplatin in Patients with Relapsed and Refractory Non-Hodgkin Lymphoma. . *Blood* 100:4722, 2002.
27. Younes A, McLaughlin P, Hagemeister FB, Pro B, Samaniego F, Romaguera JE, Dang NH, Fayad L, Goy A, Rodriguez MA, Cabanillas F. Addition of Rituximab to Taxol plus Topotecan (TTR) improves response rate and complete remission rate in patients with relapsed/refractory aggressive B-cell lymphoma. . *Annals of Oncol* 13(Suppl 2):246, 2002.
28. Younes A, Pro B, Hagemeister F, Rodriguez MA, McLaughlin P, Fayad LE, Goy A, Cabanillas F. Efficacy of Single Administration of a Fixed Dose Pegfilgrastim (Neulasta) in Inducing Neutrophil count Recovery after Paclitaxel Plus Topotecan Chemotherapy in Patients with Relapsed Aggressive Non-Hodgkin Lymphoma. *Blood* 100:2868, 2002.
29. Hagemeister F, McLaughlin P, Clemons M, Rodriguez MA, Fayad L, Romaguera J, Pro B, Goy A, Samaniego F, Dang NH, Cabanillas F. FND (Fludarabine, Mitoxantrone, Dexamethasone)- R(Rituximab) for Patients (pt) with Relapsed (Rel) or Chemotherapy Resistant (CTR) Indolent Lymphomas (IL): A Preliminary Report. *Blood* 100:4760, 2002.
30. Khouri IF, Saliba R, Hosing C, Kôrbling M, Younes A, Romaguera J, Fayad L, Cabanillas F, Champlin RE. Long-term follow-up of autologous stem cell transplantation in first remission in patients with diffuse mantle cell lymphoma. . *Annals of Oncol* 13(Suppl 2):262, 2002.
31. Romaguera J, Cabanillas F, Dang N, Goy A, Fayad LE, Hagemeister FB, McLaughlin P, Pro B, Rodriguez MA, Samaniego F, Sarris AH, Younes A, Medeiros LJ, Gagneja HK. Mantle Cell Lymphoma (MCL). Update on results after R-HCVAD without stem cell transplant (SCT). *Annals of Oncol* 13(Suppl 2):024, 2002.
32. Khouri I, Ming-Sheng L, Saliba R, Jun G, Fayad LE, Hosing C, Donato M, Pro B, Couriel D, Rodriguez MA, Korbling M, Cabanillas F, Katz R, Champlin R. Nonablative Allogeneic Stem Cell Transplantaion for Relapsed Mantle Cell Lymphoma (MCL): A Promising Strategy for an Aggressive Disease. . *Blood* 100:1652, 2002.
33. Goy A, Sarris A, Bleyer A, Duvic M, Mesina O, Dang N, Fayad LE, Hagemeister F, McLaughlin P, Pro B, Rodriguez MA, Romaguera JE, Samaniego F, Younes A, Cabanillas F. Phase II Study of Compound GW506U78 (AraG) in Patients with T-Cell and B-Cell Non-Hodgkin Lymphomas (NHL). . *Blood* 100:4757, 2002.
34. Dang N, Hagemeister F, Fayad L, Pro B, McLaughlin P, Romaguera J, Samaniego F, Younes A, Goy A, Preti A, Jones D, Sarris A, East K, Rodriguez MA, Cabanillas F. Phase II Study of Delineukin diftitox (ONTAK®) for Relapsed/Refractory B and T-Cell Non-Hodgkin's Lymphoma. . *Blood* 100:1405, 2002.
35. Pro B, Romaguera J, Macapinlac H, Fayad LE, Dang N, Samaniego F, Goy A, Rodriguez MA, McLaughlin P, Podoloff D, Hagemeister F, Younes A, Cabanillas F. Positron Emission Tomography Using Fluorodeoxyglucose but Not Gallium-67 Scintigraphy Is a Sensitive Imaging Modality in the Staging of Mantle Cell Lymphoma. *Blood* 100:3041, 2002.
36. Younes A, Fayad LE, McLaughlin P, Goy A, Romaguera J, Rodriguez MA, Hagemeister F, Samaniego F, Pro B, Medeiros J, Ha C, Wilder R, Seifert A. Rituximab Plus ABVD Therapy for Newly Diagnosed Patients with Classical Hodgkin's Disease. . *Blood* 100:4774, 2002.
37. Younes A, Fayad L, Pro B, Romaguera J, Ha CS, Wilder R. Safety and Efficacy of Prophylactic Pegfilgrastim in Patients with Hodgkin Disease Receiving ABVD Chemotherapy. . *Blood* 100:4179, 2002.
38. Romaguera JE, Hagemeister F, Fayad LE, Rodriguez MA, Medeiros LJ, Pro B, Younes A, Sarris AH, Dang N, Samaniego F, Brown HM, Gagneja HJ. The Clinical Significance of Detection of Gastrointestinal (GI) Involvement in Mantel Cell Lymphoma (MCL). *Blood* 100:4657, 2002.

39. Liu NS, Grimm E, Poindexter N, Rodriguez MA, Hagemeister F, Pro B, Fayad LE, Lee BN, Reuben JM, McLaughlin P. [1495] Antibody Dependent Cellular Cytotoxicity and Natural Killer Cell Activity in Patients with Recurrent Indolent Lymphoma Receiving Rituximab in Combination with GM-CSF. . *Blood* 102(11):411a (#1495), 2003.
40. Dang N, Hagemeister F, Fayad LE, Pro B, McLaughlin P, Romaguera JE, Samaniego F, Goy A, Wang M, Walker PL, Samuels B, Jones D, Rodriguez MA. Analysis of a Phase II Study of Denileukin Diftitox (ONTAK) for B and T-Cell Non-Hodgkins Lymphoma. . *Blood* 102(11):303b (#4935), 2003.
41. Kurbegov D, Cabanillas F, Dang NH, Goy A, McIntyre B, McLaughlin P, Pro B, Rodriguez MARomaguera J, Fayad L. Elevated serum CD44 (sCD44) level is associated with unfavorable features, shorter relapse-free survival, and worse overall survival in patients with indolent Non-Hodgkin's lymphomas. . Submitted for ASH 2003., 2003.
42. Kurbegov D, Cabanillas F, Dang NH, Goy A, McIntyre B, McLaughlin P, Pro B, Rodriguez MA, Romaguera JE, Fayad LE. Elevated Serum Soluble CD44 (sCD44) Level Is Associated with Unfavorable Features, Shorter Relapse-Free Survival, and Worse Overall Survival in Patients with Indolent Non-Hodgkin's Lymphoma (NHL). . *Blood* 102(11):632a (#2334), 2003.
43. Younes A, Pro B, Goy A, Fayad L, Romaguera J. Gemcitabine Plus Rituximab Therapy of Patients with Relapsed and Refractory Classical Hodgkin Disease. Depletion of Benign B-Cells from HD Microenvironment by Rituximab May Enhance the Activity of Gemcitabine. . *Blood* 102(11):412a (#1500), 2003.
44. Pro B, Smith MR, younes A, Dang NH, Fayad LE, Goy A, Hagemeister F, McLaughlin P, Rodriguez MA, Samuels B, Arredondo Y, Frankel SR, Zwiebel JA. Genasense (BCL-2 Antisense) plus Rituximab is active in patients with relapsed or refractory B-cell Non-Hodgkin's lymphoma. . *Blood*, 2003.
45. Khouri I, Saliba R, Acholonu S, Okoroji G, Hosing C, Fayad LE, Couriel DR, Pro B, Giralt S, Andersson B, Younes A, McLaughlin P, Champlin RE. Improved Outcome with High-Dose Rituximab (HD-R) with G/GM-CSF and Autologous Stme Cell Transplantation (ASCT) fro Relapsed Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL): The Impact of Histologies of follicular (FL) Origin. *Blood* 102(11):735a (#2716), 2003.
46. Dang NH, Hagemeister F, Fayad LE, Pro B, McLaughlin P, Romaguera JE, Samaniego F, Younes A, Goy A, Rodriguez MA. Interim analysis of a phase II study of denileukin diftiox (ONTAK) for B and T-cell non-Hodgkin's lymphoma. . *Proceedings of ASCO* 22:2292, 2003.
47. Escalon M, Champlin R, Saliba R, Acholonu A, Hosing C, Fayad LE, Ueno NT, Pro B, Giralt S, McLaughlin P, Khouri I. Non-Myeloablative Allogeneic Hematopoietic Transplantation: A Promising Salvage Therapy for Patients with Non-Hodgkins Lymphoma (NHL)Whose Disease Has Failed a Prior Autologous Stem Cell Transplantation (ASCT). . *Blood* 102(11):75a (#255), 2003.
48. Cabanillas ME, Thomas DA, Cortes J, Faderl S, O'Brien S, Beran M, Younes A, Fayad L, Koller C, Kantarjian H. Outcome with hyper-CVAD and rituximab in Burkitt (BL) and Brukitt-like (BLL) leukemia/lymphoma. . *Proc ASCO* 22:574 (#2309), 2003.
49. Levine A, Fayad L, Modiano M, Camboni G, Cabanillas F. Phase I study of BBR-2778 in BSHAP for relapsed aggressive non-Hodgkin's lymphoma. . *Exp Hematol* 31(Suppl 1):110, 2003.
50. Levine AM, Fayad L, Modiano M, Camboni G, Cabanillas F. Phase I study of Pixantrone in BSHAP for relapsed non-Hodgkin's Lymphoma. . *Proceedings of the International Society of Experimental Hematology, France* (#154), 2003.
51. Goy A, Bleyer A, Hagemeister F, Fayad LE, Pro B, Romaguera JE, Samaniego F, Sarris A, Hart S, Cabanillas F, Murgo A, Duvic M, Rodriguez MA. Phase II Study of Compound GW506U78 (AraG) for Patients with Indolent B-Cell or Peripheral T-Cell Lymphoma Previously Treated with Chemotherapy. . *Blood* 102(11):639a (#2359), 2003.
52. Goy A, Hart S, Tiongson L, Fayad LE, Romaguera JE, Younes A, Dang N, Pretti A, Samuels B, Sarris A, Gilles F, Rodriguez MA. Preliminary Report of a Phase II Study of Vincristine Sulfate Liposomes Injection (VSLI) in Patients with Relapsed or Refractory Hodgkins Disease. . *Blood* 102(11):640a (#2362), 2003.
53. Goy A, Paz Tiongson L, Hart S, Fayad L, Hagemeister F, Romaguera J, Younes A, Dang A, retti A, Samuels B, Gilles F, Rodriguez MA. Preliminary report of a Phase II study of

- Vincristine Sulfate Liposome Injection (VSLI) in patients with relapsed or refractory Hodgkin's disease. . Submitted to ASH 2003, 2003.
54. Pro B, Cabanillas F, Dang NH, Fayad LE, Goy A, McLaughlin P, Rodriguez MA, Romaguera JE, Samaniego F, Wu HH, Hess M, Gold DL, Hagemeister F. Prognostic Factors in Follicular Lymphoma: The Importance of Beta-2 Microglobulin. . *Blood* 102(11):281b (#4845), 2003.
 55. Goy AH, Hart S, Pro B, McLaughlin P, Younes B, Dang N, Fayad LE, Romaguera JE, Cabanillas F, Hagemeister F, Samaniego F, Wang M, Mesina O, Gilles F, Trehu E, Shenkein D. Report of a Phase II Study of Proteasome Inhibitor Bortezomib (VELCADE) in Patients with Relapsed or Refractory Indolent or Aggressive Lymphomas. . *Blood* 102(11):180a (#627), 2003.
 56. Goy AH, East K, Mesina O, Cabanillas F, Fayad L, Hagemeister F, Romaguera J, Scheinkein D, Trehu E, Wang M, Younes A, Gilles F, Rodriguez A. Report of a phase II study of proteasome inhibitor bortezomib in patients with relapsed or refractory indolent and aggressive B-cell lymphomas. . *Proc ASCO* 22:570 (#2291), 2003.
 57. Levine AM, Fayad LE, Tulpule A, Modiano M, Espina BM, Camboni G, Cabanillas F. Results of a Phase I/II Trial with BBR-2778 (Pixantrone), Methylprednisolone, Cisplatin, and Cytosine Arabinoside (BSHAP) in Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma (NHL). . *Blood* 102(11):640a (#2364), 2003.
 58. Tsimberidou AM, Giles F, Duvic M, Fayad LE, Razelle Kurzrock. Results of a Phase II Study of Pentostatin in Advanced T-Cell Lymphoid Malignancies. . *Blood* 102(11):639a (#2360), 2003.
 59. Younes A, McLaughlin P, Goy A, Medeiros LJ, Jones D, Fayad LE, Abruzzo L, Pro B. Rituximab Plus ABVD Therapy for Newly Diagnosed Patients with Classical Hodgkin's Disease: A Novel Combination Program Targeting the Cancer Cells and the Microenvironment. . *Blood* 102(11):27a (#83), 2003.
 60. Younes A, Fayad LE, Pro B, McLaughlin P, Hagemeister FB, Mansfield P, Clayman G, Medeiros LJ, Lewis J, Srivastava P. Safety and efficacy of heat shock protein-peptide 96 complex (HSPPC-96) in low-grade lymphoma. . *Proceedings of ASCO* 22:2294, 2003.
 61. Younes A, Fayad LE, Romaguera JE, Pro B, Dang N, Wang M. Single Administration of a Fixed Dose Pegfilgrastim (Neulasta) in Inducing Neutrophil Count Recovery after 170 Consecutive Doses of ABVD Chemotherapy in Patients with Hodgkin Lymphoma: Safety of Pegfilgrastim with q14-Day Chemotherapy Regimens. *Blood* 102(11):637a (#2352), 2003.
 62. Liu Q, Fayad LE, Hagemeister F, Rodriguez MA, Younes A, Pro B, Verstovsek S, Cabanillas F, Tsimberidou A, Hess M, Ayala A, Clemons M, McLaughlin P. Stage IV Indolent Lymphoma: 25 Years of Treatment Progress. *Blood* 102(11):398a (#1446), 2003.
 63. Younes A, McLaughlin P, Romaguera J, Hagemeister F, Pro B, Dang NH, Samaniego F, Rodriguez MA, Fayad L. Taxol Plus Topotecan Plus Rituximab (TTR) with G-CSF Support: An Effective Salvage Program for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (NHL) Who Failed CHOP-Like and Platinum-Based Therapy. *Blood* 102(11):142a (#489), 2003.
 64. Pro B, Smith MR, Younes A, Dang NH, Fayad LE, Goy A, Hagemeister F, McLaughlin P, Rodriguez MA, Samuels B, Arredondo Y, Frankel SR, Zwiebel JA. Zwiebel. Genasense (Bcl-2 Antisense) Plus Rituximab Is Active in Patients with Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma. *Blood* 102(11):410a (#1491), 2003.
 65. Camboni G, Fayad L, Tulpule A, Modiano M, Espina BM, Cabanillas F, Levine AM. A phase I/II of BBR-2778 (pixantrone), methylprednisolone, cisplatin, and cytosine arabinoside (BSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL). . *J Clin Oncol* 23:578 (#6590), 2004.
 66. Dang NH, Pro B, Hagemeister FB, Jones D, Samuels B, Rodriguez MA, Goy A, Romaguera JE, Walker P, Kwak L, Fayad L. Interim Analysis of a Phase II study of Dinileukin Diffitox (ONTAK) for relapsed/refractory T-cell Non-Hodgkin's lymphoma. . *Blood* 104(11):722a (#2641), 2004.
 67. Younes A, Fayad L, Romaguera J, Pro B, Goy A, Dang N, Wang M. Long-term safety and efficacy of single administration of a fixed dose pegfilgrastin (Neulasta) in inducing neutrophil count recovery after ABVD chemotherapy in patients with Hodgkin's lymphoma. . *Blood* 104(11):245b (#4646), 2004.

68. Pro B, Smith MR, Younes A, Fayad LE, Goy AH, Hagemeister FB, McLaughlin P, Rodriguez MA, Frankel Sr, Zwiebel JA. Oblimersen Sodium (BCL-2 antisense) plus rituximab, in patients with recurrent B-cell Non-Hodgkin's lymphoma: Preliminary Phase II results. . Proceedings ASCO J Clin Oncol 23:573 (#6572), 2004.
69. Thomas DA, Cortes J, Faderl S, O'Brien S, Beran M, Koller C, Garcia-Manero G, Younes A, Fayad, L, Wierda W, Pierce S, Giles F, Kantarjian H. Outcome with the Hyper-CVAD and Rituximab regimen in Burkitt (BL) and Burkitt-like (BLL) Leukemia/Lymphoma. . Blood 104(11):901a (#3297), 2004.
70. Yee KWL, Wierda W, O'Brien S, Thoma D, Kurzrock R, Fayad LE, Hagemeister FB, Cortes J, Prestifilippo J, Szatrowski TP, Kantarjian HM, Giles F. Phase I/II study of the Oral mTOR inhibitor RAD001 in Patients with advanced hematological malignancies. . Blood 104(11):287b (#4818), 2004.
71. Fayad L, Liebmann J, Modiano M, Cohen GI, Pro B, Romaguera J, Davite C, Lymboura M, Comis S, Laffranchi B. Preliminary results of a Phase I/II trial of BBR-2778 (pixantrone) in combination with fludarabine, dexamethasone, and rituximab (FPD-R) in the treatments of patients with relapsed/refractory indolent non-Hodgkin's lymphoma. . Blood 104(11):373a (#1324), 2004.
72. Samaniego F, Wang S, Young D, Fayad L, Wang S. Simian Virus 40 DNA sequences in non-Hodgkin's lymphoma. . J Clin Oncol 23:581 (#6604), 2004.
73. Rodriguez MA, Dang NH, Fayad L, Goy A, Hagemeister FB, McLaughlin P, Pro B, Romaguera JE, Younes A, Cabanillas F. Sphingosomal Vincristine in CHOP +/- rituximab is a promising new treatment for patients with high-risk untreated aggressive non-Hodgkin's lymphoma (NHL): Follow-up results of a phase II study. . Blood 104(11):234b (#4602), 2004.
74. Rodriguez MA, Dang NH, Fayad L, Goy A, Hagemeister FB, McLaughlin P, Pro B, Romaguera JE, Younes A, Cabanillas F. Sphingosomal Vincristine in CHOP is a promising new treatment for elderly, as well as poor prognosis patients with aggressive non-Hodgkin's lymphoma (NHL): Follow-up of a phase II study. . J Clin Oncol 23:745 (#8080), 2004.
75. Goy A, Younes A, McLaughlin P, Pro B, Romaguera J, Hagemeister F, Fayad L, Trehu EG, Schenkein D, Rodriguez MA. Update on a phase (ph) 2 tudy of bortezomib in patients (pts) with relapsed or refractory indolent or aggressive non-Hodgkin's lymphoma (NHL). . J Clin Oncol 23:575 (#6581), 2004.
76. Jones D, Patel K, Herling M, Aguilar RJ, Ueda R, Inagaki H, Fayad L, Duvic M. Upregulation of the chemokine receptor CCR4 in cutaneous T-cell lymphoma and nodal T-cell lymphoma: Implications for targeted therapy. . Blood 104(11):724a (#2646), 2004.
77. Younes A, Pro B, Fayad L, Dang N, Romaguera J. (Velcade) for the treatment of relapsed classical Hodgkin's lymphoma. . Ann Oncol 16(Suppl 5):v210 (#593), 2005.
78. Fayad L, Liebman J, Mediano M, Cohen G, Pro B, Romaguera J, Countouridis A, Lymboura M, Comis S, Laffranchi B. A phase I/II trial of pixantrone combined with fludarabine (FL), dexamethasone (DEX) and rituximab (FPD-R) for treatment of recurrent indolent B-cell non-Hodgkin's lymphomas. . Ann Oncol 16(Suppl 5):v156 (#403), 2005.
79. Pro B, Leber B, Smith MR, Younes A, Fayad LE, Hagemeister F, McLaughlin P, Rodriguez MA, Caddick Y, Zwiebel JA. A Phase II Trial of Oblimersen Sodium (G3139) plus Rituximab for Treatment of Patients with Recurrent B-cell Non-Hodgkin's Lymphoma. . Ann Oncol 16(Suppl 5):v68 (#103), 2005.
80. Younes A, Fayad L, Romaguera JE, Pro B, and Wang M. ABVD with Pegfilgrastim (Neulasta) Support in Newly Diagnosed Hodgkin Lymphoma: Long-Term Safety and Efficacy Results of a Phase-II Study. Blood 106(11):[4790], 2005.
81. Khouri IF, Saliba RM, Hosing CM, Acholonu SA, Fayad LE, Korbling MJ, Saenz C, Pro B, Samuels BI, de Lima MJ, Giralt SA, Younes A, McLaughlin P, and Champlin RE. Autologous Stem Cell (AUTO) vs Non-Myeloablative Allogeneic Transplantation (NMT) after High-Dose Rituximab (HD-R) -Containing Conditioning Regimens for Relapsed Chemosensitive Follicular Lymphoma (FL). Blood 106(11):[48] 19a, 2005.
82. Friedberg JW, Cohen P, Cheson BD, Robinson KS, Forero-Torres A, Fayad L, La Casce AL, Bessudo A, Camacho ES, Williams ME, van der Jagt RH, Oliver J, and Benaim E. Bendamustine HCl (TREANDATM) Treatment Results in High Rates of Objective Response in Patients with Rituximab-Refractory and Alkylator-Refractory Indolent B-Cell Non-Hodgkin's

- Lymphoma (NHL): Results from a Phase II Multicenter Single-Agent Study (SDX-105-01). *Blood* 106(11):[229] 70a, 2005.
83. Soriano AO, Thompson M, Romaguera J, Rodriguez MA, Hagemeister FB, Fayad L, Admirand JH, and Pro B. Follicular Dendritic Cell Sarcoma (FDSC): A Rare and Incurable Disease. *Blood* 106(11):[3892], 2005.
 84. Younes A, Fayad L, Pro B, Goy A, Romaguera JE, Hagemeister FB, and McLaughlin P. Gemcitabine Plus Rituximab Therapy of Patients with Relapsed and Refractory Classical Hodgkin Lymphoma. *Blood* 106(11):[1498] 431a, 2005.
 85. Romaguera JE, Fayad LE, Wang M, Cabanillas F, Hagemeister F, McLaughlin P, Rodriguez A, Younes A, Neelapu S, Goy AH, Beasley V, and Kwak L. High (95%) Response Rates in Relapsed/Refractory Mantle Cell Lymphoma after R-HCVAD Alternating with R-Methotrexate/Cytarabine (R-M-A). *Blood* 106(11):[2446] 688a, 2005.
 86. Romaguera J, Fayad L, Rodriguez M, Hagemeister F, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris A, Dang N, Medeiros J, Katz R, Gagneja H, Samuels B, Cabanillas F. High rates of Failure-Free Survival (FFS) and Overall Survival (OS) in untreated Mantle Cell lymphoma (MCL) after Rituximab plus HyperCVAD (R-HCVAD) alternating with rituximab plus High-Dose Methotrexate-Cytarabine (R-M/A). *Ann Oncol* 16(Suppl 5):v95 (#197), 2005.
 87. Pro B, Cabanillas F, Fayad L. High-serum b2 microglobulin is an important independent prognostic factor for disease progression in patients with follicular lymphoma. *Ann Oncol* 16(Suppl 5):v149 (#381), 2005.
 88. Fayad L, Dang J, Keating M. Hodgkin's disease variant of Richter's syndrome, an update of the M. D. Anderson experience. *Ann Oncol* 16(Suppl 5):v114 (#262), 2005.
 89. Dang NH, McLaughlin P, Fayad L, Romaguera J, Hagemeister F, Younes A, Neelapu S, Samaniego F, Jones D, Walker PL, Rodriguez MA, Kwak L, and Pro B. Interim Analysis of a Phase II Study of the Combination of Denileukin Diftitox (Ontak) and Rituximab for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma. *Blood* 106(11):[3349] 936a, 2005.
 90. Khouri IF, Saliba RM, Lee MS, Okoroji GJ, Fayad L, Maadani F, Hosing C, Samuels B, Giralt S, de Lima M, Pro B, Younes A, McLaughlin P, Kwak L, and Champlin RE. Longer Follow-Up Confirms a Low Relapse Rate after Non-Myeloablative Allogeneic Transplantation (NMT) for Non-Hodgkin's Lymphoma (NHL), Including Patients with PET or Gallium-Avid Disease. *Blood* 106(11):[44] 19a, 2005.
 91. Younes A, McLaughlin P, Romaguera J, Hagemeister F, Pro B, dang N, Samaniego F, Rodriguez M, Fayad L. Paclitaxel plus Topotecan plus Rituximab (TTR): An Effective Salvage Program for the treatment of patients with relapsed/refractory aggressive B-cell lymphoma (NHL). *Ann Oncol* 16(Suppl 5):v101 (#220), 2005.
 92. Dang NH, Pro B, Hagemeister F, Samaniego F, Jones D, Rodriguez M, Goy A, Romaguera J, Walker PL, Younes A, Neelapu S, Kwak L, and Fayad L. Phase II Study of Denileukin Diftitox (Ontak) for Relapsed/Refractory T-Cell Non-Hodgkin's Lymphoma. *Blood* 106(11):[3350] 936a, 2005.
 93. Pro B, Smith MR, Leber B, Younes A, Fayad LE, Hagemeister F, McLaughlin P, Rodriguez MA, Caddick Y, Zwiebel JA. Phase II study of Oblimersen Sodium and Rituximab in Patients with Recurrent B-cell Non-Hodgkin's Lymphoma. *J Clin Oncol* 23(16S):587S (#6611), 2005.
 94. Rodriguez MA, Dang NH, Fayad L, Goy A, Hagemeister F, McLaughlin P, Pro B, Romaguera J, Younes A, and Cabanillas F. Phase II Study of Sphingosomal Vincristine in CHOP+/- Rituximab for Patients with Aggressive Non-Hodgkin's Lymphoma (NHL): Promising 3 Year Follow-Up Results in Elderly Patients. *Blood* 106(11):[943] 277a, 2005.
 95. Jabbour E, Hosing C, Pro B, Khouri I, Fayad L. Positive Pre-transplant PET/Ga67 (Ga) predicts poor outcome in refractory and relapse Hodgkin's lymphoma. *Ann Oncol* 16(Suppl 5):v121 (#285), 2005.
 96. Jabbour E, Hosing C, Pro B, Champlin R, Khouri I, Romaguera J, Fayad LE. Pre transplant positive PET/Gallium scans predict poor outcome in relapsed/refractory Hodgkin's lymphoma (HL). *Proceedings ASCO. J Clin Oncol* 23(16S):562S (#6509), 2005.
 97. Fayad L, Romaguera J, hart S, Younes A, Pro B, Hagemeister F, McLaughlin P, Dang N, Pretti A, Sarris A, Gil F. Report of a phase II study of sphingosomal vincristine (SV) in

- patients with relapsed or refractory Hodgkin's disease. . J Clin Oncol 23(16S):591S (#6624), 2005.
98. Thompson MA, Pro B, Sarris A, Hagemeister FB, Goy A, Bleyer A, Cabanillas F, Samaniego F, and Fayad LE. Results of a Phase II Study of 506U78 (Nelarabine) in Refractory Indolent B-Cell or Peripheral T-Cell Lymphoma. Blood 106(11):[2681] 753a, 2005.
 99. Younes A, McLaughlin P, Fayad L, Goy A, Medeiros L, Pro B, Romaguera J, Rodriguez M, Samaniego F, Dang N, et al. Rituximab plus ABVD therapy for newly diagnosed patients with classical Hodgkin's lymphoma: A novel combination program targeting the cancer cells and the reactive B-cells in the microenvironment. . Ann Oncol 16(Suppl 5):v196 (#545), 2005.
 100. McLaughlin P, Liu NS, Grimm E, Fayad L, Hagemeister FB, Nunez G, Romaguera J, Goy A, Samaniego F, Wang M, Ayala A, Lee BN, Reuben JM, Kwak L, Rodriguez MA. Rituximab plus GM-CSF (Leukine) for Indolent Lymphoma. . Ann Oncol 16(Suppl 5):v68 (#104), 2005.
 101. Hagemeister FB, McLaughlin P, Fayad L, Samaniego F, Dang N, Goy A, Romaguera J, Pro B, Beasley V, Cabanillas F, and Rodriguez M. Rituximab, Fludarabine, Mitoxantrone, and Dexamethasone (R-FND) for Relapsed Indolent Lymphomas (RIL). Blood 106(11):[941] 277a, 2005.
 102. Younes A, Fayad L, Romaguera J, Pro B, Goy A, Dang N, Wang M. Safety and efficacy of single fixed dose pegfilgrastin (Neulasta) in chemotherapy regimens given every 14 days: Results of ABVD plus pegfilgrastin in patients with Hodgkin's lymphoma. . Ann Oncol 16(Suppl 5):v196 (#546), 2005.
 103. Younes A, McLaughlin P, Fayad LE, Goy A, Romaguera JE, Pro B, Rodriguez MA, Samaniego F, Kwak L, Neelapu S, and Medeiros J. Six Weekly Doses of Rituximab Plus ABVD for Newly Diagnosed Patients with Advanced Stage Classical Hodgkin Lymphoma: Depletion of Reactive B-Cells from the Microenvironment by Rituximab. Blood 106(11):[1499] 431a, 2005.
 104. McLaughlin P, Rodriguez M, Hagemeister F, Romaguera J, Sarris A, Younes A, Dang N, Goy A, Samaniego F, Hess M, Lee M, Medeiros J, Fayad L, Pro B, Jiang Y, Ayala A, Cabanillas F. Stage IV indolent Lymphoma: A randomized trial of concurrent vs. sequential FND (fludarabine, mitoxantrone, dexamethasone) and rituximab with interferon maintenance. . Ann Oncol 16(Suppl 5):v109 (#247), 2005.
 105. Cohen P, Cheson B, Friedberg J, Robinson KS, Foran J, Fayad L, Tulpule A, Bessudo A, van der Jagt R, Suster MS, Multani PS. The novel alkylator Bendamustine HCL is active in both rituximab-refractory and rituximab-sensitive relapsed indolent NHL with acceptable toxicity. . J Clin Oncol 23(16S):576S (#6564), 2005.
 106. Georgakis G, Li Y, Rassidakis G, Fayad L, Medeiros L, Younes A. Therapeutic inhibition of heat shock protein-90 function in Hodgkin's lymphoma. . Ann Oncol 16(Suppl 5):v215 (#6074), 2005.
 107. Fayad L, Pro B, Liu Q, Hess M, Hagemeister F, Romaguera J, Samaniego F, Cabanillas F, Rodriguez A, Younes A, Wang M, and McLaughlin P. Time to Treatment Failure (TTF) and FLIPI Correlate Well with Survival and Are Independent Variables in Stage IV Indolent Follicular Lymphomas (IFL). Blood 106(11):[933] 274a, 2005.
 108. Tsimberidou AM, O'Brien S, Kantarjian H, Koller C, Hagemeister F, Fayad L, Lerner S, and Keating MJ. Transformation of Chronic Lymphocytic Leukemia into Hodgkin's Disease The M D Anderson Cancer Center Experience. Blood 106(11):[976] 287a, 2005.
 109. Khouri I, Saliba R, Lee M, Okoroji GJ, Fayad L, Acholonu S, Maadani F, Hosing C, Younes A, McLaughlin P, Champlin R. Transplant Lite with rituximab-containing conditioning regimens for Non-Hodgkin's Lymphomas (NHL): An Update. . Ann Oncol 16(Suppl 5):v101 (#218), 2005.
 110. Kornblau SM, Jackson CE, Worthing A, Faderl S, Beran M, Fayad L, Ravhandi-Kashani F, Borthakur G, Gale R, Vertovsek S. A phase I trial of a novel organic arsenic S-dimethylarsino-glutathione (ZIO-101). J Clin Oncol 24 (18s):664s, 2006.
 111. Pro B, Fayad L, Romaguera J, Hagemeister FB, Samaniego F, McLaughlin P, Rodriguez AM, Kwak L, Walker P, Dang N. A phase II of HCVDDoxil alternated with methotrexate-cytarabine in patients with newly diagnosed T-cell lymphoma. J Clin Oncol 24 (18s):103s, 2006.

112. Younes A, Fanale M, Pro B, McLaughlin P, Neelapu S, Fayad L, Wedgwood A, Dubay M, Backstrom J, and Martell RE. A Phase II Study of a Novel Oral Isotype-Selective Histone Deacetylase(HDAC) Inhibitor in Patients with Relapsed or Refractory Hodgkin Lymphoma. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25(18s):8000, 2006.
113. Forero-Torres A, Cohen P, Cheson BD, Robinson KS, La Casce AS, Fayad L, Camacho ES, Williams ME, Van de Jagt RH, Friedberg JW. A phase II study of Bendamustine for rituximab refractory B-cell Non-Hodgkin's lymphoma. ESMO, 2006.
114. Pro B, Nunez RF, Romaguera J, Rodriguez MA, Hagemeister, F, and Fayad L. Achievement of FDG-PET Negativity Does Not Predict Durable Responses in T-Cell Lymphoma. Blood 108(11):[2404], 2006.
115. Fayad L and Cannata J. Adult Langerhans' Cell Histiocytosis (LCH): A Single Institution Experience. Blood 108(11):[3890], 2006.
116. Romaguera JE, Fayad L, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang L, Kantarjian HM, Beasley V, Medeiros LJ, Katz RL, and Cabanilla F. Blastoid Mantle Cell Lymphoma (MCL): 5-yr Failure-Free Survival (FFS) Rate of 50%, without Failures after 2.5 Years Following Treatment with Rituximab (R)-HyperCVAD Alternating with R-Methotrexate/Cytarabine (M/A). Blood 108(11):[2749], 2006.
117. Fayad L, Patel H, Verhoef G, Czuczmar M, Foran J, Gine E, Rohatiner A, Smith MR, Shapiro M, and Advani A. Clinical Activity of the immunoconjugate CMC-544 in B-Cell malignancies: Cohort of a Phase I Study. Blood 108(11):[2711], 2006.
118. VanRhee F, Fayad L, Borghaei H, Voorhees PM, Orlowski RZ, Furman RR, Zaki M, Prabhakar U, Jiao T, Lihou C, Garay CA, and Kurzrock R. CNTO 328, an Anti-Interleukin (IL)-6 Monoclonal Antibody (mAb) – Prelimi Subjects with Castleman's Disease from a Phase 1 Study in Selected Hematolog Malignancies. Blood 108(11):[2728], 2006.
119. Khouri IF, Saliba RM, Hosing C, Valverde R, Erwin WD, Fayad L, Maadani F, Korbling MJ, Okoroji GJ, Stachowiak AM, Samuels BI, Anderlini P, Couriel DR, de Lima M, Giralt S, Popat U, kebriyai P, Ueno N, Qazilbash MH, McLaughlin P, Hagemeister FB, Younes A, Podoloff DA, and Champlin RE. Efficacy and Safety of Yttrium 90 (90Y) Ibritumomab Tiuxetan in Autologous and Nonmyeloablative Stem Cell Transplantation (NST) for Relapsed and Non-Hodgkin's Lymphoma (NHL). Blood 108(11):[315], 2006.
120. Fayad L, Overman M, Pro B, McLaughlin P, Samaniego F, Younes A, Romaguera JE, Hagemeister FB, kwak L, and Rodriguez MA. Favorable Results of Rituximab in Combination with CHOP in the Front-Line Treatment of Follicular Lymphoma Grade 3. Blood 108(11):[2770], 2006.
121. Teegala S, Zhou X, Huen A, Ji Y, Fayad L, Romaguera JE, Hagemeister FB, and Vadhan-Raj S. High Incidence of Venous Thromboembolism in Patients with Lymphoma Receiving Chemotherapy: Assessment of Risk Factors. Blood 108(11):[4103], 2006.
122. Huen A, Zhou X, Teegala S, Ji Y, Fayad L, Romaguera JE, Hagemeister FB, Vadhan-Raj S. Incidence and Risk Factors for Severe Thrombocytopenia in Lymphoma Patients Receiving Chemotherapy. Blood 108(11):[3994], 2006.
123. Samaniego F, Fayad L, Pro B, McLaughlin P, Rodriguez MA, Hagemeister FB, Fanale M, Neelapu S, Younes A, and Kwak L. Pentostatin Combined with Cyclophosphamide, and Rituximab Induces High Response Rates in Patients with Untreated Indolent B-Cell Lymphoma. Blood 108(11):[4722], 2006.
124. Kurzrock R, Voorhees P, Fayad L, Orlowsky R, Van Thee F, Furman R, Borghaei H, Zaki MH, Prabhakar U, Garay C. Phase I, multicenter trial of CNTO 328, an anti-interleukin (IL)-6 monoclonal antibody (mAb) in subjects with hematology malignancies. J Clin Oncol 24(18s):664s, 2006.
125. Fayad L, Liebmann J, Modiano M, Cohen G, Pro B, Romaguera J, and Stromatt S. Results of a Phase I/II Trial of Pixantrone in combination with Fludarabine, Dexamethasone, and Rituximab in the Treatment of Patients with Relapsed Refractory Indolent Non-Hodkin's Lymphoma (NHL). Blood 108(11):[2758], 2006.
126. Younes A, Fayad L, Goy A, McLaughlin P, Pro B, Romaguera J, Hagemeister F, Rodriguez MA, Samaniego F, Kwak L, Neelapu S, Medeiros LJ, Wedgwood A, and Fanale M. Results of Rituximab Plus ABVD in 65 Newly Diagnosed Patients with Classical Hodgkin Lymphoma:

- Improvement of Event Free Survival (EFS) in All International Prognostic Score (IPS) Groups. *Blood* 108(11):[2742], 2006.
127. Kadia T, Fayad L, Rodriguez MA, McLaughlin P, and Pro B. Retrospective Review of Angioimmunoblastic T-Cell Lymphoma: The MD Anderson Cancer Experience. *Blood* 108(11):[4690], 2006.
 128. Morschhauser F, Leonard JP, Fayad L, Coiffier B, Schuster S, Dyer MJS, Petillon MO, Coleman M, Bahkti A, Horen H, Xu L, Teoh N, Wegener W, and Goldenberg DM. Rituximab-Relapsing Patients with Non-Hodgkins Lymphoma Respond Even at Lower Doses of Humanized Anti-CD20 Antibody, IMMU-106 (hA20): Phase I/II Results. *Blood* 108(11):[2719], 2006.
 129. Faderl S, Ferrajoli A, Wierda WG, O'Brien S, Ravandi-Kashani F, Fayad L, Thomas D, Kantarjian H, Browning ML, and Keating MJ. The Combination of Alemtuzumab [Continuous Intravenous Infusion (civ) Followed by Subcutaneous Injection (sc)] Plus Rituximab Has Activity in Patients (pts) with Relapsed Chronic Lymphocytic Leukemia (CLL). *Blood* 108(11):[2827], 2006.
 130. Wang S, Wang S, Maeng H, Young DP, Prakash OM, Fayad LE, Younes A, Samaniego F. K1 protein of human herpesvirus 8 suppresses lymphoma cell Fas-mediated apoptosis. *Blood* 109, 3/2007.
 131. Zhou X, Huen A, Teegala A, Ji Y, Fayad LE, Hagemester F, Vadhan-Raj S. Higher Incidence of Venous Thromboembolism Is Associated with Initial Cycles of Chemotherapy in Lymphoma Patients: Creatinine and Hemoglobin as Key Risk Factors. *Blood* 110(11):66B, 11/2007.
 132. Younes A, Pro B, Fanale M, McLaughlin P, Neelapu S, Fayad LE, Wedgwood A, Buglio D, Patterson T, Dubay M, Li Z, Martell RE, Ward MR, Bociek RG. Isotype-Selective HDAC Inhibitor MGCD0103 Decreases Serum TARC Concentrations and Produces Clinical Responses in Heavily Pretreated Patients with Relapsed Classical Hodgkin Lymphoma (HL). *Blood* 110(11):756a, 11/2007.
 133. Wang M, Fayad LE, Hagemester F, Neelapu S, Samuels B, Samaniego F, Pro B, Yi Q, Bell N, Byrne C, Weaver P, Hartig K, Knight R, Zeldis J, Kwak L, Romaguera JE. Lenalidomide (Len) in Combination with Rituximab (R) Demonstrated Early Evidence of Efficacy in a Phase I/II Study in Relapsed/Refractory Mantle Cell Lymphoma (MCL). *Blood* 110(11):755a, 11/2007.
 134. Thomas D, Kantarjian H, Cortes J, Faderl S, Ravandi-Kashani F, Wierda W, Rodriguez MA, Fayad LE, O'Brien S. Long-Term Outcome after Hyper-CVAD and Rituximab Chemoimmunotherapy for Burkitt (BL) or Burkitt-Like (BLL) Leukemia/Lymphoma and Mature B-Cell Acute Lymphocytic Leukemia (B-ALL). *Blood* 110, 11/2007.
 135. Tam CS, Ledesma C, Korbling M, Fayad LE, Wang M, Alousi A, Hosing C, Kebriaei P, Rondon G, Giralt SA, Anderlini P, Popat U, Couriel D, Pro B, Samuels B, Hagemester F, Champlin RE, Khouri I. Non-Myeloablative Allogeneic Stem Cell Transplantation (NMT) Overcomes the Adverse Effects of Treatment Resistance and High Beta-2-Microglobulin in Patients with Mantle Cell Lymphoma (MCL): An Analysis of 123 Transplantations at the MD Anderson Cancer Center. *Blood* 110(11):149a, 11/2007.
 136. Khouri I, Saliba R, Korbling M, Hosing C, Fayad LE, Lee MS, Samaniego F, Samuels BI, Couriel D, Hagemester F, McLaughlin P, Champlin RE. Nonmyeloablative Allogeneic Transplantation (NMT) for Relapsed Follicular Lymphoma (FL): Continuous Complete Remission with Longer Follow-Up. *Blood* 110(11):150a, 11/2007.
 137. Rodriguez MA, Fanale M, Hagemester F, McLaughlin P, Pro B, Romaguera JE, Kwak L, Fayad LE, Huang X, Durand JBE. Phase II Study of RCHOP with Pegylated Liposomal Doxorubicin (DRCOP) for Patients > 60 Years Old with Untreated Diffuse Large B Cell Lymphoma (DLBCL). *Blood* 110(11):187B, 11/2007.
 138. Pro B, Fayad LE, Romaguera JE, Fanale M, Younes A, Hagemester F, Samaniego F, McLaughlin P, Rodriguez MA, Kwak L, Dang NH. Preliminary Results of a Phase II Study of HCVIDDoxil Alternated with Methotrexate-Cytarabine in Patients with Newly Diagnosed T-Cell Lymphoma. *Blood* 110(11):1013A, 11/2007.
 139. Fayad LE, Pro B, Hagemester F, Cabanillas F, Samaniego F, McLaughlin P, Wang M, Neelapu S, Kwak L, Romaguera JE, Rodriguez MA. R-HCVAD/R-MTX-ARAC Is an Effective

- Regimen for Untreated Diffuse Large B-Cell Lymphoma (DLBCL) with Aggressive Features in Patients Younger Than 60 Years. *Blood* 110, 11/2007.
140. Wedgwood AR, Fanale M, Fayad LE, McLaughlin P, Hagemeister F, Pro B, Romaguera JE, Rodriguez MA, Samaniego F, Younes A. Rituximab + ABVD Improves Event-Free Survival (EFS) in Patients with Classical Hodgkin Lymphoma in All International Prognostic Score (IPS) Groups and in Patients Who Have PET Positive Disease after 2–3 Cycles of Therapy. *Blood* 110(11):71a, 11/2007.
 141. Fanale M, Fayad LE, Pro B, Samaniego F, Zachariah G, Nunez CA, Ji Y, Younes A. Safety and Efficacy of Bortezomib Plus ICE (BICE) for the Treatment of Relapsed/Refractory Classical Hodgkin's Lymphoma. *Blood* 110(11):198B, 11/2007.
 142. Overman MJ, Feng L, Pro B, McLaughlin P, Hess M, Samaniego F, Younes A, Romaguera JE, Hagemeister F, Kwak L, Cabanillas F, Rodriguez MA, Fayad LE. The Addition of Rituximab to CHOP Chemotherapy Improves Response Rate, Failure-Free Survival and Overall Survival for Follicular Grade 3 Lymphoma Compared to CHOP Alone. *Blood* 110, 11/2007.
 143. Alousi AM, Hosing C, Saliba RM, Valverde RB, Maadani F, Korbling M, Okoroji GJ, Fayad LE, Stachowiak AM, Erwin WD, Anderlini P, de Lima MJ, Giralt SA, Popat UR, Kebriaei P, Ueno NT, McLaughlin P, Pro B, Wang M, Rodriguez MA, Hagemeister F, Macapinlac HA, Podoloff DA, Champlin RE, Khouri I. Zevalin®/BEAM/Rituximab vs BEAM/Rituximab and Autologous Stem Cell Transplantation (ASCT) for Relapsed Chemosensitive Diffuse Large B-Cell Lymphoma (DLBCL): Impact of the IPI and PET Status. *Blood* 110(11):191a, 11/2007.
 144. Wang M, Fayad L, Hagemeister F, Neelapu S, Bell N, Byrne C, Knight R, Zeldis J, Kwak L, and Romaguera J. A Phase I/II Study of Lenalidomide (Len) in Combination with Rituximab (R) in Relapsed/Refractory Mantle Cell Lymphoma (MCL) with Early Evidence of Efficacy. ASCO Annual Meeting Proceedings Part 1. *J Clin Oncol* 25(18s):[8030], 2007.
 145. Falchook GS, Dhillon N, Moulder S, Duvic M, Ng C, Hong D, Camacho L, Lim J, Wang M, Fayad L, and Kurzrock R. Age-Stratified Phase I Trial of a Combination of Bortezomib, Gemcitabine, and Liposomal Doxorubicin in Patients with Advanced Malignancies. ASCO Annual Meeting Proceedings Part I. *J Clin Oncol* 25(18s):14087, 2007.
 146. Lenihan DJ, Massey MR, Baysinger K, Steinert D, Fayad L, Yusuf SW, Chiu A, Durand A, and Yeh ET. Early Detection of Cardiotoxicity During Chemotherapy Using Biomarkers. ASCO Annual Meeting Proceedings Part I. *J Clin Oncol* 25(18s):19521, 2007.
 147. Huen A, Romaguera JE, Fayad LE, Teegala SR, Ji Y, and Vadhan-Raj S. Increased Toxicity Associated with Delayed Clearance of Methotrexate (MTX) in Patients with Lymphoma Receiving High-Dose MTX. ASCO Annual Meeting Proceedings Part I. *J Clin Oncol* 25(18s):[19578], 2007.
 148. Morschhauser F, Leonard JP, Fayad L, Coiffier B, Petillon M, Coleman M, Horne H, Teoh N, Wegner WA, and Goldenberg DM. Low Doses of Humanized Anti-CD20 Antibody, IMMU-106 (hA20), in Refractory or Recurrent NHL: Phase I/II Results. ASCO Annual Meeting Proceedings Part I. *J Clin Oncol* 25(18s):8032, 2007.
 149. Rodriguez MA, Temple S, Fayad L, Hagemeister F, McLaughlin P, Romaguera J, and Cabanillas F. Predictive Value for Survival of a Risk Model of Two Serological Markers, Beta-2-Microglobulin (B2M) and Lactic Dehydrogenase (LDH), in Diffuse Large Cell Lymphoma (DLCL). *J Clin Oncol* 25(18s):10599, 2007.
 150. Fayad L, Temple S, Pro B, Hagemeister F, Cabanillas F, Samaniego F, McLaughlin P, Wang M, Kwak L, Romaguera J, and Rodriguez MA. R-HCV AD/R-MTX-ARAC is an Effective Regimen for Untreated Diffuse Large B-Cell Lymphoma (DLBCL) with Aggressive Features: M.D. Anderson Experience in 40 Patients. ASCO Annual Meeting Proceedings Part I. *J Clin Oncol* 25(18s):8058, 2007.
 151. Teegala SR, Zhou X, Huen A, Ji Y, Fayad LE, Romaguera JE, and Vadhan-Raj S. Risk Factors for Neutropenic Fever in Lymphoma Patients Receiving Chemotherapy. ASCO Annual Meeting Proceedings Part I. *J Clin Onco* 25(18s):19616, 2007.
 152. Zhou X, Teegala SR, Huen A, Ji Y, Fayad LE, Romaguera JE, Hagemeister FB, and Vadhan-Raj S. Risk Factors for Severe Anemia Requiring Red Blood Cell Transfusions in Lymphoma Patients Receiving Chemotherapy. ASCO Annual Meeting Proceedings Part I. *J Clin Oncol* 25(18s):19537, 2007.

153. Rodriguez MA, Fanale M, Hagemeister FB, McLaughlin P, Pro B, Romaguera JE, Kwak L, Fayad LE, Durand J. Activity and toxicity of pegylated liposomal doxorubicin in combination regimen (DRCOP) for patients >60 years old with untreated diffuse large B cell lymphoma (DLBCL): A phase II study. *J Clin Oncol* 26(15S):725s (#20505), 5/2008.
154. Cultrera JL, Nunez RF, Romaguera JE, Hagemeister FB, Rodriguez MA, Fayad LE, Pro B. Early Fluoro-2-deoxy-D-glucose positron emission tomography/computerized tomography (PET/CT) imaging as a tool for response assessment in T-cell non-Hodgkin's lymphoma (TCL): An update to a phase II study of HCVIDD alternated with methotrexate (MTX) and cytarabine (Ara-C). *J Clin Oncol* 26(15S):463s (#8538), 5/2008.
155. Zhou X, Huen A, Teegala S, Ji S, Fayad LE, Hagemeister FB, Vadhan-Raj S. Incidence and significant predicting factors for chemotherapy-induced severe thrombocytopenia in lymphoma patients. *J Clin Oncol* 26(15S):726s (#20519), 5/2008.
156. Goldenberg DM, Chang C, Rossi EA, Cardillo TM, Wegener WA, Teoh N, Leonard JP, Fayad LE, Colffier B, Morchhauser F. Laboratory and clinical studies of high anti-lymphoma potency with anti-CD20 veltuzumab and differentiation from rituximab. *J Clin Oncol* 26(15S):142s (#3043), 5/2008.
157. Suh GK, McLaughlin P, Romaguera JE, Hagemeister FB, Pro B, Khouri IF, Samaniego F, Rodriguez MA, Fayad LE, FENG I, Younes A. Long-term follow-up of paclitaxel and topotecan plus rituximab (TTR) for patients with relapsed and refractory B-cell non-Hodgkin's lymphoma. *J Clin Oncol* 26(15S):478s (#8599), 5/2008.
158. Shah N, Cabanillas F, Feng L, McIntyre B, McLaughlin P, Rodriguez MA, Romaguera JE, Younes A, Hagemeister FB, Kwak L, Fayad LE. Prognostic value of serum CD44, ICAM-1 and VCAM-1 levels in patients with indolent non-Hodgkin's lymphomas. *J Clin Oncol* 26(15S):475s (#8589), 5/2008.
159. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korblin M, Lee MS, Medeiros LJ, Fayad L, Samaniego F, Alousi A, Anderlini P, Couriel D, de Lima M, Giralt S, Neelapu SS, Ueno NT, Samuels BI, Hagemeister F, Kwak LW, Champlin RE. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. *Blood* 111(12):5530-6, 6/2008.
160. Fanale MA, Fayad LE, Pro B, Samaniego F, Zachariah G, Nunez CA, Ji Y, Younes A. A phase I study of bortezomib in combination with ice (bice) in patient with relapsed/refractory classical hodgkin lymphoma. *Blood* 112(3048), 11/2008.
161. Kurzrock R, Fayad LE, Voorhees P, Furman RR, Lonial S, Borghaei H, Jagannath S, Sokol L, Cornfeld M, Qi M, Jiao T, Herring J, Qin X, van Rhee F, . A phase I study of CNTO 328, an anti-interleukin-6 monoclonal antibody in patients with B-cell non-hodgkin's lymphoma, multiple myeloma, or castlemans disease. *Blood* 112(1009), 11/2008.
162. Cataldo VD, Thompson MA, Toth BB, Sanjorjo P, Bekele BN, Jimenez C, Murphy WA, Huen AO, Arbuckle RB, Fanale M, Fayad LE, Fowler N, Kwak LW, McLaughlin PW, Neelapu SS, Pro B, Rodriguez AM, Shah J, Hagemeister FB. Bone loss in patients with previously untreated lymphoma: the effect of periodontal disease on the use of zoledronic acid. *Blood* 112(5297), 11/2008.
163. Van Rhee F, Fayad LE, Voorhees P, Furman RR, Borghaei H, Lonial S, Sokol L, Crawford J, Cornfeld M, Qi M, Herring J, Qin X, Kurzrock R. CNTO 328, a monoclonal antibody to interleukin-6, is active as a study agent in Castleman's disease: preliminary results of a phase I study. *Blood* 112(1008), 11/2008.
164. Wang M, Zhang L, Fayad LE, Hagemeister F, Neelapu S, Samaniego F, Pro B, Younes A, Miller S, Knight RD, Zeldis JB, Yi Q, Romaguera JE. Lenalidomide and rituximab are a promising combination in vitro, in vivo preclinically and in a phase I/II clinical trial in relapsed/refractory mantle cell lymphoma. *Blood* 112(3058), 11/2008.
165. Thomas DA, Kantarjian HM, Cortes J, Faderl S, Wierda WG, Ravandi F, Rodriguez MA, Fayad LE, O'Brien S. Long-term outcome after hyper-CVAD and rituximab chemoimmunotherapy for burkitt (BL) or burkitt-like (BLL) leukemia/lymphoma and mature B-cell acute lymphocytic leukemia (ALL). *Blood* 112(1929), 11/2008.
166. Mazloom A, Reed VK, Cabanillas F, Fayad LE, Pro B, Iyengar P, McLaughlin P, Urbauer DL, Dabaja BS. Marginal zone lymphoma: factors that affect the final outcome, a study of 275 patients. *Blood* 112(3764), 11/2008.

167. Samaniego F, Fanale M, Pro B, Hagemeister FB, McLaughlin P, Romaguera JE, Neelapu S, Rodriguez MA, Fayad LE, Younes A, Kwak L. Pentostatin, cyclophosphamide, and rituximab (PCR) achieve high response rates in indolent B-cell lymphoma without prolonged myelosuppression. *Blood* 112(835), 11/2008.
168. Romaguera JE, Fayad LE, McLaughlin P, Pro B, Rodriguez MA, Wang M, Weaver P, Hartig K, Kwak L, Feldman T, Smith J, Ford P, Goldberg S, Pecora A, Goy A. Phase I trial of bortezomib in combination with rituximab-hyperCVAD/methotrexate and cytarabine for untreated mantle cell lymphoma. *Blood* 112(3051), 11/2008.
169. Garg RJ, Wierda W, Fayad LE, Estrov Z, Bickel SM, O'Brien, S. Phase II study of dasatinib in patients with relapsed CLL. *Blood* 112(4197), 11/2008.
170. Romaguera JE, Fayad LE, Rodriguez AM, Hagemeister FB, Pro B, McLaughlin PW, Younes A, Samaniego F, Shah J, Weaver P, Hartig K, Cabanillas F, Kwak L, Kantarjian H, Wang M. Rituximab (R) + hypercvad alternating with r-methotrexate/cytarabine after 9 years: continued high rate of failure-free survival in untreated mantle cell lymphoma (MCL). *Blood* 112(833), 11/2008.
171. Fayad LE, Patel H, Verhoef G, Smith MR, Johnson PWM, Czuczman MS, Coiffier B, Hess G, Gine E, Advani Anjali, Offner F, Vandendries ER, Shapiro M, Dang NH. Safety and clinical activity of the anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) in combination with rituximab in follicular lymphoma or diffuse large B-cell lymphoma: preliminary report of a phase 1/2 study. *Blood* 112(266), 11/2008.
172. Goldenberg DM, Chang C, Rossi EA, Cardillo TM, Wegener WA, Teoh N, Leonard JP, Fayad L, Coiffier B, Moschhauser F. Activity of Veltuzumab, a Second-Generation Humanized Anti-CD20 MAB, in Laboratory and Clinical Studies. *Annals of Oncology* 19(4):iv130 (#144), 2008.
173. Berkova Z, Maeng H, Wang S, Wang S, Wise J, Hawke D, Campbell M, Fayad L, Kwak L, Samaniego F. CD74 Associates with FAS and Inhibits FAS-Mediated Apoptotic Signaling. *Annals of Oncology* 19(4):iv169 (#287), 2008.
174. Wang M, Fayad L, Hagemeister F, Neelapu S, Samuels B, Samaniego F, Pro B, Yi Q, Bell N, Byrne C, Weaver P, Hartig K, Knight R, Zeldis J, Kwak L, Romaguera J. Lenalidomide in Combination with Rituximab is Effective with Manageable Toxicity in a Phase I/II study in Relapsed/Refractory Mantle Cell Lymphoma. *Annals of Oncology* 19(4):iv174 (#306), 2008.
175. Samaniego F, Fanale M, Pro B, Hagemeister F, McLaughlin P, Romaguera J, Neelapu S, Rodriguez A, Fayad L, Younes A, Kwak L. Pentostatin Combined with Cyclophosphamide, and Rituximab (PCR) Achieve High Response Rates in Indolent B-Cell Lymphoma. *Annals of Oncology* 19(4):iv182 (#334), 2008.
176. Romaguera JE, Pro B, Fayad L, McLaughlin P, Wang M, Weaver P, Hartig K, Hagemeister F, Rodriguez MA, Younes A, Samaniego F, Fanale M, Kwak L, Feldman T, Goy A. Phase I Trial of Bortezomib in Combination with Rituximab-HyperCVAD/Methotrexate and Cytarabine for Untreated Mantle Cell Lymphoma. *Annals of Oncology* 19(4):iv214 (#444), 2008.
177. Hamlin PA, Moskowitz CH, Wegner B, Noy A, Gerecitano J, Palomba ML, Portlock C, Straus D, Pro B, Fayad L, Rodriguez A, Zelenetz AD. Sequential RCHOP and YTTTRIUM-90 Ibritumomab Tiuxetan (RIT) is a highly effective regimen for High Risk Elderly Patients with Untreated DLBCL. *Annals of Oncology* 19(4):iv100 (#054), 2008.
178. Fowler N, McLaughlin P, Kwak LW, Hagemeister F, Fanale M, Fayad L, Pro B, Samaniego F. Lenalidomide and rituximab for untreated indolent non-Hodgkin's lymphoma. *J Clin Oncol* 27(15S):445, 5/2009.
179. Fowler N, McLaughlin P, Hagemeister FB, Kwak L, Fanale M, Neelapu S, Fayad LE, Pro B, Sergent C, White S, Samaniego F. A Biologic Combination of Lenalidomide and Rituximab for Front-Line Therapy of Indolent B-Cell Non-Hodgkin's Lymphoma. *Blood (ASH Annual Meeting Abstracts)* 114:1714, 11/2009.
180. Wang M, Fayad LE, Hagemeister FB, Neelapu S, Samaniego F, McLaughlin P, Samuels B, Yi Q, Pro B, Fanale M, Shah J, Younes A, Bell N, Knight R, Zeldis JB, Cabanillas F, Kwak L, Romaguera JE. A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma. *Blood (ASH Annual Meeting Abstracts)* 114:2719, 11/2009.
181. Dang NH, Smith MR, Offner F, Verhoef G, Johnson P, Rohatiner AZ, Kaufman JL, Gine E, Coiffier B, Czuczman MS, Foran J, Durrant S, Hua S, Vandendries ER, Fayad LE. Anti-CD22

- Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab: Clinical Activity Including Survival in Patients with Recurrent/Refractory Follicular or 'Aggressive' Lymphoma. *Blood (ASH Annual Meeting Abstracts)* 114:584, 11/2009.
182. Westin JR, Thompson MW, Cataldo V, Toth BB, Sanjorjo P, Bourgeois S, Jimenez C, Murphy WA, Fanale M, Fayad LE, Fowler N, Kwak LW, McLaughlin P, Neelapu S, Pro B, Rodriguez MA, Shah JJ, Hagemeister FB. Bone Loss in Lymphoma Patients Receiving Frontline Therapy: Urine NTx and Bone Specific Alkaline Phosphatase Provide Early Evidence of Zoledronic Acid Response. *American Society of Hematology (Blood)* 114(22):3922, 11/2009.
 183. Westin JR, Thompson MA, Cataldo V, Toth BB, Sanjorjo P, Bourgeois S, Jimenez C, Murphy WA, Fanale M, Fayad LE, Fowler N, Kwak L, McLaughlin P, Neelapu S, Pro B, Rodriguez MA, Shah J, Hagemeister FB. Bone Specific Alkaline Phosphatase Provide Early Evidence of Zoledronic Acid Response. *Blood (ASH Annual Meeting Abstracts)* 114:3922, 11/2009.
 184. Younes A, Copeland A, Romaguera JE, Fayad LE, Fanale M, de Castro Faria S, Medeiros LJ, Percy Ivy S. Clinical and Biologic Activity of the Heat Shock Protein-90 (HSP-90) Inhibitor 17-AAG in Patients with Relapsed Lymphoma. *Blood (ASH Annual Meeting Abstracts)* 114:3744, 11/2009.
 185. Jones D, Windham J, Stewart B, Fayad LE, Rodriguez MA, Hagemeister FB. Differential JAK-STAT Pathway Activation in Primary Mediastinal Large B-Cell Lymphoma: Two Subgroups with Differential Cytokine Activation Patterns and Predicted Responses to Kinase Inhibitors. *Blood (ASH Annual Meeting Abstracts)* 114:968, 11/2009.
 186. Hagenbeek A, Fayad LE, Delwail V, Rossi JF, Jacobsen E, Kuliczowski K, Link BK, Pinter-Brown L, Radford J, Hellmann A, Gallop-Evans E, Gupta I, Arning M, Begtrup K, Schultz M, Bang B, Russell C, Czuczman MS. Evaluation of Ofatumumab, a Novel Human CD20 Monoclonal Antibody, as Single Agent Therapy in Rituximab-Refractory Follicular Lymphoma. *Blood (ASH Annual Meeting Abstracts)* 114:935, 11/2009.
 187. Thomas DA, Faderl S, O'Brien S, Wierda WG, Ravandi F, Garcia-Manero G, Verstovsek S, Kornblau S, Fayad LE, Cortes J, Kantarjian HM. Favorable Outcome for Lymphoblastic Lymphoma (LL) After Frontline Therapy with the Hyper-CVAD Regimens: An Update. *Blood (ASH Annual Meeting Abstracts)* 114:4099, 11/2009.
 188. Copeland AR, Cao Y, Fanale M, Fayad LE, McLaughlin P, Pro B, Hagemeister F, Romaguera JE, Samaniego F, Rodriguez MA, Younes A. Final Report of a Phase-II Study of Rituximab Plus ABVD for Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma.: Results of Long Follow up and Comparison to Institutional Historical Data. *Blood (ASH Annual Meeting Abstracts)* 114:1680, 11/2009.
 189. Younes A, Gordon L, Kim S, Romaguera JE, Copeland AR, de Castro Faria S, Kwak L, Fayad LE, Hagemeister F, Fanale M, Lambert J, Bagulho T, Morariu-Zamfir R. Phase I Multi-Dose Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous (IV) Infusion Every 3 Weeks to Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL). *Blood (ASH Annual Meeting Abstracts)* 114:585, 11/2009.
 190. Vadhan-Raj S, Fayad LE, Fanale M, Pro B, Rodriguez MA, Hagemeister F, Ames K, Bueso-Ramos CE, Zhou X, McLaughlin P, Fowler N, Shah J, Samaniego F, Younes A, Kwak L, Romaguera JE. Randomized Clinical Trial of Rasburicase Administered as a Standard Fixed Five Days Dosing Vs a Single Dose Followed by as Needed Dosing in Adult Patients with Hematologic Malignancies at Risk for Developing Tumor Lysis Syndrome. *Blood (ASH Annual Meeting Abstracts)* 114:105, 11/2009.
 191. Khouri IF, Harrell R, Valverde R, Korbling M, Manshoury T, Samuels B, Maadani F, Okoroji G, Bassett, Jr. R, Amin A, Anderlini P, De Lima M, Giralt S, Hosing C, Kebriaei P, Popat U, Qazilbash M, Ueno N, Stachowiak AM, Erwin B, Fayad LE, Pro B, Fowler N, McLaughlin P, Neelapu S, Younes A, Champlin R, Podoloff D. Stem Cell Transplantation with 90yttrium Ibritumomab Tiuxetan(90YIT) in Non-Hodgkin's Lymphoma (NHL): Observations From PET Pre-Treatment Imaging and Responses in Allografted Refractory Follicular Histologies. *Blood (ASH Annual Meeting Abstracts)* 114:868, 11/2009.
 192. Jones D, Windham J, Stewart B, Fayad L, Rodriguez A, Hagemeister F. Differential JAK-STAT pathway activation in primary mediastinal large B-cell lymphoma produces distinct

- patterns of cytokine pathway response and predicted sensitivity to small molecule inhibitors. *Blood*, 2009.
193. Pro B, Perini G, Feng L, Romaguera J, Rodriguez MA, McLaughlin P, Hagemeister F, Fayad L, Kadia TM. Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma. *J Clin Oncol (Meeting Abstracts)* 28:8048, 6/2010.
 194. Fowler M, McLaughlin P, Hagemeister F, Kwak L, Fanale M, Neelapu A, Fayad LE, Orlowski R, Wang M, Samaniego F. Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma. *J Clin Oncol (Meeting Abstracts)* 28:8036, 6/2010.
 195. Perini G, Romaguera JE, Rodriguez MA, Pro B, Younes A, Fowler N, Hagemeister F, Samaniego F, Kwak LW, Fayad LE. Diffuse large B-cell lymphoma (DLBCL) with bone marrow (BM) involvement. clinical presentation, central nervous system (CNS) relapses, and outcomes of 121 patients treated at M. D. Anderson Cancer Center. *J Clin Oncol (Meeting Abstracts)* 28:8072, 6/2010.
 196. Pozadzides JV, Perini G, Hess M, Romaguera JE, Hagemeister FB, McLaughlin P, Fayad LE, Khouri IF, Hosing C, Pro B. Prognosis and treatment of patients with peripheral T-cell lymphoma: The M. D. Anderson Cancer Center experience. *J Clin Oncol (Meeting Abstracts)* 28:850, 6/2010.
 197. Manoukian G, Hagemeister F, McLaughlin P, Fayad L, Samaniego F, Goy A, Romaguera JE, Pro B, Cabanillas F, Rodriguez MA. Rituximab, fludarabine, mitoxantrone, and dexamethasone (R-FND) for patients with relapsed indolent B-cell lymphoma (RIL). *J Clin Oncol (Meeting Abstracts)* 28:8078, 6/2010.
 198. Hamlin PA, Rodriguez MA, Noy A, Portlock CS, Straus D, McLaughlin P, Pro B, Fayad L, Hagemeister FB, Wegner B, Dumitrescu O, Pandit Tasker N, Moskowitz CH, Zelenetz AD. Final Results of a Phase II Study of Sequential R-CHOP and Yttrium-90 Ibritumomab Tiuxetan (RIT) for Elderly High Risk Patients with Untreated Diffuse Large B-Cell Lymphoma (DLBCL). *American Society of Hematology (Blood)* 116(21):1793, 11/2010.
 199. Thomas DA, Faderl S, O'Brien S, Wierda WG, Garcia-Manero G, Verstovsek S, Konopleva M, Kadia T, Kornblau S, Fayad LE, Romaguera JE, Cortes JE, Kantarjian H. Long-Term Outcome for De Novo Lymphoblastic Lymphoma (LL) After Frontline Therapy with Hyper-CVAD Regimen and Variants. *American Society of Hematology (Blood)* 116(22):2831, 11/2010.
 200. Okoroji GJ, de Padua Silva G, Saliba RM, Korbling M, McLaughlin P, Hosing C, Anderlini P, Alousi A, de Lima M, Kebriaei P, Popat U, Qazilbash M, Fayad LE, Samaniego F, Fowler N, Champlin R, Hagemeister FB, Khouri I. Outcome In Follicular Lymphoma (FL) Patients (pts) Relapsing After Autologous Stem Cell Transplantation (ASCT): Allografting Vs. Conventional Therapy. *American Society of Hematology (Blood)* 3510 116(21):3510, 11/2010.
 201. Fanale MA, Lai CM, McLaughlin P, Romaguera JE, Fayad LE, Hagemeister F, Samaniego F, Rodriguez MA, Neelapu SS, Shah JJ, Kwak LW, Dong W, Reed V, Dabaja BS, Popat U, Younes A. Outcomes of Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Patients Treated with R-CHOP. *American Society of Hematology (Blood)* 116(2812), 11/2010.
 202. Younes A, Copeland A, Fanale MA, Hagemeister F, Fayad LE, Pro B, Faria SC, Ji Y, Medeiros JL, Berry DA, Buglio D. Phase I/II Study of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) In Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma. *American Society of Hematology (Blood)* 116(3964), 11/2010.
 203. Al-Ameri AM, Badoux X, Ferrajoli A, Wierda W, Fayad LE, Estrov Z, Bickel S, Keating MJ, O'Brien S. Phase II Study of Dasatinib In Patients with Relapsed Chronic Lymphocytic Leukemia. *American Society of Hematology (Blood)* 116(21):4488, 11/2010.
 204. Raj SV, Hagemeister F, Fayad LE, Zhou X, ORoark SS, Ames K, Rodriguez MA, Fanale MA, Pro B, Johnson MM, McLaughlin P, Bueso-Ramos CE, Younes A, Kwak LW, Romaguera JE. Randomized, Double-Blind, Placebo-Controlled, Dose and Schedule-Finding Study of AMG 531 In Chemotherapy-Induced Thrombocytopenia (CIT): Results of a Phase I/II Study. *American Society of Hematology (Blood)* 116(21):1544, 11/2010.

205. Dabaja BS, Phan J, Medeiros LJ, Chuang H, Fayad LE, Hagemeister F, Shihadeh FDA, Allen P, Rodriguez MA. Clinical implications of PET-negative residual disease at the completion of chemotherapy for diffuse large b-cell lymphoma. *J Clin Oncol* 29(15):2011, 6/2011.
206. Samaniego F, Hagemeister F, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Neelapu SS, Fayad LE, Orlowski RZ, Wang M, Lacerte L, Fowler N. High response rates with lenalidomide plus rituximab for untreated indolent b cell non-hodgkins lymphoma, including those meeting GELF criteria. *J Clin Oncol* 29(15):8030, 6/2011.
207. Fanale M, Vigil K, Lai CM, Feng L, Dong W, Younes A, Romaguera JE, Fayad LE, Hagemeister FB, Mulanovich V. Outcomes of HIV positive lymphoma patients treated in the highly active antiretroviral therapy (HAART) era. *J Clin Oncol* 29(15):2011, 6/2011.
208. Younes A, Kim S, Romaguera JE, Copeland A, de Castro Fariel S, Kwak LW, Fayad LE, Hagemeister F, Fanale M, Lambert LM, Morariu-Zamfir R, Gordon L. Phase I multi-dose escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory b-cell lymphoma. *J Clin Oncol*, 6/2011.
209. Rodriguez MA, Durand JB, Astrow AB, Bury MJ, Fanale M, Hagemeister FB, Huang X, McLaughlin P, Neelapu SS, Pro B, Kwak LW, Fayad LE, Romaguera JE, Younes A, Fish M. Phase II study of RCHOP with pegylated liposomal doxorubicin (DRCOP) for patients >60 years old with untreated diffuse large b cell lymphoma (DLBCL). *J Clin Oncol* 29(15):8053, 6/2011.
210. Romaguera J, Wang M, Hagemeister F, Weaver P, Hartig K, Fanale M, Fayad LE, Fowler N, Orlowski R, Feldman T, Wagner-Bartak N, Smith J, Ford P, Kwak L, Goy A. Phase I-II study of bortezomib in combination with R-HCVAD and R-Methotrexate/ cytarabine (R-MA) in untreated mantle cell lymphoma (MCL). 11th International Conference on Malignant Lymphoma, Lugano, Switzerland, 6/2011.
211. Romaguera J, Wang M, Hagemeister F, Weaver P, Hartig K, Fanale M, Fayad LE, Fowler N, Orlowski R, Feldman T, Wagner-Bartak N, Smith J, Ford P, Kwak L, Goy A. Phase I-II study of bortezomib in combination with R-HCVAD and R-Methotrexate/ cytarabine (R-MA) in untreated mantle cell lymphoma (MCL). 16th European Hematology Conference, London, England 22(4):218, 6/2011.
212. Hainsworth JD, Arrowsmith E, McCleod M, Fayad LE, Hamid O, Davis L, Lin BK. Randomized phase II study of r-CHOP plus enzastaurin versus r-Chop in the first-line treatment of patients with intermediate and high-risk diffuse large b-cell lymphoma (DLBCL) - preliminary analysis. *J Clin Oncol* 29(15):8016, 6/2011.
213. Matasar MJ, Czuczman MS, Rodriguez MA, Fennessy M, Shea TC, Spitzer G, Lossos IS, Kharfan-Dabaja MA, Joyce R, Fayad LE, Liao Q, Edvardsen K, Lisby K, Moskowitz CH. A Phase II Study of Ofatumumab in Combination with ICE or DHAP Chemotherapy in Relapsed or Refractory Aggressive B-Cell Lymphoma Prior to Autologous Stem Cell Transplantation (ASCT). *Blood (ASH Annual Meeting Abstracts)* 118(957), 11/2011.
214. Samaniego F, Wise J, Fayad LE, Fanale M, Hagemeister F, Sevaraj V, Goldenberg D, Kwak LK, Berkova Z. Anti-CD74 antibody hLL1 effects including bone marrow homing in lymphoma and chronic lymphocytic leukemia. *Blood (ASH Annual Meeting Abstracts)* 118(1796), 11/2011.
215. Pham LV, Tamayo AT, Li C, Lee J, Fayad LE, Ford RJ. Chemo-Resistance in Diffuse Large Cell Lymphoma: Novel Drug Combinations Targeting NFAT/NF-Kb Growth/Survival/Chemo-Resistance Signaling Pathways in Validated Novel Experimental Systems. *Blood (ASH Annual Meeting Abstracts)* 118(1428), 11/2011.
216. Dabaja BS, Phan J, Medeiros JL, Hagemeister FB, Chuang H, Fayad LE, Shihadeh F, Allen P, Wogan C, Rodriguez MA. Clinical Implications of PET-Negative Residual Disease At the Completion of Chemotherapy for Diffuse Large B-Cell Lymphoma. *Blood (ASH Annual Meeting Abstracts)* 118(2695), 11/2011.
217. Bollard CM, Gottschalk S, Sheehan AM, Carrum G, Liu H, Pro B, Fayad LE, Younes A, Mims M, Gee AP, Brenner MK, Rooney CM, Heslop HE. Complete Tumor Responses in Lymphoma Patients Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein Barr Virus (EBV) - Latent Membrane Proteins. *Blood (ASH Annual Meeting Abstracts)* 118(956), 11/2011.

218. Vadhan-Raj S, Spasojevic I, Zhou X, Romaguera JE, Fanale MA, Fayad LE, Fowler NH, Huen A, Hagemeister FB, Rodriguez MA, Neelapu SS, Samaniego F, Younes A, Kwak LW. Effects of Aprepitant on Drug Metabolism in Lymphoma Patients Receiving Multi-Day Chemotherapy Regimen of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, + Rituxan (R/CHOP): Randomized, Cross-Over Study. *Blood (ASH Annual Meeting Abstracts)* 118(1613), 11/2011.
219. Thomas DA, Kantarjian HM, Faderl S, Wierda WG, Jabbour E, Garcia-Manero G, Ferrajoli S, Verstovsek S, Burger JA, Fayad LE, Romaguera JE, Garris R, Cortes JE, O'Brien S. Hyper-CVAD and Rituximab for De Novo Burkitt Lymphoma/Leukemia. *Blood (ASH Annual Meeting Abstracts)* 118(2698), 11/2011.
220. O'Brien S, Thomas DA, Ohanian M, Jorgensen JL, Kebriaei P, Jabbour E, Rytting ME, York S, Ravandi F, Kwari M, Faderl S, Rios MB, Cortes JE, Fayad LE, Tarnai R, Wang SA, Champlin R, Advani AS, Kantarjian HM. Inotuzumab Ozogamycin (IO), a CD22 Monoclonal Antibody Conjugated to Calecheamicin, Is Active in Refractory-Relapse Acute Lymphocytic Leukemia (R-R ALL). *Blood (ASH Annual Meeting Abstracts)* 118(875), 11/2011.
221. Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad LE, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani S, van de Velde H, Qin X, Qi M, Cornfeld MJ, van Rhee F. Long-Term Safety in a Phase 1 Study of Siltuximab (CNTO 328), an Anti-Interleukin-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease,. *Blood (ASH Annual Meeting Abstracts)* 118(3959), 11/2011.
222. Younes A, Copeland A, Fanale M, Fayad LE, Romaguera JE, Kwak LW, Neelapu S, Hagemeister F, Pro B, de Castro Faria S, Ji Y, Berry D, Buglio D, Medeiros J. Safety and efficacy of the novel combination of panobinostat (LBH589) and everloimus (RAD001) in relapsed/refractory hodgkin and non-hodgkin lymphoma. *Blood (ASH Annual Meeting Abstracts)* 118(3718), 11/2011.
223. Thompson MA, Wei C, Moyer AM, Cunningham JM, Wang L, Fayad LE, Feng L, Rodriguez MA, Cabanillas F, Kantarjian HM, Kwak LW, Romaguera JE. Single Nucleotide Polymorphisms (SNPs) in Genes for Glutathione-Related Metabolism, Cyclin D1, and DNA Repair As Predictive Biomarkers in Mantle Cell Lymphoma Patients Treated with R-HyperCVAD with Ten Year Clinical Follow-up. *Blood (ASH Annual Meeting Abstracts)* 118(3650) (#3650), 11/2011.
224. Wang M, Fayad L, Wagner-Bartak N, Hagemeister F, Neelapu S, Finale M, Younes A, Cabanillas F, Zhang L, Champlin R, Kwak L, Feng L, Bell N, Zeldis J, Romaguera J. Oral lenalidomide plus 4 doses of rituximab induced prolonged remissions in relapsed/refractory mantle cell lymphoma: a completed phase I/II clinical trial. 11th International Conference on Malignant Lymphoma (ICML), Lugano, 2011.
225. Batty N, Ghonimi E, Feng L, Fayad LE, Younes A, Rodriguez MA, Romaguera JE, McLaughlin P, Samaniego F, Kwak LW, Hagemeister FB. Comparison of the international prognostic factors index (IPI) with the absolute monocyte and lymphocyte prognostic index (AMLPI) for patients (Pts) with diffuse large b-cell lymphoma (DLBCL) receiving R-CHOP. *J Clin Oncol* 30(8067), 6/2012.
226. Jabbour E, O'Brien SM, Thomas D, Jorgensen JL, Kebriaei P, Rytting ME, York S, Ravandi F, Kwari M, Faderl S, Rios MB, Cortes JE, Fayad LE, Tarnai R, Wang S, Champlin RE, Advani AS, Kantarjian H. Inotuzumab ozogamycin (IO), a CD22 monoclonal antibody conjugated to calecheamicin, given weekly, for refractory-relapse acute lymphocytic leukemia (R-R ALL). *J Clin Oncol* 30(6501), 6/2012.
227. Pham LV, Rollo A, Tamayo AT, Lee J, Zuo Z, Sun L, Zhang L, Ou Z, Fayad LE, Wang M, Ford RJ. Biological Significance of the Immumoproteasome Subunits Mecl-1 and LMP-2 in Diffuse Large B-Cell Lymphoma. *Blood (ASH Annual Meeting Abstracts)* 120(2717), 11/2012.
228. Khouri IF, Rima SM, Turturro F, Korbliing M, Ledesma C, Rondon G, Alousi AM, Anderlini P, Bash Q, Ciurea SO, Hosing CM, Popat UR, Charafeddine Y, Oki Y, Fayad LE, Champlin RE. Bortezomib and BEAM-Rituximab Reduced-Intensity Conditioning for High-Risk Lymphoma Patients Who Are Not Eligible for Nonmyeloablative Allogeneic Stem Cell Transplantation. *Blood (ASH Annual Meeting Abstracts)* 120(4157), 11/2012.
229. Fowler NH, Neelapu SS, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Orlowski RZ, Wang M, Turturro F, Oki Y, Lacerte L, Samaniego F.

- Lenalidomide and Rituximab for Untreated Indolent Lymphoma: Final Results of a Phase II Study. *Blood (ASH Annual Meeting Abstracts)* 120(901), 11/2012.
230. Westin JR, Chu F, Fayad LE, Kwak LW, Fowler NH, Romaguera JE, Hagemester FB, Fanale M, Samaniego F, Allen R, Feng L, Baladandayuthapani V, Rotem-Yehudar R, Neelapu SS. Phase II Safety and Efficacy Study of CT-011, a Humanized Anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma. *Blood (ASH Annual Meeting Abstracts)* 120(793), 11/2012.
231. Fanale MA, Lai CM, Rimes SA, Ramirez MM, Hagemester FB, Fowler NH, Younes A, Fayad LE, Rodriguez MA, Turturro F, Samaniego F, Romaguera JE, Levin VA, Horowitz SB, Woolery JE, Milbourne A. Positive Maternal-Fetal Outcomes with Treatment of Lymphoma During Pregnancy: UT MD Anderson Cancer Center Prospective Experience. *Blood (ASH Annual Meeting Abstracts)* 120(3670), 11/2012.
232. Samaniego F, Wise JF, Tao RH, Zhu H, Ao X, Chen Z, Zhuang W, Braun FK, Mathur R, Romaguera JE, Fayad LE, Wang M, McLaughlin P, McDonnell TJ, Patel KP, Neelapu SS, Kwak LW, Berkova Z. Regulation of Fas-mediated Apoptosis in B-Cell Lymphomas by Nucleolin. *Blood (ASH Annual Meeting Abstracts)* 120(2406), 11/2012.
233. Zhang K, Pham LV, Tamayo AT, Lee J, Bryant J, Younes A, Fayad LE, Yang DJ, Ford RJ. Reversing Metabolic and Epigenetic Cellular Alterations to Overcome Chemo-Resistance in Aggressive B Cell Lymphomas. *Blood (ASH Annual Meeting Abstracts)* 120(1305), 11/2012.
234. Oki Y, Westin JR, Fowler N, Neelapu S, Hagemester FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad LE. R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL. *Blood (ASH Annual Meeting Abstracts)* 120(3707), 11/2012.
235. Takahashi K, Sivina M, Oki Y, Fayad LE, Neelapu SS, Kwak LW, Xiao L, Huang X, Fu K, Chung Chan W, Vose J, Kantarjian HM, Keating M, Burger JA. Serum CCL3 and CCL4 Levels Function As Novel Prognostic Markers in Diffuse Large B Cell Lymphoma. *Blood (ASH Annual Meeting Abstracts)* 120(2709), 11/2012.
236. Oki Y, Chuang H, Chasen B, Pan T, Fanale MA, Dabaja BS, Fowler NH, Romaguera JE, Fayad LE, Hagemester FB, Rodriguez MA, Neelapu SS, Samaniego F, Kwak LW, Younes A. The Prognostic Value of Interim PET Scan in Patients with Classical Hodgkin Lymphoma. *Blood (ASH Annual Meeting Abstracts)* 120(1529), 11/2012.
237. Wang M, Fowler N, Wagner-Bartak N, Hagemester F, Neelapu S, Fanale M, Younes A, Zhang L, Sun L, Badillo M, Bejarano M, Champlin R, Kwak L, Feng L, Byrne C, Bell N, Zeldis J, Romaguera J, Fayad L. Oral lenalidomide plus 4 doses of rituximab induced prolonged remissions in a cohort of patients with DLBCL and grade 3 follicular lymphoma: a completed phase II clinical trial. 16th Congress of the European Hematology Association (EHA) (#237), 2012.
238. Hong DS, Younes A, Fayad LE, Fowler NH, Hagemester FB, Mistry R, Nemunaitis JJ, Borad MJ, Bryce AH, Yamashita M, Hughes SG, Kwok TJ, MacLeod AR, Norris D, Baldwin R, Hung G, Monia BP, Kurzrock R. A phase I study of ISIS 481464 (AZD9150), a first-in-human, first-in-class, antisense oligonucleotide inhibitor of STAT3, in patients with advanced cancers. *J Clin Oncol*, 6/2013.
239. Leppä S, Fayad LE, Lee JJ, Rocco A, Ogura M, Hagberg H, Schnell F, Rifkin RM, Mackensen A, Offner F, Pinter-Brown, Smith SO, Tobinai K, Yeh SP, Zhu J, Hahka-Kemppinen M, Thornton D, Shi P, Lin, Kahl BS, Schmitz N, Savage KJ, Habermann TM. A Phase III Study Of Enzastaurin In Patients With High-Risk Diffuse Large B Cell Lymphoma Following Response To Primary Treatment: The Prelude Trial. *Blood (ASH Annual Meeting Abstracts)* 122(21):371, 2013, 12/2013.
240. Casper C, Voorhees PM, Fayad LE, van de Velde H, Vermeulen J, Qin X, Qi M, Tromp B, Kurzrock R. An Open-Label, Phase 2, Multicenter Study Of The Safety Of Long-Term Treatment With Siltuximab (an Anti-Interleukin-6 Monoclonal Antibody) In Patients With Multicentric Castleman's Disease. *Blood (ASH Annual Meeting Abstracts)* 122(21):1806, 12/2013.
241. Neelapu SS, Fanale MA, Kwak LW, Fayad LE, Rodriguez AM, Wallace M, Carlton V, Kong K, Faham M, Younes A. Detection Of Classical Hodgkin Lymphoma In Peripheral Blood Using

- High-Throughput Sequencing Assay. *Blood (ASH Annual Meeting Abstracts)* 122(21):627, 2013, 12/2013.
242. Noorani M, Davis RE, Neelapu SS, Rodriguez A, Hagemeister FB, Fowler N, Wang M, Fanale MA, Samaniego F, Dabaja BS, Pinnix C, Kwak LW, Romaguera JE, Khouri I, Westin JR, Fayad LE. Double Hit Lymphoma: M.D. Anderson Experience. *Blood (ASH Annual Meeting Abstracts)* 122(21):1776, 2013, 12/2013.
 243. Kantarjian HM, Cortes JE, Jabbour EJ, Faderl SH, Wierda WG, Garcia-Manero G, Ferrajoli A, Verstovsek S, Burger JA, Fayad LE, Romaguera JE, Garris R, Ravandi R, O'Brien S, Thomas D. Long Term Follow-Up Of De Novo Or Minimally Treated Burkitt Lymphoma/Leukemia (BL/B-ALL) After Frontline Therapy Per The Hyper-CVAD Regimen With Or Without Rituximab: 20-Year Cumulative Experience. *Blood (ASH Annual Meeting Abstracts)* 122(21):3917, 2013, 12/2013.
 244. Rodriguez MA, Deitcher SR, Younes A, Fayad LE, Goy A, Dang NH, Forman A, McLaughlin P, Pro B, Romaguera JE, Samaniego F, Silverman JA, Sarris AH, Cabanillas F. Long Term Results Of a Phase 2 Study Of Vincristine Sulfate Liposome Injection (Marqibo®) Substituted For Non-Liposomal Vincristine In CHOP With Or Without Rituximab For Patients With Untreated Aggressive Non-Hodgkin's Lymphomas. *Blood (ASH Annual Meeting Abstracts)* 122(21):3033, 2013, 12/2013.
 245. Romaguera JE, Kwak LW, Hagemeister FB, Rodriguez MA, Oki Y, Westin JR, Turturro F, Overman MJ, Neelapu SS, Fowler N, Fayad LE. Long-Term Remissions Of Patients With Follicular Lymphoma Grade 3 Treated With Rituximab, Cyclophosphamide, Doxorubicine, Vincristine and Prednisone (R-CHOP). *Blood (ASH Annual Meeting Abstracts)* 122(21):3028, 12/2013.
 246. Matasar MJ, Czuczman MS, Rodriguez MA, Fennessy M, Shea TC, Spitzer G, Lossos IS, Kharfan-Dabaja MA, Joyce R, Fayad LE, Henkel K, Liao Q, Edvardsen K, Jewell RC, Fecteau D, Singh R, Lisby S, Moskowitz CH. Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. *Blood (ASH Annual Meeting Abstracts)* 122(21):499-506, 12/2013.
 247. Saliba RM, Xu-Monette ZY, Rondon G, Valverde R, Korbling M, Gulbis AM, Anderlini P, Sairah A, Hosing CM, Popat UR, Kebriaei P, Fayad LE, Westin JR, Turturro F, Medeiros LJ, Champlin RE, Young KH. Outcomes Following Autologous Stem Cell Transplantation (ASCT) In Patients With Germinal Center B (GCB) and Non-GCB Cell-Like Diffuse Large B Cell Lymphomas (DLBCL) According To Conditioning With BEAM-Rituximab (Standard vs. High-Dose) Vs. BEAM/Yttrium-90 Ibritumomab Tiuxetan (90YIT). *Blood (ASH Annual Meeting Abstracts)* 122(21):3350, 12/2013.
 248. Fanale MA, Samaniego F, Fayad LE, Hagemeister FB, McLaughlin P, Rodriguez MA, Weaver P, Hartig K, Badillo M, Kwak LW, Younes A, Pro B, Wang M. Phase II Trial Of Bortezomib In Combination With Fractionated Cyclophosphamide and Rituximab (BCR) For Relapsed/Refractory Mantle Cell Lymphoma (MCL). *Blood (ASH Annual Meeting Abstracts)* 122(21):5122, 12/2013.
 249. Garrido-Laguna I, Velez-Bravo V, Falchook GS, Subbiah V, Hong DS, Oki Y, Westin JR, Nunez CA, Fayad LE, Kwak LW, Shpall EJ, Wheler JJ, Liang W, Salhia B, Meric-Bernstam F, Kurzrock R, Fanale MA. Significant Activity Of The mTOR Inhibitor Sirolimus and HDAC Inhibitor Vorinostat In Heavily Pretreated Refractory Hodgkin Lymphoma Patients. *Blood (ASH Annual Meeting Abstracts)* 122(21):3048, 12/2013.
 250. Nastoupil LJ, Neelapu SS, Samaniego F, Hagemeister FB, Romaguera JE, Kwak LW, Wang M, Fayad LE, Fanale MA, Oki Y, Westin JR, Rodriguez MA, Cabanillas F, McLaughlin P, Fowler NH. 10-year remission rates following rituximab (R) and FND chemotherapy (fludarabine, mitoxantrone, dexamethasone) with interferon (IFN) maintenance in indolent lymphoma: Results of a randomized study. *J Clin Oncol ASCO MEETING(8528)*, 6/2014.
 251. Janku F, Oki Y, Falchook GS, Subbiah V, Naing A, Velez Bravo VM, Hong DS, Westin JR, Nunez C, Fayad LE, Neelapu SS, Kwak LW, Shpall EJ, Wheler JJ, Barnes T, Liang WS, Salhia B, Meric-Bernstam F, Kurzrock R, Fanale MA. Activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated refractory Hodgkin lymphoma patients. *J Clin Oncol ASCO MEETING(8508)*, 6/2014.

252. Dang NH, Ogura M, Castaigne S, Fayad LE, Jerkeman M, Radford JA, Pezzutto A, Bondarenko I, Stewart DA, Shnaidman M, Sullivan S, Vandendries E, Tobinai K, Ramchandren R, Hamlin PA, Gine E, Ando K. Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab (R-InO) versus chemotherapy for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL). *J Clin Oncol ASCO MEETING(8529)*, 6/2014.
253. Jain P, Patel K, Bueso-Ramos CE, Romaguera JE, Fayad LE, Kwak LW, Fowler N. Treatment of dendritic cell sarcoma: 18-year experience at the MD Anderson Cancer Center. *J Clin Oncol ASCO MEETING(8596)*, 6/2014.
254. Ahmed MA, Barac R, Medeiros LJ, Ma L, Fayad LE, Romaguera JE, Oki Y, Rodriguez MA, Pinnix C, Kwak LW, Hagemester FB, Davis RE, Westin JR. Treatment outcomes and prognostic factors for primary mediastinal B-cell lymphoma: The MD Anderson experience. *J Clin Oncol ASCO MEETING(8564)*, 6/2014.
255. Sehn LH, Goy A, Offner FC, Martinelli G, Caballero MD, Gadeberg O, Baetz T, Zelenetz AD, Gaidano G, Fayad LE, Buckstein R, Friedberg JW, Crump M, Jaksic B, Zinzani PL, Padmanabhan Iyer S, Sahin D, Chai A, Fingerle-Rowson G, Press OW. Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study. *J Clin Oncol*:3467-3474, 10/2015.
256. Fowler N, Pinto R, Cheah CY, Neelapu S, Turturro F, Hagemester F, Romaguera JE, Fanale MA, Fayad LE, Forbes S, Khan J, Feng L, Samaniego F, Nastoupil L. A Phase I Study of Lenalidomide Plus a Next Generation Anti-CD20 Antibody, Obinutuzumab, in Relapsed Indolent Lymphoma. *Blood (ASH Annual Meeting Abstracts)* 126(23):2742, 12/2015.
257. Yasenchak CA, Halwani A, Advani R, Ansell S, Budde LE, Burke JM, Farber CM, Holkova B, Fayad LE, Kolibaba KS, Knapp M, Li M, Manley TJ, Patel-Donnelly D, Seetharam M, Yimer HA, Bartlett NA. Brentuximab Vedotin with RCHOP As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL): Results from an Ongoing Phase 2 Study. *Blood (ASH Annual Meeting Abstracts)* 126(23):814, 12/2015.
258. Fanale MA, Wang A, Ma W, Oki Y, Hagemester FB, Fayad LE, Fowler N, Romaguera JE, Shah N, Chuang HH, Lei F, Horowitz SB, Chihara D, Wesson E, Hutto T, Ruben C, Samaniego F, Muzzafar T, Piekarz R, Davis RE. Gene Expression Profiling for Molecular Features of Response in a Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B- and T-Cell Lymphomas. *Blood (ASH Annual Meeting Abstracts)* 126(23):2705, 12/2015.
259. Chihara D, Oki Y, Westin JR, Nastoupil L, Fayad LE, Samaniego F, Wesson E, Ruben C, Horowitz SB, Feng L, Garg N, Ahmed S, Khouri IF, Hosing CM, Romaguera JE, Fowler N, Fanale MA. High Response Rate of Romidepsin in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: Updates of Phase I Trial. *Blood (ASH Annual Meeting Abstracts)* 126(23):3987, 12/2015.
260. Khouri I, Sui D, Turturro F, Erwin WD, Bassett Jr. RJ, Korbling M, Valverde R, Ahmed S, Alousi AM, Anderlini P, Bashir Q, Ciurea S, Oran B, Olson A, Popat, Patel KK, Qazilbash M, Fanale MA, Fayad LE, Nastoupil L, Westin JR, Gulbis AM, Medeiros LJ, Young KH, Jessop A. In-Vivo Purging with Rituximab (R) Followed By Z/BEAM Vs BEAM/R Autologous Stem Cell Conditioning for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Mature Results from a Combined Analysis of 3 Trials. *Blood (ASH Annual Meeting Abstracts)* 126(23):3192, 12/2015.
261. Wang Y, Wagner-Bartak N, Zhou S, Fowler N, Lourdes Dela Rosa M, Zhao D, Romaguera JE, Neelapu SS, Hagemester FB, Fanale MA, Oki Y, Shah JJ, Thomas SK, Hosing CM, Zhang L, Badillo M, Chen W, Cai Q, Zou D, Champlin R, Fayad LE, Lee HJ, Wang M. Lenalidomide Plus Rituximab for Relapsed or Refractory Diffuse Large B-Cell, Follicular and Transformed Lymphoma: Final Data Analysis of a Phase 2 Trial. *Blood (ASH Annual Meeting Abstracts)* 126(23):3969, 12/2015.
262. Chihara D, Ahmed MA, Oki Y, Westin JR, Hagemester FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu SS, Rodriguez A, Fowler N, Wang M, Fayad LE, Davis RE, Nastoupil L. Management Strategies and Outcomes for Very Elderly Patients with

- Diffuse Large B-Cell Lymphoma (DLBCL). *Blood* (ASH Annual Meeting Abstracts) 126(23):1502, 12/2015.
263. Ahmed MA, Oki Y, Noorani M, Nastoupil L, Fayad LE, Hagemeister FB, Rodriguez A, Davis RE, Westin JR. The Clinical Outcome of Newly Diagnosed Patients >60 Years of Age with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Standard or Liposomal Chemotherapies. *Blood* (ASH Annual Meeting Abstracts) 126(23):3965, 12/2015.
 264. Chihara D, Fanale MA, Noorani M, Westin JR, Nastoupil L, Hagemeister F, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez A, Wang M, Fowler N, Miranda RN, Hosing CM, Nieto Y, Davis RE, Oki Y. The Survival Outcome of the Patients with Relapsed/Refractory Anaplastic Large-Cell Lymphoma. *Blood* (ASH Annual Meeting Abstracts) 126(23):2738, 12/2015.
 265. Chihara D, Fanale MA, Noorani M, Westin JR, Nastoupil L, Hagemeister F, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez A, Wang M, Fowler N, Miranda RN, Hosing CM, Nieto Y, Davis RE, Oki Y. The Survival Outcome of the Patients with Relapsed/Refractory PTCL-NOS and AITL. *Blood* (ASH Annual Meeting Abstracts) 126(23):3984, 12/2015.
 266. Crump M, Leppä S, Fayad LE, Lee JJ, Di Rocco A, Ogura M, Hagberg H, Schnell F, Rifkin R, Mackensen A, Offner F, Pinter-Brown L, Smith S, Tobinai K, Yeh SY, Hsi ED, Nguyen T, Shi P, Hahka-Kemppinen M, Thornton D, Lin B, Kahl B, Schmitz N, Savage KJ, Habermann T. Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphom. *J Clin Oncol* 34:2484-2492, 6/2016.
 267. Simar KA, Sathyanarayanan V, Issa AK, Ahmed MA, Noorani M, Fanale MA, Oki Y, Hagemeister FB, Neelapu SS, Nastoupil LJ, Fowler N, Turturro F, Davis RE, Rodriguez MA, Wang M, Feng L, Young KH, McDonnell TJ, Pinnix CC, Fayad LE, Westin JR. Analyzing Patient Characteristics Who Received (DA) EPOCH-R for High Risk Diffuse Large B-Cell Lymphoma: MD Anderson Cancer Center Experience. *Blood* (2016 ASH Annual Meeting) 128(26):4208, 12/2016.
 268. Jain P, Kanagal-Shamanna R, San Lucas F, Wang M, Romaguera JE, Fayad LE, Oki Y, Westin JE, Medeiros LJ, Fowler N. Characteristics, Outcome and Pattern of Mutations in Patients with Follicular Lymphoma Who Progressed on BTK Inhibitors (Ibrutinib and acalabrutinib). *Blood* (2016 ASH Annual Meeting) 128(26):2975, 12/2016.
 269. Wang M, Lee HJ, Thirumurthi S, Chuang HH, Hagemeister FB, Westin JR, Fayad LE, Samaniego F, Turturro F, Chen W*, Oriabure O*, Huang SY, Li S, Zhang L, Badillo M, Hartig KH*, Ahmed M, Nomie K, Lam LT, Addison AA, Romaguera JE. Chemotherapy-Free Induction with Ibrutinib-Rituximab Followed By Shortened Cycles of Chemo-Immunotherapy Consolidation in Young, Newly Diagnosed Mantle Cell Lymphoma Patients: A Phase II Clinical Trial. *Blood* (2016 ASH Annual Meeting) 128(26):147, 12/2016.
 270. Sathyanarayanan V, Oki Y, Issa AK, Ahmed MA, Noorani M, Fanale MA, Hagemeister FB, Neelapu SS, Nastoupil LJ, Fowler N, Turturro F, Davis ER, Rodriguez AM, Wang M, Feng L, Young KH, McDonnell TJ, Pinnix CC, Fayad LE, Westin JR. High Risk Diffuse Large B Cell Lymphoma: A Comparison of Aggressive Subtypes Treated with Dose Adjusted Chemotherapy—the University of Texas MD Anderson Experience. *Blood* (2016 ASH Annual Meeting) 128(26):106, 12/2016.
 271. Budde LE, Halwani A, Yassenchak CA, Farber CM, Burke JM, Fayad LE, Holkova B, Knapp M, Kolibaba KS, Advani RH, Ansell SM, Patel-Donnelly D, Yimer HA, Smith SE, Yair Levy M, Seetharam M, Belada D, Brooks D, Kingsley EC, Klein LM, Wagner-Johnston N, Ruffner K, Bartlett NL. Results of an Ongoing Phase 2 Study of Brentuximab Vedotin with Rchp As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL). *Blood* (2016 ASH Annual Meeting) 128(26):104, 12/2016.
 272. Hu B, Younes A, Claret L, Feng L, Westin JR, Fowler N, Neelapu SS, Hagemeister FB, Rodriguez MA, Samaniego F, Fayad LE, Nastoupil LJ, Copeland AR, Fanale MA, Oki Y. The Final Report of a Phase I/II Study of Panobinostat in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients (pts) with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL). *Blood* (2016 ASH Annual Meeting) 128(26):1833, 12/2016.

273. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler N, Medeiros LJ, Davis RE, Oki Y. The Risk of Central Nervous System (CNS) Relapses in Patients with Peripheral T-Cell Lymphoma. *Blood* (2016 ASH Annual Meeting) 128(26):4153, 12/2016.
274. Hu B, Loghavi S, Fayad LE, Noorani M, Fowler NH, Hagemeister FB, Lee HJ, Nastoupil LJ, Neelapu SS, Fanale MA, Samaniego F, Turturro F, Wang M, Davis RE, Westin JR, Medeiros LJ, Oki Y. Outcomes of De Novo CD5+ Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab (R) Era. *J Clin Oncol ASCO* 2017, 6/2017.
275. Khashab T, Niaz O, Hagemeister FB, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad LE, Younes A, Feng L, Berkova Z, Jain N, Sehgal L, Vega F, Kwak LW, Samaniego F. Ten-year follow-up of Pentostatin Combined with Cyclophosphamide, and Rituximab in untreated indolent B-Cell Lymphoma. *J Clin Oncol ASCO* 2017, 6/2017.
276. Paolo Strati, Yasuhiro Oki, Luis E. Fayad, Loretta Nastoupil, Nathan H. Fowler, F. B. Hagemeister, Larry W Kwak, Hun Ju Lee, Michael Wang, Jason R. Westin, Charnelle Ruben, Emily Wesson and Michelle A. Fanale. A Phase 1 Trial of Alisertib and Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas. *Blood* 130:4074, 12/2017.
277. Issa F. Khouri, Elias J. Jabbour, Celina Ledesma, Martin Korbling, Amin M. Alousi, Paolo Anderlini, Betul Oran, Stefan O. Ciurea, Luis E. Fayad, Roland L. Bassett Jr. and Alison M. Gulbis. Bcr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning for Lymphoid Malignancies: 8-Year Results. *Blood* 130:2036, 12/2017.
278. Preetesh Jain, Rashmi Kanagal-Shamanna, Ahmad Ghorab, Loretta Nastoupil, Luis E. Fayad, Jeffrey Medeiros, Shimin Hu, Sattva S. Neelapu, Jason R. Westin, Yasuhiro Oki, Michael Wang and Nathan H. Fowler. Characteristics, Treatments, and Outcomes of Patients with Lymphomatoid Granulomatosis—MD Anderson Cancer Center Experience. *Blood* 130:2852, 12/2017.
279. Dai Chihara, Nathan H. Fowler, Yasuhiro Oki, Michelle A. Fanale, Loretta Nastoupil, Jason R. Westin, Luis E. Fayad, Sattva S. Neelapu and Chan Yoon Cheah. Difference in Survival Outcome of Primary Central Nervous System Lymphoma By Histologic Types. *Blood* 130:4137, 12/2017.
280. Jason R. Westin, Yasuhiro Oki, Loretta Nastoupil, Luis Fayad, Sattva S. Neelapu, Francesco Turturro, F. B. Hagemeister, Maria Alma Rodriguez, Hun Ju Lee, Ken H. Young, Timothy J. McDonnell, Richard J. Ford and R. Eric Davis. Lenalidomide and Obinutuzumab with CHOP for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase I/II Results. *Blood* 130:189, 12/2017.
281. Issa F. Khouri, Hui Gao, Denái R. Milton, Martin Korbling, Celina Ledesma, Luis E. Fayad, Elias J. Jabbour, Alison M. Gulbis and James M. Reuben. Ofatumumab, Very Late Antigen 4 (VLA4), and Dendritic Cells in Patients Undergoing Autologous Peripheral Blood Stem Cell (PBSC) Mobilization and Transplantation (ASCT) for Relapsed b-Cell Non-Hodgkin's Lymphomas (NHL). *Blood* 130:1925, 12/2017.
282. Melody R Becnel, Loretta Nastoupil, R. Eric Davis, F. B. Hagemeister, Michelle A. Fanale, Luis Fayad, Jason R. Westin, Michael Wang, Yasuhiro Oki, Linda Claret, Sheryl G Forbes, Lei Feng, Felipe Samaniego, Sattva S. Neelapu and Nathan Fowler. Safety and Activity of Lenalidomide and Rituximab in Previously Untreated Marginal Zone Lymphoma: Subgroup Analysis and Long-Term Follow-up of an Open-Label Phase II Trial. *Blood* 130:4040, 12/2017.
283. Dai Chihara, Yasuhiro Oki, Michelle A. Fanale, Jason R. Westin, Loretta Nastoupil, Sattva S. Neelapu, Luis E. Fayad, Nathan H. Fowler and Chan Yoon Cheah. Stage I Lymphoma: Difference in Survival Outcome By Site of Involvement. *Blood* 130:1569, 12/2017.

Book Chapters

1. Fayad L O'Brien S. Chronic lymphocytic leukemia and associated disorders . In: *Medical Oncology a comprehensive review.*, 37-56, 1995.

2. Fayad L Estrov Z. Role of cytokines and adhesion molecules in chronic myeloid leukemia. .
In: Medical Management of Chronic myelogenous leukemia. Marcel Dekker Inc, 363-393,
1995.

Books (edited and written)

N/A

Letters to the Editor

N/A

Manuals, Teaching Aids, Other Teaching Publications

N/A

Other Publications

N/A

EDITORIAL AND REVIEW ACTIVITIES

Editor/Service on Editorial Board(s)

Reviewer, Journal of Clinical Oncology, 2009

Member of Editorial Review Board

N/A

Journal Reviewer

Reviewer, American Journal of Hematology, 2003-present

Reviewer, British Journal of Hematology, 2003-present

Reviwer, Cancer, 2003-present

Reviewer, Lymphoma/Leukemia, 2003-present

Other Editorial and Review Activities

N/A

TEACHING

Teaching Within Current Institution -

Formal Teaching

Courses Taught

N/A

Training Programs

Lecturer, A Comprehensive Board Review in Hematology and Medical Oncology
2004

Lecturer, A Comprehensive Board Review in Hematology and Medical Oncology
2005

Other Formal Teaching

N/A

Supervisory Teaching

Committees

Advisory Committees

N/A

Supervisory Committees

N/A

Examining Committees

N/A

Direct Supervision

Undergraduate and Allied Health Students

N/A

Medical Students

N/A

Graduate Students

N/A

Postdoctoral Research Fellows

N/A

Clinical Residents and Fellows

Faculty, Jorge Medina, 2/2002-9/2002

Faculty, Medical Oncology Program, Jeffrey Jones, 6/2003-6/2004

Faculty, Medical Oncology Program, Elias Jabbour, 6/2004-6/2005

Faculty, Medical Oncology Program, Joseph Dang, 6/2004-6/2005

Faculty, Medical Oncology Program, Michael Overman, M.D., 6/2004-6/2005

Faculty, Medical Oncology Program, Estuko Aoki, 6/2005-6/2006

Faculty, Medical Oncology Program, Peter Johnson, 6/2005-6/2006

Other Supervisory Teaching

Faculty, Dr. Lina Cassol, Clinical Residents and Fellows, 8/2002-9/2002

Faculty, Dr. Dax Kurbegov, Clinical Residents and Fellows, 8/2002-present

Faculty, Dr. Fan Zhang, Clinical Residents and Fellows, 9/2002-present

Faculty, Dr. Anthony Ruggeri, Clinical Residents and Fellows, 3/2003-present

Teaching Outside Current Institution

Formal Teaching

Courses Taught

N/A

Training Programs

N/A

Other Formal Teaching

N/A

Supervisory Teaching

Committees

Advisory Committees

N/A

Supervisory Committees

N/A

Examining Committees

N/A

Direct Supervision

Undergraduate and Allied Health Students

N/A

Medical Students

N/A

Graduate Students

N/A

Postdoctoral Research Fellows

N/A

Clinical Residents and Fellows

N/A

Other Supervisory Teaching

N/A

CONFERENCES AND SYMPOSIA

Organization of Conferences/Symposia (Include chairing session)

ASH Annual Meeting, New Orleans, LA, Moderator, 12/2009
CMC 2005 Accrual Workshop, Pfizer, New York, NY, Moderator, 4/2010
American Society of Hematology, San Diego, CA, Moderator, 12/2011
ASCO Conference 2012, Chicago, IL, Moderator, 6/2012
ASH Annual Meeting, Chicago, IL, Moderator, 12/2012
55th Annual ASH Meeting and Exposition 2013, New Orleans, LA, Moderator, 12/2013
ASCO, Chicago, IL, Moderator, 6/2015
ICML Congress 2015, Lugano, Switzerland, Moderator, 6/2015
NCCN NHL Panel Meeting, Philadelphia, PA, Moderator, 6/2015
ASCO, Chicago, IL, Moderator, 6/2016
American Society of Hematology, San Diego, CA, Moderator, 12/2016
14th International Conference of Malignant Lymphoma, Lugano, Switzerland, Moderator, 6/2017
ASH annual meeting 2017, Atlanta, GA, Moderator, 12/2017
ASH Annual Meeting 2018, San Diego, CA, Moderator, 12/2018
NCCN NHL Panel Meeting, Philadelphia, PA, Moderator, 9/2019
ASH Conference, Orlando, FL, Moderator, 12/2019

Presentations at National or International Conferences

Invited

Mantel Cell Lymphoma, University of Miami, Miami, FL, 5/1/2002
Treatment of Diffuse Large Cells in Lymphoma, UT M.D. Anderson, Houston, TX, 5/1/2002
Lymphoma Cases, Telemedicine Conference, Orlando, FL, 6/1/2002
Advances in the management of Lymphoma, Manejo Actualizado del Linfoma, Guayaquil, Ecuador, 7/1/2002
Lymphoma Cases, Telemedicine Conference with Sao Paulo, Brazil, 7/1/2002
Lymphoma Cases, Telemedicine Conference with Sao Paulo, Brazil, 8/1/2002
Lymphoma Cases, Telemedicine Conference with Sao Paulo, Brazil, 9/1/2002
Aggressive NHL and Rituxin, Christus Spohn Hospital Shoreline, Corpus Christi, TX, 10/2002
Small Lymphocytic Lymphomas, Nevada Cancer Center, Las Vegas, NV, 10/2002
Hodgkin's lymphoma in adults, NHL in adults, International Oncology Congress SOLCA, Guayaquil, Ecuador, 4/14/2003
Non-Hodgkin's Lymphoma, CHRISTUS St. Frances Cabrini Hospital, Alexandria , LA, 5/1/2003
Post-ASCO Highlight Update, Tulsa , OK, 6/1/2003
Lymphoma Cases, Telemedicine Conference with Sao Paulo, Brazil, 8/1/2003
"Advances in Type B Aggressive Lymphomas," , Lima, Peru, 9/1/2003
"Treatment of Hodgkin's Lymphoma," , Lima, Peru, 9/1/2003

Innovations in Lymphoma Treatments, Conference for the Lymphoma Research Foundation, 9/1/2003

Aggressive NHL-Frontline and Salvage Treatment, Advances in Lymphoid Malignancies: An Expert Forum, San Antonio , TX, 10/1/2003

Lymphoma Update, Las Vegas, NV, 10/1/2003

NHL, Abilene, TX, 10/1/2003

NHL, Brownsville, TX, 10/1/2003

Radioimmunoisotopes in Lymphoma, San Francisco, CA, 11/1/2003

2003 ASH Update, Las Vegas, NV, 12/1/2003

2003 ASH Update, Arlington, TX, 12/1/2003

2003 ASH Update, Tyler, TX, 1/27/2004

2003 ASH Update, Longview, TX, 1/27/2004

2003 ASH Update, Wichita Falls, TX, 1/27/2004

NHL Competitive Agents Review, San Francisco, CA, 2/25/2004

Non-Hodgkin's Lymphoma, Santa Rosa, CA, 3/24/2004

Perspectives on Treatment Options for Indolent Lymphoma, Seattle, WA, 3/30/2004

Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma, Cuenca, Ecuador, 4/14/2004

New Therapeutic Options in the Management of Non-Hodgkin's Lymphoma, Corpus Christi, TX, 6/17/2004

Zevalin Forum, Dallas, TX, 6/18/2004

Expanding Treatment Options for Indolent Non-Hodgkin's Lymphoma, San Antonio, TX, 6/22/2004

New Therapeutic Options in the Management of Non-Hodgkin's Lymphoma, Lackland AFB, TX, 6/22/2004

New Therapeutic Options in the Management of Non-Hodgkin's Lymphoma, Lubbock, TX, 6/23/2004

The Emerging Role of Radioimmunotherapy in the Treatment of Non-Hodgkin's Lymphoma, Lubbock, TX, 6/23/2004

Oncology Education Continuum: A Continuing Medical Education Initiative Evaluating Monoclonal Antibody Therapy for B-Cell Malignancies, Orange Beach, AL, 7/17/2004

Follicular Lymphoma, Houston, TX, 8/27/2004

Oncology Education Continuum: A Continuing Medical Education Initiative Evaluating Monoclonal Antibody Therapy for B-Cell Malignancies, West Palm Beach, FL, 9/25/2004

Advances and Controversies in the Management of Large Cell Lymphoma, Las Vegas, NV, 9/27/2004

Latest Treatment Strategies Regarding Indolent NHL, Lake Charles, LA, 9/29/2004

Advances in the Treatment of Non-Hodgkin's Lymphoma: A Focus on Radioimmunotherapy, Arlington, TX, 10/1/2004

Questions and Answers about Lymphoma, A comprehensive Board Review in Hematology and Medical Oncology, 10/2/2004

The Emerging Role of Radioimmunotherapy in the Treatment of Non-Hodgkin's, Baton Rouge, LA, 10/6/2004

The Emerging Role of Radioimmunotherapy in the Treatment of Non-Hodgkin's, Metairie, LA, 10/7/2004

Roche Mexico Round Table Discussions: Use of Rituximab as Primary Therapy in Aggressive NHL, Mexico City, Mexico, 10/18/2004

The Role of VSLI in Strategies for Treating NHL Advisory Board, Philadelphia, PA, 11/4/2004

Meet the Expert on Non-Hodgkin Lymphoma, Tyler, TX, 11/13/2004

New Therapeutic Options in the Management of Non-Hodgkin's Lymphoma, Harlingen, TX, 11/16/2004

Use of Rituximab as Primary Therapy in Aggressive NHL, Panama City, Panama, 11/18/2004

Ask the Doctor, Houston, TX, 12/15/2004

Favrille Clinical Advisory Board Meeting, Dallas, TX, 4/2005

Meet the Expert: Non-Hodgkin Lymphoma, Spartanburg, SC, 4/2005

Oncology Education Continuum: A continuing Medical Education Initiative Evaluating Monoclonal Antibody Therapy for B-cell Malignancies., Fort Lauderdale, FL, 5/2005

New Advancements in the Treatment of Mantel Cell Lymphoma, Winship Cancer Institute at Emory University, Atlanta, GA, 6/2005

Ontak clinical Advisory Forum, Miami, FL, 6/2005

Optimizing Therapy for CD20-Expressing B-Cell Malignancies, Integris Southwest Medical Center, Oklahoma, OK, 7/2005

Optimizing Therapy for CD20-Expressing B-Cell Malignancies, Oklahoma University Health Sciences Center, Oklahoma, OK, 7/2005

Overview on Protocol Utilization at MD Anderson Cancer Center, Houston, TX, 8/2005

A Comprehensive Board Review in Hematology and Medical Oncology, Houston, TX, 9/2005

Zevalin Forum, Fayetteville, AR, 10/2005

Zevalin Forum, Shreveport, LA, 10/2005

Novel Therapies in Lymphoma, Tampa, FL, 11/2005

Update In the Management of DLBCL, MDACC experience., Madrid, Spain, 3/2007

New basic and practical clinical knowledge in lymphomas, leukemias, multiple myeloma and cancer related thrombosis, Instituto Nacional de Cancerologia, Instituto Nacional de Cancerologia, Puerto Morelos, Quintana Roo, Mexico, 10/30/2009

Spanning the Continuum of Care: Optimizing Patient Outcomes in NHL, Millennium, Clinical Care Options Oncology, Miami, FL, 3/24/2010

Alternative Monoclonal Antibodies for the treatment of NHL, MDACC, MDACC and University of Zagreb, Croatia, Dubrovnik, Croatia, 9/21/2011

XXXIV World Congress of the International Society of Hematology, Sanofi Oncology, Cancun, Mexico, 4/25/2012

NCCN NHL Panel Meeting, National Comprehensive Cancer Network, Philadelphia, PA, 6/15/2012

Treatment Breakthroughs in Relapsed Refractory DLBCL, MDACC 2012 GAP Workshop, Bangkok, Thailand, 8/2012

Fayad, LE. Diffuse b cell lymphomas, Chilean Hematology Society, XIX Congress of Hematology, Puerto Varas, Chile, 10/2014

Fayad, LE. The Use of Molecular targets in Lymphoma, Society of Ecuadian Oncology, 2nd International Simposium about New Molecular Targets, Guayaquil, Ecuador, 10/2014

Fayad, LE. The Use of Molecular targets in Lymphoma, Association of Colombia Microbiology, XXII Latin American Congress of Microbiology, Cartagena, Colombia, 11/2014

Treatments of Hodgkins Lymphoma, VIII Curso Gotel De Formacion En Linfomas, Madrid, Spain, 4/17/2015

Treatments of Hodgkins Lymphoma, 56th Congress AMEH, Acapulco, Mexico, 5/1/2015

Updates on Various Treatments of Lymphoma, Citizen's Medical Center, Victoria, TX, 5/6/2015

Fayad, LE. Diffuse large b cell lymphoma, MD Anderson Cancer Center Global Affairs, International Academic Oncology, Cancun, Mexico, 9/2015

Fayad, LE. FDA Approval for Brentuximab Vedotin updates, Seattle Genetics, Memorial Cancer Institute, Hollywood, FL, 9/2015

Fayad, LE. CLL Moon Shot Talk, MD Anderson Cancer Center Gap Affairs, Gap 2016 Conference, Sao Paulo, Brazil, 4/2016

Fayad, LE. Diffuse b cell lymphoma, Infinity, Pharmaceuticals, Denver, CO, 4/2016

Fayad, LE. Current State of the Art and future approaches in the treatment and diagnosis of Hodgkins Lymphoma, Takeda Oncology, Albert Einstein Hospital, Sao Paulo, Brazil, 6/28/2016

Fayad, LE. Myeloid and lymphoid neoplasms - Diffuse large b cell lymphoma - current status, Albert Einstein Hospital, Sao Paulo, Brazil, 6/29/2016

Fayad LE. Large B Cell Lymphoma 2018, NCI Mexico, 5th Annual Meeting for Mexican College for Cancer Research, Puebla, Mexico, 9/2018

Fayad LE. Agressive NHL, Amgen, 1st Course of Hematology for Latin America, Bogota, Colombia, 11/9/2018

Fayad LE. DLBCL Heterogeneity: What is new?, Roche Pharma, XVII Lymphoma Interchange Meeting, San Paulo, Brazil, 3/29/2019

Fayad LE. Hematologic Malignancies - Leukemia, ASCO, ASCO Direct Highlights St. Louis Agenda, St. Louis, MO, 6/29/2019

Fayad L. Tratamiento del linfoma difuso de celulas grandes refractario e en recaida: nuevos abordajes, Grupo Aran Communications, Spanish Lymphoma Oncology Group, Malaga, Spain, 3/27/2020

Other, Including Scientific Exhibitions

International Society of Experimental Hematology, Paris, France, 1/1/2003

IL-6 consultants' Conference, Montpellier, France, 2005

Oral Presentation, 9th International conference on Malignant Lymphoma, Lugano, Switzerland, 6/2005

Optimizing Therapy for CD20-Expressing B-Cell Malignancies, Galveston, TX, 8/2005

IL-6 Consultants' Conference, Montpellier, France, 9/2005

ASH 2005 Update, University of Louisville, Louisville, KY, 2/2006

Optimizing Therapy for CD20-Expressing B-Cell Malignancies, Destin, FL, 9/2006

Poster Presentation in Phase I study with a new compound BBR2778 in combination with Area C, platinum for aggressive NHL, International Society of Experimental Hematology, Paris, France, 3/2007

Rituximab + ABVD Improves Event-Free Survival (EFS) in Patients with Classical Hodgkins Lymphoma in All International Prognostic Score (IPS) Groups and in Patients Who Have PET Positive Disease after 2-3 Cycles of Therapy, ASH Annual Meeting, American Society of Hematology, GA, 12/2007

Luis E Fayad. Global Academic Conference, Norwegian Cancer Consortium, Oslo University Hospital, Oslo, Norway, 5/14/2012

57th Annual ASH Meeting and Exposition 2015, ASH, Orlando, FL, 12/2015

Seminar Invitations from Other Institutions

International Castleman's Disease 2009 Summit, Johnson and Johnson, OrthoBiotech, New Orleans, LA, 12/2/2009

New Therapeutic Options in Follicular Lymphoma, Mexican Society of Hematology, Mexican Society of Hematology, Puebla, Mexico, 4/29/2010

EPIC Physician Overview, MD Anderson Cancer Center, Mazdison, WI, 7/2015

Diffuse large b cell lymphoma and updates for 2016, The medical educator consortium, New Orleans, LA, 7/2016

New Classification of lymphoid neoplasms 2016, Honduran Society of Oncology, Roatan, Honduras, 7/2016

Updates on Large B Cell Lymphoma, Solca Cancer Center, Solca Cancer Center, Guayaquil, Ecuador, 11/2017

Lectureships and Visiting Professorships

N/A

Other Presentations at State and Local Conferences

Gemtuzumab, Bosutinik/SKI-606 and Inotuzumab/CMC-544, Hematology Advisory Board Meeting, Pfizer Oncology, Pfizer Oncology, Houston, TX, 3/10/2010

PROFESSIONAL MEMBERSHIPS/ACTIVITIES

Professional Society Activities, with Offices Held

National and International

American College of Physicians
Member, 1994-present

American Society of Bone Marrow Transplantation
Member, 1997-present

American Society of Hematology
Member, 1997-present

American Society of Internal Medicine
Member, 1997-present

American Society of Oncology
Member, 1997-present

European Society of Medical Oncology
Member, 1998-present

Nevada State Medical Association
Member, 1998-present

NCCN Hon Hodgkin's Lymphoma Panel
Member, 2005-present

Local/State

Texas Medical Association, Austin, TX
Member, 1996-present

UNIQUE ACTIVITIES

N/A

DATE OF LAST CV UPDATE

3/2/2021